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Our aim is to help put nuclear medicine at the forefront of quantitation on the path to realization of 
personalized medicine. We propose and evaluate (Part I) advanced image reconstruction and (Part 
II) robust radiomics (large-scale data-oriented study of radiological images). The goal is to attain 
significantly improved diagnostic, prognostic and treatment-response assessment capabilities. 
Part I presents a new paradigm in point-spread function (PSF)-modeling, a partial volume correction 
method in PET imaging where resolution-degrading phenomena are modeled within the 
reconstruction framework. PSF-modeling improves resolution and enhances contrast, but 
significantly alters noise properties and induces edge-overshoots. Past efforts involve a dichotomy 
of PSF vs. no-PSF modeling; by contrast, we focus on a wide-spectrum of PSF models, including under- 
and over-estimation of the true PSF, for the potential of enhanced quantitation in standardized 
uptake values (SUVs).  
We show for the standard range of iterations employed in clinic (not excessive), edge enhancement 
due to overestimation actually lower SUV bias in small regions, while inter-voxel correlations 
suppress image roughness and enhance uniformity. An overestimated PSF yields improved contrast 
and limited edge-overshoot effects at lower iterations, enabling enhanced SUV quantitation. Overall, 
our framework provides an effective venue for quantitative task-based optimization. 
Part II proposes robust and reproducible radiomics methods. Radiomics workflows are complex, 
generating hundreds of features, which can lead to high variability and overfitting, and ultimately 
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hampering performance. We developed and released a Standardized Environment for Radiomics 
Analysis (SERA) solution to enable robust radiomics analyses. We conduct studies on two unique 
imaging datasets – renal cell carcinoma SPECT and prostate cancer PET – identifying robust and 
reproducible radiomic features.  
In addition, we evaluate a novel hypothesis that radiomic features extracted from clinically normal 
(non-ischemic) myocardial perfusion SPECT (MPS) can predict coronary artery calcification (CAC; as 
extracted from CT). This has important implications, since CAC assessment is not commonly-
performed nor reimbursed in wide community settings. SERA-derived radiomic features were 
utilized in a multi-step feature selection framework, followed by the application of machine learning 
to radiomic features. Our results show the potential to predict CAC from normal MPS, suggesting 
added usage and value for routine standard MPS. 
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Nuclear medicine imaging technology, coupled with image generation techniques, has dramatically 
improved compared to a few decades ago. At the same time, the apparent complexity and/or limited 
accuracy of quantitation methods remain bottlenecks that motivate developmental research. Our aim 
in this dissertation is to help put nuclear medicine at the forefront of quantitation on our path to the 
realization of personalized medicine. Our work proposes, implements and evaluates advanced image 
reconstruction as well as image processing techniques in nuclear medicine imaging, aiming to attain 
significantly improved diagnostic, prognostic, and treatment response assessment capabilities. 
1.1. Medical Imaging in Today’s Medicine 
Clinical practice has commonly consisted of diagnostic, prognostic, and treatment-related tasks [1]. 
Medical imaging has been a staple of clinical diagnosis workflow across many different specialties for 
decades and has substituted the need for some invasive procedures, particularly explorative 
surgeries.  
At the same time, applications of medical imaging have also gone beyond diagnosis to other clinical 
territories. Many studies use interpretations from medical images to improve prognosis in oncology 
[2-6], cardiology [7-12], and neurology [13-17]. Furthermore, medical imaging and in particular 
functional imaging modalities that capture the functionality of tissue cells, such as positron emission 
tomography (PET), are widely utilized in treatment planning [18-20], treatment monitoring [21-24], 
and treatment response assessment [25-30]. Medical imaging has also stepped up to enable newly-
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developed frontiers in medicine. An example is computer-aided diagnosis (CAD), which has been 
increasingly investigated and applied to assess diverse types of abnormalities as imaged via different 
modalities [31-39]. CAD-based assessment of breast cancer from mammograms is now a part of 
routine clinical work at many hospitals [31, 40-43], and there is significant research on different 
fronts.  
Another emerging area that has benefited significantly from medical images is theranostics. 
Theranostics, a combination of the terms therapeutics and diagnostics, describes the integration of 
targeted therapy and targeted diagnostic tests; e.g. use of a radioactive drug to image (diagnose) and 
another radioactive drug to deliver therapy (treat) cancerous tissue [44, 45]. The idea is “to treat 
what we see and to see what we treat”. Specific multifunctional materials can be employed for 
theranostics including polymers, magnetic, and inorganic nanoparticles that deliver therapeutic use, 
in addition to the ability to be fully functionalized with imaging agents. The latter enables one or more 
diagnostic imaging techniques such as MRI, nuclear medicine imaging (PET, single photon emission 
computed tomography (SPECT)), and even optical and fluorescence imaging [44, 46-52].  
Overall, advancements in imaging techniques have made medical imaging an essential component in 
most episodes of care. An important branch of medical imaging is nuclear medicine imaging, which 
presently enjoys numerous clinical applications and wide clinical usage. Our dissertation focuses on 
the development and validation of image reconstruction and processing techniques towards 
improved quantitation in nuclear medicine imaging. In what follows, we provide a brief introduction 
to nuclear medicine imaging. Subsequently, we discuss medical image quantitation and the concept 
of biomarkers in order to clarify the aims of our efforts. Specifically, we elaborate on the link between 
image quantitation and personalized medicine. We then introduce the field of radiomics, an “image 
processing” technique to characterize phenotypes of regions of interests in medical images. 
Following these introductions, we re-capture and summarize our motivations for this research and 




1.2. Nuclear Medicine and Tomographic Imaging 
The field of nuclear medicine involves the administration of a radioactive-labeled pharmaceutical, or 
radiopharmaceutical, with the aim of providing diagnostic and/or therapeutic information in a wide 
range of disease states. Nuclear medicine imaging involves injecting a patient with a compound 
labeled with a gamma-emitting or positron-emitting radiopharmaceutical. These 
radiopharmaceuticals are sometimes referred to as radiotracers, or simply tracers. The tracer results 
in the emission of high-energy photons, some of which can exit the body. A set of detectors can then 
detect these exiting high-energy photons. The resulting data can be subsequently reconstructed to 
generated images of the distribution of the radiotracer inside the subject [53].  
Unlike X-ray and CT imaging where X-rays are emitted from an external source, transmitting through 
the body. In nuclear medicine imaging, photons are emitted from inside the body. Hence, X-ray and 
CT images are produced through transmission, while nuclear medicine images are obtained through 
emission of photons. Moreover, in contrast to X-ray, CT and MRI modalities that often produce images 
of anatomical structures (hence performing structural imaging), in nuclear medicine, the explicit aim 
is always to capture the biological behavior of a substance in the body [54]. The biodistribution of a 
given radiotracer is determined by physiological and biochemical functioning of the body that may 
not be apparent via structural imaging; thus, nuclear medicine is considered a functional imaging 
modality.  
Nuclear medicine imaging mainly consists of two broad classes: single photon emission, and positron 
annihilation photon emission. The former is the basis of 2D planar imaging (also known as 
scintigraphy or gamma scan), as well as single photon emission computed tomography or SPECT 
imaging, and the latter forms positron emission tomography or PET imaging. In what follows, we first 
discuss single photon imaging including basics of Anger cameras and SPECT imaging, followed by a 
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discussion of positron emission and PET imaging. Subsequently, we discuss tomographic image 
reconstruction, and specifically, statistical image reconstruction. We then elaborate on the causes of 
degradation in quality and quantitative accuracy for nuclear medicine images.  
 
1.2.1. Single photon emission 
1.2.1.1. Anger camera 
Single photon imaging involves the use of radiotracers that emit gamma-rays upon decay. It enables 
detection of a two-dimensional (2D) projection of the three-dimensional (3D) biodistribution of the 
radiotracer in the body. The resulting planar image, though 2D (with no explicit depth resolution) 
can still be diagnostically useful. Once the radiotracer is administered to the patient through 
injection, inhaling, etc., it gets circulated around the body and gets accumulated at certain tissue cells, 
e.g. bones, based on the type of the pharmaceutical. Subsequently, a considerable number of gamma-
rays will be emitted, especially originating at these target sites. On the outside, a gamma camera can 
be used to detect these incoming gamma-rays, convert the absorbed energy from the incoming 
gamma-rays to the detectors to electrical signals, and then form or reconstruct the image using 
reconstruction algorithms. This process happens in the so-called Anger scintillation camera or the 
gamma camera, which was invented in the late 1950s by Hal Anger of the Donner Lab at the 
University of California at Berkeley [54].  
The Anger camera is the most commonly-used imaging instrument in nuclear medicine today [54]. A 
simple diagram of its components is shown in Figure 1-1. The first component the gamma-rays 
encounter is the multi-hole lead collimator with a narrow gap that allows only the incoming photons 
at nearly normal angels to pass through. The gamma-rays originating from the body are emitted 
randomly in all direction. As such, the job of a collimator is to ensure that the detector only captures 
photons from a see-through angle of the collimator and prevent off-angled incoming photons to be 
Figure 1-1. Components of a typical Anger camera 
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a burst of light in the crystal comprising thousands of light (scintillation) photons [54]. This light is 
then channeled out of the back of the crystal where it arrives at an array of photomultiplier tubes 
(PMTs). PMTs receive photons at their front photocathode. For every photon received at the 
photocathode, an electron is released on the inside of the PMT (via the photoelectric effect). The 
electron subsequently goes through a series of electrodes called dynodes and is amplified. Each 
dynode release 3-6 electrons upon receiving one electron, and thus, through having 10-14 successive 
dynodes, one electron that arrives at the photocathode results in 106 to 108 electrons at the other end 
of the PMT (the anode). The output of the anode arrives at a positioning logic circuit, which 
determines the location of the events occurring on the face of the crystal and the combined output of 
all the PMTs [53, 56].  
Another component of the camera is the pulse height analyzer. The collimator only allows photons 
traveling in a predetermined direction to pass through and arrive seamlessly at the crystal; thus, a 
line originated at the scintillation event at the crystal through the collimator hole is assumed to arrive 
at the site of the origin of the photon, which is where the gamma-ray has left the radiotracer in the 
patient’s body. However, it is possible for the gamma-ray to undergo Compton scattering during this 
path. In Compton scattering, an incident photon ejects a valence electron from the outer shell of an 
atom. The incident photon then loses some of its own energy and changes its direction. A photon is 
said to be attenuated when it goes through one or more scatterings and gets distracted from its 
original path or completely loses its energy. Now, if a photon undergoing this phenomenon passes 
through the collimators and reaches to the detectors, then the line drawn from the scintillation 
passing through the collimator hole may not arrive at the location where the gamma-ray was actually 
emitted from. Ideally, we do not want to include such scattered photon in the formation of the image. 
One solution to exclude such photons is by using the pulse height analyzer. Photons that have gone 
through Compton scattering have lost some of their energy relative to a typical photon that arrives 
at the detector without being scattered. The pulse height analyzer only accepts photons with their 
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energy in a certain range called acceptance interval or acceptance window and rejects many 
scattered photons that have been detected. The output of the Anger camera is interfaced to a 
computer where an image is being generated.   
1.2.1.2. Single Photon Emission Computed Tomography (SPECT) 
While the Anger camera is readily used for planar nuclear medicine scanning, it can be used in a 
slightly modified setting to provide a 3D image that contains the biodistribution of the radiotracer 
with depth information inside the body. The process of generating a 3D image from multiple 2D 
projections is referred to as “tomography”. Tomography consists of two Greek words: “tomos” 
meaning ‘slice’ or ‘section’, and “graphō” meaning ‘to write’. Since this is performed digitally, it is 
referred to as computed tomography. Therefore, single photon emission computed tomography or 
SPECT is the process of imaging a sample using the single photon emission technique by acquiring 
projection data multiple times at different orientations, ultimately yielding a 3D image of the sample 
structure using reconstruction algorithms. As such, tomographic reconstruction enables looking at 
slices through the investigated object without physically cutting it. Modern SPECT cameras consist of 
two or three camera heads, like the one in Figure 1-1, mounted on a single rotating gantry, that can 
move around the patient and cover various angles to detect a larger fraction of emitted photon. This 
yields an increase in signal-to-noise ratio and produces a 3D tomographic image [53, 54, 56].  
1.2.1.3. SPECT/CT and its applications in nuclear medicine  
Nowadays, SPECT systems increasingly include a CT component. Such a system, the SPECT/CT, 
allows the use of CT imaging to also estimate and compensate for attenuation of emitted photons [53, 
54].  The CT image is also used to create fused SPECT/CT images in the three orthogonal planes for 
anatomical localization. The addition of CT component, in general, leads to improved sensitivity and 
specificity of single photon emission imaging, due to attenuation correction, as well as anatomical 
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localization, and morphological characterization rendered by the CT, while also facilitating contrast-
enhanced CT scanning as part of the examination [57].  
The significant role of SPECT/CT in nuclear medicine has been reviewed extensively [58-61]. An 
example clinical applications of SPECT/CT include characterization and localization of solitary 
pulmonary nodules and lung cancers, brain tumors, lymphoma, prostate cancer, neuroendocrine and 
endocrine tumors, as well as malignant and benign bone lesions [58]. SPECT/CT is also applied to 
thyroid and parathyroid imaging [62], breast cancer [63, 64], radio-guided biopsy [65] and cerebral 
masses [66]. Other non-oncological applications include infection and inflammation, and to precisely 
localize infectious foci that can be problematic [67, 68], gastrointestinal (GI) diseases such as 
upper/lower GI bleeding [69, 70], pulmonary embolism [71] and neurodegenerative disorders [72]. 
Another major application of SPECT/CT is in patients diagnosed or suspected of coronary artery 
disease. At the same time, myocardial perfusion SPECT (MPS) imaging maintains a dominant and 
unique place for evaluation of the physiological significance of coronary artery problems and 
atherosclerosis [73]. While SPECT has many oncological and neurological applications, most SPECT 
scans are performed in cardiology [74]. One of our main projects targets MPS imaging and will be 
discussed in chapter 4 of this dissertation. 
 
1.2.2. Positron Emission 
Positron-emitting radionuclides can also be used to label pharmaceutical compounds. Once the 
radiotracer is administrated intravenously to the patient and distributed in tissues in a manner 
determined by its biochemical properties, they decay by ejecting a positron from the nucleus. 
Positron-emitters include 11C, 18F, 13N, 15O, etc. that occur naturally in biological molecules, allowing 
them to be more readily incorporated into a wide variety of useful radiotracers, which is an 
advantage over commonly-used SPECT radionuclides such as 99mTC.  
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A neutron-deficient nucleus can become stable by either capturing a new electron that is 
subsequently captured by a proton thus transforming into a neutron or by emitting positron that 
happens from a proton 𝑝 decay. In this case, the following transmission takes place: 
𝑝 → 𝑛 + 𝛽+ + 𝜈𝑒  1.1 
where 𝑛 is the neutron, 𝛽+ is the positron, and 𝜈𝑒  is another subatomic particle called neutrino. For 
a typical radionuclide 𝑋𝑍
𝑀  with mass number 𝑀 and atomic number 𝑍, the following process occurs:  
𝑋𝑍
𝑀 → 𝑋𝑍−1
𝑀 + 𝛽+ + 𝜈𝑒 1.2 
Positrons are emitted with a continuous range of energies up to a maximum, due to the presence of 
neutrino. The freed positrons give up their enormous kinetic energy mostly through Compton 
scattering with electrons within the surrounding medium, until they reach thermal energies. At this 
stage, they start to interact by electrons, mostly leading to positron annihilation1. Higher energy 
positrons require to traverse a larger distance (on average) in the medium before reaching thermal 
energies and interacting with electrons. This distance is referred to as the positron range. Properties 
of commonly-utilized positron-emitting isotopes are more elaborated in [75]. 
Table 1-1. Properties of commonly-utilized positron-emitting isotopes [76, 77] 
 
 𝑻𝟏/𝟐 (min) 𝑬𝒂𝒗𝒈(MeV) 𝑬𝒎𝒂𝒙 (MeV) Mean range in water 
(mm) 
C-11 20.3 0.39 0.96 1.1 
N-13 9.97 0.49 1.19 1.5 
O-15 2.03 0.73 1.79 2.5 
F-18 109.8 0.24 0.64 0.6 
Cu-64 762 0.28 0.66 6.07 
Ga-68 4,086 0.83 1.9 2.9 
Rb-82 1.25 1.52  3.38 5.9  
I-124 6,019 0.69 2.15 3.46 
                                                             
1 A second possibility for positron-electron interaction is the formation of a hydrogen-like orbiting couple called 
positronium. In this case they may either decay by self-annihilation and generating two 511 keV photons (for 




When a positron and an electron annihilate, based on the mass-energy equivalence principle, they 
emit two gamma-ray photons.  Given 𝐸 = 𝑚𝑐2, inserting the masses of an electron and a positron, 
yields an energy of 511 keV for each of the two emitted photons. These two photons travel almost 
anti-parallel at a 180° angle. The two 511 keV photons can be detected via detectors connected to a 
coincidence-detection circuit that only accepts two incoming photons at two detectors within a short 
timing-window at the order of nanoseconds, just enough to capture photons emitted from the same 
annihilation. This scenario is depicted in Figure 1-2.  
1.2.2.1. Positron emission tomography (PET)  
Imaging in vivo using positron emission makes use of radiopharmaceuticals that decay by emitting 
positrons. The resulting anti-parallel 511 keV photons are subsequently detected by a 360° ring of 
detectors. The data is collected in many angles and is processed with a tomographic reconstruction 
algorithm to produce an image of radiotracer distribution in the body. Such a procedure is referred 
to as positron emission tomography or PET imaging. Although these gamma-ray photons can also be 
detected using SPECT system that operates in a single-photon-counting mode, they are not optimally 
designed for the relatively high energy of 511 keV photons and have low detection efficiency at this 
energy range. More importantly, PET replaces physical collimation that comes with a cost of reduced 
sensitivity with coincidence detection circuit that acts as electronic collimation, increasing sensitivity 
by at least one order of magnitude [54, 56]. PET imaging has gained widespread clinical application 
and is commonly utilized along with other imaging modalities such as CT, MRI, and SPECT.  
1.2.2.2. Image acquisition in PET 
In single photon imaging, as shown in Figure 1-1, collimators restrict the acceptance angle of 
incoming photons, and without them, a detected photon could have come from any region in the field 
of view (FoV). In positron emission imaging, however, much higher sensitivity is achieved by noting 
that collimation can be performed electronically as depicted in Figure 1-2.  The coincidence detection 
Figure 1-2. Positron annihilation. A) positron reaches thermal energy and meets an electron. B) they annihilate, producing two 
511 keV gamma-ray photons travel 180° apart. A coincidence detection circuit can then determine whether they originate from 
a single annihilation event. 
PET scintillation crystals 
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3- Spectral distribution—wavelength of the output light from the crystal that should be 
efficiently detected by PMTs  
4- Linearity—proportionality of the amount of light produced to the energy deposited by 
radiation,  
5- Conversion efficiency—a fraction of the radiation energy converted to detectable scintillator 
light.  
Table 1-2 provides a list of such properties for some of the commonly-used scintillation crystals. In 
the past, bismuth germanate (BGO) was commonly used in PET scanners, whereas, nowadays, LSO 
(Lutetium Oxyorthosilicate), or its yttrium-doped version, LYSO, are used more often due to the 
improved decay time, high conversion efficiency, and energy resolution.  
Table 1-2. Table of commonly-used scintillation materials. Bismuth germanate (BGO), lutetium oxyorthosilicate (LSO), sodium 
iodide (NaI), and gadolinium oxyorthosilicate (GSO).  
   NaI[Tl] BGO LSO GSO 
Atomic No. (Z) 50 73 66 59 
Lin. atten. coef. (cm-1) 0.34 0.92 0.87 0.62 
Index of refraction 1.85 2.15 1.82 1.85 
Light yield [%NaI:Tl] 100 15 75 41 
Peak wavelength (nm) 410 480 420 430 
Decay const. (nanosec.) 230 300 40 56 
Fragile Yes No  No No 
Hygroscopic Yes No No No 
 
 
 PMTs and photo-detectors 
Originally, PET scanners involved the one-to-one coupling of detector crystals and PMTs. In 1985, a 
new technology was developed to couple one PMT to a block of crystals [78], which continues to this 
day. In this scheme, a block of crystals (e.g. 8x8) is coupled to four PMTs, so that one crystal can 
disperse light in all four PMTs based on their distance and the crystal pattern. The crystal position 
and thus the location of the incident photon can be determined by linear averaging of the light output 
in all four PMTs.  
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In recent years, there has been an increased interest to replace PMTs with light-sensitive 
semiconductor detectors such as silicon photomultipliers (SiPMs). These detectors consist of an 
array of microscopic, parallel connected avalanche photodiodes that operate in limited Geiger-mode. 
In this mode of operation, each cell is biased enough just above the breakdown threshold, resulting 
in a cumulative avalanche breakdown within the diode depletion-region that results in an excessive 
current upon encountering a light photon [79, 80]. They exhibit a higher quantum efficiency (fraction 
of incident photons absorbed in the photosensitive area, QE) compared to PMTs, yet essentially do 
not amplify the signal internally like PMTs. The Silicon photodiodes have an internal gain that enables 
the detection of low light levels with a good signal-to-noise ratio in a very small size of only a few 
millimeters thick [81, 82]. Table 1-3 provides a comparison between PMTs and SiPMs. Some of the 
key advantages of SiPM over PMT is as follows: 
• Solid-state (SiPM) vs. vacuum-tube technology 
• Higher quantum efficiency for SiPM (25% to 40% vs. up to 80%) 
• Lower operation voltage (20-40 V vs. 1-3 kV) 
• Insensitivity to the magnetic field (SiPM) 
• Miniaturization (SiPM) 
• No damage in bright light (SiPM) 
Table 1-3. Comparison of two types of photo-detectors typically used in PET: PMTs and SiPMs [83] 
 PMT SiPM 
Gain 106 ~106 
Rise time (ns) ~1 ~1 
QE at 420 nm (%) ~25 ~25 – 75 
Bias (V) >1,000 30 – 80 
Temperature sensitivity (%/° C) < 1 1 – 8 
Magnetic field sensitivity Yes No 





Time-of-flight (ToF) PET 
Theoretically, it is possible to precisely determine the location along the LOR between two detectors 
at which the annihilation photons originated. This can be done using the exact difference in the time 
at which the dual photons arrived at the pair of detectors defining the LOR. As such, for a system with 
superb timing resolution, there would be no need for reconstruction algorithms, as the point of the 
original can be identified. However, such technology is presently far-fetched. With advances in 
scintillation and detector technology, detector response time has improved as short as a few hundred 
nanoseconds; however, this is enough to only narrow down the probability of annihilation to an 
interval of a few centimeters along the LOR. This technology that utilizes the differences between the 
two detection times to somewhat localize the annihilation is called time-of-flight or ToF. Let us 
denote the difference in arrival times of the two photons by ∆𝑡. In that case, the location of the 






where 𝑐 is the speed of light at ~3×1010 cm/sec. Based on this equation, to achieve a 1 cm resolution 
requires a timing resolution of about 66 picoseconds. Nowadays, superfast electronics can handle 
such speeds, but the bottleneck is the rise time of light outputs from scintillators currently available 
for PET imaging that are too slow to provide this level of timing resolution. The fastest clinical ToF 
technology up-to-date is 214 picoseconds with the Siemens Biograph Vision [84], which narrows 
down the localization to ~3.2 cm along the LOR. Images acquired at such timing resolution, though 
not improving on the resolution, still have a significantly higher signal-to-noise ratios images 
reconstructed with no ToF information. This is because individual events can now be constrained 
within a smaller interval in the image reconstruction process, thus limiting propagation of noise in 
the projection operations within image reconstruction.  
Figure 1-3. ToF PET. A) a pair of photons from an annihilation is emitted and detected by opposing detectors. B) without ToF, 
there is no information regarding the whereabouts of the source along the LOR. During the backprojection, the event is 
backprojected with a uniform probability of originating anywhere along the LOR. C) In the presence of ToF information, some 
degree of localization is possible. 
1.2.2.3. Hybrid PET/CT and PET/MRI 
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It should be noted that since most PET systems have an axial FoV ~15-26 cm, they often image the 
whole-body using a motorized bed that can operate in the so-called step-and-shoot mode. In this 
method, the patient body is scanned for some minutes at every bed position and then is moved to the 
subsequent bed position. Newer generation PET scanners (e.g. improved crystal/electronics 
technology including improved ToF) have enabled high-quality images with scan times of ~2-4 min 
depending on the application and patient size [89]. Some recent PET scanners can also run under 
continuous bed motion acquisition mode, where the bed is continuously moving, also allowing with 
variable scan times for different parts of the body [90]. The advantage of such systems is the ability 
to customize the speed to specifically reduce the speed during the acquisition over more important 
organs to capture more incoming photons, thus improving signal-to-noise ratios.  
 
1.2.2.4. Applications of PET imaging 
PET is considered both research and clinical tool. Its main application is in clinical oncology but also 
includes applications in other clinical areas such as cardiology and neurology, in addition to 
supporting drug development and pre-clinical studies. 
One important component of a PET scan procedure is the specific radiotracer administrated to the 




Table 1-4. Examples of positron-emitting radiotracers used in PET imaging, including targets and clinical applications. 
 Isotope Compound Target Clinical application 
Oncology   
 F-18 FDG Glucose metabolism Tumor imaging 
 F-18 FMISO Hypoxic cell tracer Hypoxic tumor imaging 
 F-18 FET Amino acids Glioma  
 F-18 DCFPyL Prostate specific membrane antigen 
(PSMA) 
Prostate cancer tumors 
 C-11 Acetate Intracellular phosphatidylcholine 
membrane  
Tumor imaging 
 C-11 Choline Phospholipids synthesis Cancer cell proliferation 
 Ga-68 PSMA-11 PSMA  Prostate cancer tumors 
Cardiology   
 O-15 Water Blood flow Myocardial perfusion 
 N-13 Ammonia Blood flow Myocardial perfusion 
 Rb-82 Chloride Myocardiocytes  Myocardial perfusion 
 C-11 Acetate Myocardial oxidative metabolism Myocardial blood flow 
Neurology   
 F-18 FDOPA Pre-synaptic dopaminergic Nigrostriatal dopaminergic pathway 
 F-18 Amyvid β-amyloid neurotic plaque Diagnosis of Alzheimer’s disease 
 C-11 Raclopride  Dopamine D2 receptor Movement disorders  
 C-11 SCH23390 Dopamine D1 receptor Schizophrenia  
 C-11 NMSP Dopamine, serotonin   Neural stem cells transplant 
 O-15 Oxygen Oxygen metabolism Cerebral blood volume 
 
 
PET in oncology 
The most widely-used radiotracer in PET imaging is fluorine-18 fluorodeoxyglucose, or [18F]-FDG. 
FDG is a glucose analog taken up by the tumor cells, then phosphorylated to FDG-6 phosphate by 
hexokinase, and then trapped in the cell in almost all tissues because further downstream glycolysis 
is not possible [91]. Tumor cells require more energy than other normal cells, resulting in 
significantly higher glucose metabolism in malignant cells. As this tracer is trapped in the cell, the 
attached F-18 radionuclide decays by emitting positrons that are detected by the PET scan. [18F]-FDG 
is the staple of initial cancer staging, restaging, recurrence, and monitoring response to treatment in 
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many types of cancers and are covered by the Centers for Medicare and Medicaid Services (CMS) [92-
95].  
A range of other radiotracers is used in oncological clinical practice and research settings. Here we 
mention one very active research area in PET oncology, namely that of imaging prostate cancer 
patients using radiotracers targeting the prostate-specific membrane antigen (PSMA) molecule, 
which is a transmembrane protein that is considerably overexpressed in most prostate cancer cells 
[96]. PSMA imaging is shown to have increased sensitivity and specificity compared with current 
standard imaging with CT, MRI and bone scintigraphy in patients with primary intermediate or high 
risk of prostate cancer [97]. Just as PSMA has gained interest in molecular imaging with PET, it has 
also gained interest in targeted radioligand therapy [98]. Furthermore, new concepts have emerged 
on PSMA targeted theranostics using PSMA tagged by Ga-68 for PET imaging and by Lu-177 for 
therapy and SPECT imaging [99].  
 
PET in cardiology 
Although SPECT imaging dominates nuclear cardiology imaging, PET is also used as a clinical imaging 
tool for quantitative assessment of myocardial perfusion and characterization of tissue viability in 
patients with coronary artery disease [100]. Cardiac PET can accurately identify and assess coronary 
artery stenosis severity as a basis for choosing and following effects of interventions. PET imaging is 
not only a reliable tool for managing coronary artery disease in traditional cardiology practice based 
on symptoms but also facilitates management of asymptomatic coronary atherosclerosis non-
invasively. Such accurate evaluations can be used to identify patients who need cardiac 
catheterization and avoid unnecessary invasive procedures in patients with mild/no coronary artery 
disease [101]. Evaluating blood pool activity and perfusion defect severity, comparing myocardial 
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metabolism to perfusion, and acquiring PET imaging in conjunction with electrocardiogram (ECG) 
gating are among other PET imaging applications in nuclear cardiology [102]. 
 
PET in neurology 
PET has numerous applications in neurology and brain imaging. It can provide information to 
pinpoint and evaluate a range of brain pathologies. Certain radiotracers like O-15 oxygen and [18F]-
FDG can be used to measure brain oxygenation and metabolism, respectively, which significantly 
decrease in patients with Alzheimer’s disease [103]. Unlike surface electroencephalogram (EEG), 
depth electrocorticography, interoperative corticography, and structured MRI that lack high 
specificity in determining epilepsy, PET image can provide information about information about the 
regions of the brain that is causing seizure [104]. PET is also useful in evaluating neurodegenerative 
disease such as Huntington’s disease [105, 106], Parkinson’s disease [107, 108], Alzheimer’s disease 
[109-112], and multiple sclerosis [113, 114]. It is also used in neuropsychology and cognitive 
neuroscience to explore links between specific psychological processes or disorders, and the brain 
activity [115, 116].  
 
Dynamic PET  
Current clinical PET protocols use patterns established for traditional nuclear medicine, where they 
are optimized for qualitative as opposed to quantitative assessment. The radiotracer is administered 
to the patient who then waits for a period prior to image acquisition, which in the case of [18F]-FDG 
is ~60 minutes. This period allows the radiotracer to accumulate in the organs of interest and to 
washout from surrounding organs [117]. Then the patient is imaged on the PET scanner based on 
protocol (e.g. 20 minutes depending on center, scanner, and patient), as a result, a single static image 
is acquired during this acquisition time. However, radiotracer distribution in the body is a dynamic 
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process that is essentially different for normal organs, different tumors, and among different patients 
[118, 119]. An alternative approach involves the dynamic acquisition of temporal images that enables 
a more complete measurement of tracer kinetics between different physically or chemically-distinct 
states or compartments. The exchange of tracer between compartments can be modeled using 
ordinary differential equations, whose coefficients are kinetic parameters. These resulting kinetic 
parameters and models have been validated to produce reliable quantitative measurements of 
various clinically important physiological processes [120-122].  
An example of a widely-popular compartmental method is the Patlak model [123]. This graphical 
analysis method evaluates sequential data such as tissue and blood concentrations over time. It uses 
linear regression to analyze pharmacokinetics of tracers such as [18F]-FDG [124]. This method 
assumes that the tracer can be modeled as having by a nearly irreversible compartment where the 
radiotracer enters and gets trapped during the measurement [125]. Patlak linear graphical analysis 
directly estimates the tracer influx or uptake rate constant 𝐾𝑖  and blood distribution volume 𝑉, which 
when quantified at the individual voxel-level enable parametric imaging. Assuming reversible 
dynamics only, alternative non-Patlak graphical methods can be used  (e.g. Logan method [126]). 
Dynamic imaging and kinetic modeling can provide more accurate quantitation of the tracer relative 
to conventional standard uptake value (SUV) in PET imaging, as discussed in 1.3.2.1. Figure 1-4 shows 
an example co ofnventional SUV image vs. parametric images obtained from kinetic modeling of 
dynamic images of a patient scanned with [18F]-FDG PET. The Patlak 𝐾𝑖  image has significantly 
reduced background uptake compared to conventional SUV, while high background PET signals are 




Figure 1-4. An illustration of static and dynamic PET. A) static conventional SUV imaging (70-90 minutes post-FDG injection). 
Dynamic (parametric) images (0-90 minutes) of b) 𝐾𝑖 , and c)𝑉, generated from a dynamic whole-body PET scan using Patlak 
plot with an image-derived input function and linear regression. Note the tumor uptake marked with a purple arrow on top of 
the liver that is notably visible in “b” but has dissolved in the background uptake in “a”.  
Parametric kinetic uptake imaging has implications in various sectors of clinical practice. Dynamic 
cardiac PET followed by kinetic modeling has significant applications in the clinic [127]. In oncologic 
PET, dynamic imaging and trace uptake quantification based on compartmental modeling has been 
shown to improve tumor characterization and treatment response monitoring [128-133]. In the past, 
dynamic imaging was mostly limited to a single bed position over the organ of the interest, but 
recently whole-body parametric imaging protocols have been introduced [134, 135], which refers to 
coverage of the body using multiple bed positions [136] or using the continuous bed motion 
technique [137], both involving multiple passes. The patient is sometimes injected with the 
radiotracer right on the scanner bed to capture the blood input function over the heart and can be 
scanned up to 95 minutes based on different imaging protocols [138]. Alternatively, population-
based input functions can be used, and scaled for the specific patient. Dynamic whole-body PET is an 
emerging technology with promising clinical potential, specifically for improved quantification and 
assessment of systemic disease, including cancer, inflammation, and infection[138]. It combines 
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visualization and tracer uptake quantitation across the whole body, while minimizing dependence 
on SUV activity. It removes background uptake that allows small and less FDG avid tumors to be 
identified. In addition, conventional SUV image can be readily obtained by summation of multiple 
passes through the patient [138]. For more clinical applications of dynamic whole-body imaging, its 
advantages and challenges please refer to [138].  
 
1.2.3. Tomographic image reconstruction  
1.2.3.1. Image reconstruction basics  
In this subsection, we discuss the basics of tomographic image reconstruction. Our focus is on PET 
imaging, but application to SPECT is very straightforward. First, we elaborate on the line-integral 
model. Without considering some degradation effects such as attenuation, scatter and randoms, 
detector deficiency, etc. that will be discussed in section 1.2.4, the total number of detected 
coincidences is related to the total amount of tracer contained in the volume or line of response 
(LOR), a tube that joins two face-to-face detectors. In what follows, we will discuss the 2D 
tomographic reconstruction. For more information regarding 3D PET reconstruction please consult 
[53, 54, 139].  
2D PET imaging only considers LORs lying within a specific imaging plane from a 2D object 𝑓(𝑥, 𝑦) 
as indicated in Figure 1-5. Values of 𝑝(𝑠, 𝜙) are the line integral of the object across the LOR for a 
fixed 𝜙. The collection of all projections for 0 ≤ 𝜙 ≤ 2𝜋 creates a 2D map of 𝑠 and 𝜙, referred to as a 
sinogram (Figure 1-5). The name “sinogram” comes from the fact that if there is a point-source in the 
object, it will create a sinusoidal trend on the sinogram.  
Figure 1-5. A projection  is generated from integration along all parallel LORs at an angle . The projections from all 







Images of radiotracer activity concentration can be reconstructed from the projection data by solving 
the inverse of equation 1.5. Image reconstruction algorithms can be categorized into 1) analytical and 
2) statistical reconstruction methods. The focus in this dissertation is on statistical image 
reconstruction which we discuss next; for details on analytical reconstruction methods such as the 
Fourier slice theorem and filtered back-projection, readers are referred to other references [53, 54].  
1.2.3.2. Statistical image reconstruction 
Maximum-likelihood expectation-minimization (ML-EM) 
Statistical image reconstruction has demonstrated superior performance over analytical methods 
[140]. Statistical methods allow (i) accurate modeling of statistical noise, (ii) complex detector 
geometrics, as well as (iii) the ability to include corrections for various image degradation effects 
(section 1.2.4) [141, 142]. Here we briefly discuss the mathematics of image reconstruction in PET 
[143]. 
Let 𝑌𝑖 , 𝑖 = {1, … , 𝑀} denote the projection data as elements of the sinogram matrix, where 𝑀 is the 
number of sinogram bins. Each 𝑌𝑖  can then be modeled as an independent Poisson random variable: 
𝑌𝑖~Poisson{𝑦?̅?} 1.6 
Let 𝒚 = [𝑦1 𝑦2 ⋯ 𝑦𝑀]𝑇 and ?̅? = [𝑦1̅̅ ̅ 𝑦2̅̅ ̅ ⋯ 𝑦𝑀̅̅ ̅̅ ]𝑇  denote column vectors of the measured and 
expected counts, respectively. The expected counts are related to the unknown activity distribution 
𝒙 ∈ ℝ𝑁 by an affine transform: 
?̅? = 𝑷𝒙 + 𝒓 1.7 
where 𝑷 ∈ ℝ𝑀×𝑁denotes the detection probability matrix, or the forward projection operator with 
each element (𝑖, 𝑗) referring to the probability of detecting an event from the 𝑗th voxel at the 𝑖th 
detector pair, and  𝒓 ∈ ℝ𝑀 is the contributions of scatter and random events in the projection data 
(see section 1.2.4). Now, the log-likelihood function for the Poisson distributed projection data can 
be written as: 
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The image reconstruction task can be framed as an optimization problem and can be solved using the 
maximum-likelihood expectation-minimization (ML-EM) [144, 145]. The ML-EM has been proven to 
converge, and in addition, it incorporates a non-negativity constraint such that if the initial estimate 
is non-negative, image estimates at every iteration are non-negative. The inverse problem or the 
maximum likelihood estimate can be then written as: 








where 𝒙𝑛 is the image estimate at the 𝑛th iteration, 𝑷𝑇  is the backprojection operator, and 𝐼𝑀 is a 
column vector of ones.  
An accelerated version of ML-EM algorithm is called the ordinary-subset expectation-minimization 
(OS-EM) algorithm [146]. It divides the projection data into subsets and uses those subsets to 
iteratively update the estimation image. The number of OS-EM subsets are approximately equal to 
its speed-up factor. However, unlike ML-EM, OS-EM is not necessarily convergent, though some 
subsidized algorithms have been proposed that can converge [147, 148].  
Noise in statistical reconstruction  
Tomographic reconstruction is an ill-posed problem, and the ML estimates are extremely noisy. The 
convergence property of ML-EM is for its noise-free implementation, which is quite unrealistic. In 
practice, noise contributes to the detected counts. Moreover, as the number of ML-EM (or OS-EM) 
iterations increase, the impact of noise on the reconstructed images are more pronounced. That is 
why in practical implementations of ML-EM, the number of iterations is fixed somewhere around 60 
to 80 updates, which for instance, correspond to 3 to 4 iterations with ~20 OS-EM subsets. 
Furthermore, the noise will be further reduced by post-smoothing the image with a Gaussian filter.  
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Other methods have been proposed to regularize noise to obtain more accurate estimates of activity 
distributions, such as using a penalized likelihood function [149, 150], where instead of maximizing 
the log-likelihood function, a penalized log-likelihood function is maximized that encourages smooth 
solutions with a penalty function and a tuning parameter (hyperparameter) 𝛽 to control the 
contribution of the penalty function and the resolution-noise properties of image estimates [151-
153]. Although penalized (also known as Bayesian) reconstruction has recently become available on 
commercial PET scans [154], the hyperparameter 𝛽 can pose a challenge since it may have to be finely 
tuned for different patients/radiotracer/reconstruction settings.  The penalty function is obtained by 
incorporating a priori distribution on the estimated image; i.e. 𝑝(𝑥) =
1
𝑍
𝑒−𝛽𝑅(𝑥), where 𝑍 is a 
normalizing constant, and 𝑅(𝑥) is a penalty function. The penalized log-likelihood is also called 
maximum a posteriori or MAP estimate [155-158].  
 
1.2.4. Causes of image degradation and quantitative inaccuracy in nuclear medicine  
The relationship between the object and the projection space can be defined by a system matrix, 
which is the detection probability matrix 𝑷 introduced in equation 1.7. Statistical reconstruction 
methods allow modeling of physical degradation factors which will be presented in the next section 
in the reconstruction framework. The system matrix can be factorized as [159]: 
𝑷 =  𝑷𝑑𝑒𝑡.𝑠𝑒𝑛𝑠𝑷𝑟𝑒𝑠.𝑏𝑙𝑢𝑟𝑷𝑎𝑡𝑡𝑛𝑷𝑔𝑒𝑜𝑚𝑷𝑝𝑜𝑠𝑖𝑡𝑟𝑜𝑛 1.11 
where 𝑷𝑝𝑜𝑠𝑖𝑡𝑟𝑜𝑛 models positron range in the image space, 𝑷𝑔𝑒𝑜𝑚 is the detection probability matrix, 
𝑷𝑎𝑡𝑡𝑛 is a diagonal matrix of attenuation correction factors, 𝑷𝑟𝑒𝑠.𝑏𝑙𝑢𝑟 accounts for phenomena that 
result in resolution blur, and finally 𝑷𝑑𝑒𝑡.𝑠𝑒𝑛𝑠 is a diagonal matrix containing detector block 
normalization factors. We elaborate more on these degradation factors in the subsequent section. 
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PET imaging is impacted by several physical phenomena that result in degradation in image quality 
and quantitation. It is important to understand these phenomena to develop correction methods to 
restore the quality of the image to a better extent. Some of the most important factors are: 
1) Attenuation of annihilation photons 
2) Detection of scattered events 
3) Detection of random events 
4) Positron range effect 
5) Photon non-collinearity 
6) Detection deadtime  
7) Detector blurring  
8) Variations in detector sensitivity 
9) Decay of radioactivity 
10) Geometric correction 
11) Patient motion 
From the above list, items 2, 4, 5, 10, and 11 are specific to PET, while others are common between 
PET and SPECT. Corrections for detector blurring, positron range, and photon non-collinearity have 
been traditionally ignored because of the inherent low resolution of the PET camera. However, with 
the advent of higher-resolution scanners, it has become more important to account for these factors 
in the reconstruction task.  Compared to SPECT imaging, attenuation fractions are larger in PET, but 
their corrections are easier. Meanwhile, detection of scattered evens is much more prevalent in 3D 
PET and complicates quantitative reconstruction using PET.  
Before we discuss these phenomena, we need a clear understanding of a true event. This is similar in 
both PET and SPECT, though we explain it from the perspective of PET. As mentioned in section 1.2.2, 
once a positron annihilates, it produces two anti-parallel gamma-ray photons. In a degradation-free 
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system, these photons will travel in straight lines (along a LOR) towards the detectors and fall within 
the coincidence time window. Such an annihilation event that has not been diverted from its LOR and 
has arrived within the coincidence time window is called a true event. In the following subsections, 
we discuss the various phenomena and briefly review some of the related correction techniques. 
Later in this dissertation, we model a number of these phenomena and present a novel method for 
their correction in chapter 2: Adaptive Point-Spread Function (PSF) Modeling for Enhanced 
Quantitation in PET Image Reconstruction.  
 
1.2.4.1. Attenuation  
Gamma-rays interact with matter as they travel through a medium, through photoelectric absorption, 
or Compton scattering. Photoelectric absorption is the dominant photon-matter interaction in tissue 
for photon energies below 100 keV. On the other hand, Compton scattering is more dominant for 
photon energies between 100 keV and 2 MeV [53], and is the only important interaction process at 
511 keV within subjects. As discussed in section 1.2.1, in a Compton interaction, the photon interacts 
with a free or outer-shell electron, causing a decrease in the energy of the photon and a change in its 








where 𝐸0 is the energy of the gamma photon before interaction and 𝜃 is the angle of scattering. This 
phenomenon can cause the scattered photon to be deflected out of the FoV so as (i) it is not detected, 
or (ii) it arrives at another detector and is detected by it. Either of these cases results in a loss of the 
true LOR. This phenomenon is referred to as attenuation. Attenuation correction should be 
incorporated in the image reconstruction process to avoid underestimation of the radiotracer 
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distribution. Defining the survival probability 𝐴𝑎 as the probability of a photon not interacting as it 
propagates along a path 𝑎, the Beer-Lambert law, or simply Beer’s law says: 
𝐴𝑎 =  𝑒
− ∫ 𝜇(𝑥) 𝑑𝑥𝑎  1.13 
where 𝜇(𝑥) is the linear attenuation coefficient of the medium photon is traveling in. Linear 
attenuation coefficient provides insights on how effective a given material is in promoting photon 
interactions at position 𝑥 per unit thickness. It increases with higher matter densities and decreases 
with higher photon energies. Subsequently, the probability of attenuation often called attenuation 
factor (AF) is given by 1 − 𝐴𝑎, which is the probability that a photon travels through a medium 
without interacting with matter. 
The survival probability of photons along a LOR is the product of the probabilities of each photon not 
interacting as they propagate along their paths 𝑎 and 𝑏: 
𝐴𝐿 =  𝑒
− ∫ 𝜇(𝑥) 𝑑𝑥𝑎 × 𝑒− ∫ 𝜇(𝑥) 𝑑𝑥𝑏 =  𝑒− ∫ 𝜇(𝑥) 𝑑𝑥𝐿  1.14 
where 𝐿 refers to the union of 𝑎 and 𝑏, or the entire LOR. In PET imaging, more than 60% of all emitted 
photons interact with tissue; however, equation 1.14 shows that attenuation along a LOR in PET is 
independent of the position of the annihilation event along the LOR. This contrasts with SPECT where 
attenuation is depth-dependent on the distance to the detector. This key observation result in more 
straightforward attenuation correction in PET compared to SPECT.  
Nowadays the most widely-used method of attenuation correction involves the use of the CT image, 
a key motivation behind PET/CT and SPECT/CT scanners. The CT component of the system can 
quickly acquire an image of the body, with its voxel intensities corresponding to the attenuation 
coefficients of that location in the body. Historically, PET-only scanners used a transmission scan for 
attenuation correction, which would rotate a radioactive source around the patient inside the 
detector gantry and acquire the image without and with the object inside the FoV. Then the ratio 
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between these two scans along each LOR was a measure of the probability that the generated 
annihilation photons are not attenuated along each LOR. This method was much more time 
consuming than CT, and its quality was inferior to a CT image in terms of statistics. Examples non-
attenuation-corrected (NAC) attenuation-corrected (AC) PET images are depicted in Figure 1-6. The 
CT image in (C) is used to correct the PET image shown in part B, and the image is usually displayed 
as a fused form of CT and AC PET, as shown in (D), to be able to anatomically localize the PET uptake 
using CT. Part A of this figure demonstrates some common artifacts encountered because of 
attenuation: unusually-high uptake can be seen on the skin, and the general uptake decreases as we 
track the image from the skin towards the inner parts of the body. By contrast, in the AC PET image, 
high skin uptake is gone, and inner-body uptake is more uniform.  
 
Figure 1-6. Effect of attenuation correction in PET imaging. A) Non-attenuation-corrected (NAC) PET image, B) Attenuation-
corrected (AC) image using C) CT image acquired with the PET/CT. D) A fused attenuation-corrected and CT image together.   
One point to remember is that the energy level of the photons generated by the x-ray tube of the CT 
component is of the order of 40~140 keV, which is less than 511 keV of the annihilation gamma-rays 
[160]. As previously mentioned, the linear attenuation coefficient is dependent on the energy level of 
the photon in the medium. Therefore, some corrections are required to convert the linear attenuation 
correction of the image from the CT scan to those that would be obtained at 511 keV [160, 161], 
posing some challenges. More discussion about attenuation correction in PET/CT and PET/MRI 
systems was provided in section 1.2.2.3. 
1.2.4.2. Scattered events 




comparisons of 2D and 3D distributions [166], or direct calculation of scattering distribution using 
the Klein-Nishina equation [167, 168], the latter being the most commonly invoked. 
 
1.2.4.3. Random events 
A random event occurs when two gamma-rays originating from two distinct annihilation events are 
detected within the coincident time window. To understand this, note that only a ‘single event’ can 
be detected from two anti-parallel photons corresponding to a given annihilation. As such, a random 
event occurs when two independent single events occur within a coincidence time window. Random 
events cause localization of an annihilation event along an incorrect LOR. Single events occur because 
of one of the following reasons: 
1) One gamma-ray photon is attenuated (due to photoelectric absorption or scattering) and is 
not detected 
2) One photon passes through the detectors without being detected 
3) One photon does not arrive at the detector at all due to the location and direction of the 
originally emitted gamma-rays 
These are depicted in Figure 1-8. The rate of random events along a LOR connecting detectors 𝑖 and 
𝑗 is given by: 
𝑅𝜏 = 2𝜏𝑆𝑖𝑆𝑗  1.15 
where 𝜏 is the coincidence time windows, and 𝑆𝑖  and 𝑆𝑗 refer to the single event rates at the two 
detectors. From the above equation, one may infer that 1) reducing the coincidence time windows 
results in reduced random coincidences, and 2) since single rates are proportional to the activity in 
the subject, random rates are quadratically proportional to the activity. This implies that higher 
Figure 1-8. Examples of single events that may contribute to random events. A) one photon never gets to the detectors due to 
photoelectric absorption or scattering. B) one photon passes through detectors without being detected. C) One photon does not 
meet detectors due to the orientation of the annihilation. The detection of the two single events, like in “A”, that happens within 
the coincidence time window, results in a random event. 
1.2.4.4. Positron range effect 
Figure 1-9. Positron range effect. The emitted positron travels a distance and reduces its kinetic energy to thermal energy and 
annihilate upon meeting an electron. The detected LOR does not necessarily pass through the location where positron was 
emitted.  
1.2.4.5. Photon non-collinearity 
Figure 1-10. Photon non-collinearity effect. A slight deviation of two gamma-rays from 180° results in detecting the incidence 
from an incorrect LOR (dashed red) instead of the true LOR (dashed green).  
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1.2.4.6. Detection deadtime 
Deadtime refers to the time it takes to process an event, and it limits the counting rate of the scanner. 
As the incoming count rate increases, e.g. due to the higher dose of radioactivity injected to the 
subject, a larger portion of the incoming counts are lost due to deadtime effects. As such, this is 
another condition that limits the injected radioactivity to a patient for optimal imaging. The 
bottlenecks that contribute to deadtime can be the scintillator decay time, crystal identification, 
energy discrimination, overall coincidence detection, or delays in electronics. Therefore, deadtime 
effects can occur at the level of the crystal, block or the subsequent electronic circuitry. Deadtime can 
be corrected by scaling the measured counts by deadtime correction factors measured from the 
single rates [53].  
 
1.2.4.7. Detector blurring 
An incoming photon to a crystal excites electrons in the crystal by Compton scattering and/or 
photoelectric absorption. If all these processes occur in a single crystal where the phone had entered, 
the event and subsequently the LOR will be properly positioned. However, three complications may 
happen: 
Inter-crystal penetration  
 The first issue is when the incident photon enters a crystal at an oblique angle, passing through the 
crystal undetected and only detected in the adjacent crystal. This is referred to as inter-crystal 
penetration, and results in a mispositioned LOR. Subsequently, as the annihilation event originates at 
a distance from the center of the FoV and closer to the edges of the scanner, photons enter the 
detector at a higher angle, with a higher likelihood of penetration. This results in the so-called depth 
of interaction effect (elaborated more later) and manifests itself in the reconstructed images as the 
Inter-crystal scattering 
inter-crystal scattering
Figure 1-11. Detector blurring effects. A) inter-crystal penetration, where the photon penetrates the adjacent crystal where it 
gets detected and causes a mispositioned LOR. B) inter-crystal scattering, where the scattering scintillation light gets detected 
on the other end of the crystal at an adjacent detector, causing a mispositioned LOR. 
Depth of interaction 
depth of interaction
Figure 1-12. The depth of interaction effect. It lowers the resolution for incidents occurs farther from the center of the FoV.  
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This equation shows that the depth of interaction is described by a multiplicative factor applied to 
detector resolution at a midpoint between a pair of directly opposing detectors. For a typical PET 
scanner with 𝑥 around 2 to 3 cm, 𝑑 around 0.3 to 0.6 cm, and a diameter of 80 cm, the DOI effect 
causes around 40% less resolution degradation at 10 cm away from the center of the FoV [53]. 
Some PET scanners such as the high-resolution research tomograph (HRRT) [179] handle DOI effect 
through a method called DOI-encoding. In DOI-encoding used in HRRT scanners, the crystal block 
comprises of a double scintillator crystal layer that provides some discrete level of DOI information 
and minimizes the misplacement of LORs [180]. 
 
1.2.4.8. Variations in detector sensitivity 
The various detectors in a PET (or SPECT) camera may have variations in their efficiencies, which 
are determined by several factors including (i) the cross-section or effective surface area of the 
crystal, (ii) the change in the effective depth-of-interaction of crystals, (iii) crystal material 
imperfections, (iv) light guide (i.e. isolation between crystals) variations and imperfections, (v) PMT 
gain inconsistencies, and (vi) further inconsistencies in electronics to detect PMT signals. To correct 
for detector variations, usually a positron-emitting germanium cylindrical phantom with uniform 
activity is scanned by the PET scanner for a long period during the quality check (QC) process. In this 
case, all detectors presumably should have uniform inputs. This scan is called a normalization scan 
that produces a normalization sinogram, which provides coefficients that are proportional to the 
reciprocal of the number of counts obtained for each LOR. More details are provided in other 
references [181-184]. An example of a normalization sinogram is provided in Figure 1-13. 
Figure 1-13. An example of a normalization sinogram for a 2D transaxial slice of a GE discovery PET scanner.  
1.2.4.9. Decay of radioactivity 
1.2.4.10. Geometric correction 
41 
 
1.2.4.11. Patient motion 
Today’s PET scanners have a spatial resolution of 3.5 to 6 mm FWHM. With such improvements in 
spatial resolution, patient movement during the scan can become more apparent and contribute 
more to image quality degradation. In a very general sense, patient motion can be categorized into: 
motion due to the movements of the lungs (respiratory motion), movements due to heart functioning 
(cardiac motion), and other unintentional or intentional patient body movements (bulk motion). 
Motion correction in PET has been a large field of research for decades and is beyond the scope of 
our work.  For more information please refer to review articles [186-193] 
  
1.3. Medical Imaging Quantitation and Biomarkers 
Modern medical imaging modalities have experienced tremendous progress and can provide an 
unprecedented level of spatial details and cellular/functional information [194]. At the same time, 
there have been advancements in our understanding of the molecular underpinnings of disease and 
the rise of more statistical and evidence-based approaches to diagnosis and treatment. This has 
paved the way to leverage quantitative techniques in medical imaging for supporting a diverse set of 
clinical and research goals [195, 196]. In this section, we explain the basics of image quantitation, 
following by quantitative imaging biomarkers, and we briefly discuss one of the commonly-used 
quantitative imaging biomarkers in PET.  
1.3.1. Image quantitation 
Quantitative imaging refers to the extraction and utilization of quantifiable features from medical 
images for assessment of normality or the severity, degree of change, and status of a disease relative 
to normal conditions [197, 198]. Research in quantitative imaging includes the development, 
optimization, standardization, and application of anatomical, molecular and functional imaging 
acquisition protocols, structured reports, data analyses, and validation against other clinical data 
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[198, 199]. The concept of medical imaging quantitation is relatively close to the definition of 
biomarkers, defined as a characteristic objectively-measured and evaluated, which indicates a 
normal biologic or pathologic process, or response to a therapy [200]. Subsequently, a quantitative 
imaging biomarker can be defined as an objectively-measured characteristic derived from a medical 
image and can be correlated with relevant physiological and anatomical parameters such as disease 
presence, characterization, and severity, as well as its prognosis (predicted disease course with or 
without treatment), and treatment response monitoring and assessment [197]. More relevant 
definitions to quantitative imaging biomarker development are provided in Table 1.  
Table 1-5. Definitions related to quantitative imaging and biomarkers [197, 198, 201] 
Term  Definition  
biomarker A characteristic that is objectively measured and evaluated as an 
indicator of normal biologic or pathogenic processes, or response to a 
therapeutic intervention 
Predictive biomarker A biomarker that is used to forecast the efficacy of a therapy/therapies  
Diagnostic biomarker A biomarker that improves the accuracy of patient diagnosis 
Prognosis biomarker A biomarker that improves the accuracy of patient prognosis 
Response biomarker A biomarker whose change after treatment predicts if treatment would 
lead to a beneficial outcome 
Monitoring 
biomarker 
A biomarker that (usually) is regularly measured to detect relapse or 
emergence of toxicity 
Quantitative imaging The extraction and utilization of various quantitative features, such as 
numerical and statistical, from medical images 
Quantitative imaging 
biomarker 
An objectively-measured characteristic derived from an in vivo image as 
an indicator of a normal biological or pathogenic process, or a response 
to a treatment  
Repeatability  The amount of agreement between subsequent measurements 
measured under the same condition 
Reproducibility  The amount of agreement between subsequent measurements 
performed under varying conditions 
 
 
Quantitative imaging has significantly contributed to the value of diagnostic testing and become more 
prominent in preclinical studies, clinical practice and clinical research [202-206]. The main 
advantage of quantitative imaging is its potential for standardization and higher precision of image 
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interpretation. It further helps with increased diagnostic accuracy, improved reproducibility across 
multiple devices/centers, decreased variability and subjectivity, more structured reporting, and 
more robust association of image findings with clinical and biological data [207]. Evidence-based 
medicine is also another driver for developing quantitative imaging as diagnoses in many clinical 
fronts can be reinforced with quantitative imaging data and biomarkers [208, 209]. Clinical trials are 
another demanding area for quantitative imaging, in which quantitative measurements of tumor 
response are measured and reported to assess the efficacy of investigational therapy. Another long-
term stipulated utilization of quantitative data has been in guidelines for image-based response 
assessment such as response evaluation criteria in solid tumors (RECIST) [210], that is based on the 
measurement of tumor size and frequently used for response assessment in oncology, and have been 
widely used for many years and successfully validated against long-term patient outcomes [211, 
212].  
 
1.3.2. Quantitative imaging biomarkers  
Biomarkers are useful only if they provide added value in predicting a clinical outcome [198]. These 
biomarkers can be derived via methods as simple as using calipers (e.g. to measure the length), or a 
complex measurement of a functional parameter associated with a dynamic relationship of image 
measurements to an external stimulus. Quantitative imaging biomarkers can be generally classified 
as structural, morphological, textural, functional or physical [213]. Nevertheless, there are factors 
that can inherently affect the measuring of quantitative imaging biomarkers and thus reducing their 
reliability, repeatability, and reproducibility, which need to be properly addressed and investigated. 
More information regarding necessary attributes of biomarkers, as well as methods for assessing 
these attributes (e.g. reproducibility) are discussed later (section 3.2.1). As an example, the next 
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subsection 1.3.2.1 discusses a very important and widely popular quantitative image biomarker in 
nuclear medicine imaging. Another set of biomarkers will be introduced in subsequent section 1.4.  
1.3.2.1. Standard Uptake Value (SUV)—an important quantitative biomarker 
A well-known example of a quantitative imaging biomarker is the standard uptake value (SUV) in 
PET imaging with 2-deoxy-2-(18F)fluoro-D-glucose or fludeoxyglucose F-18, also known as [18F]-FDG, 
for oncologic imaging. Increased accumulation of FDG in tumors relative to normal tissue is shown 
to be a useful marker for detection and staging in many cancers [214]. Moreover, since changes in 
FDG accumulation have been shown to provide useful information for assessing response to a 
therapy, SUV is also being used for monitoring individual treatment response as well as an evaluation 
tool for new drugs and therapies [215]. In PET scanners, the in vivo radioactivity concentration is 
quantified (e.g. in kBq/ml or mCi/cc). The tissue uptake varies between patients due to different 







where 𝑐(𝑡) is the radioactivity activity concentration [kBq/ml] measured by PET for a region of 
interest (ROI) at time 𝑡 and is decay-corrected to 𝑡 = 0, 𝐼 is the injected dose [kBq] to the patient at 
time 𝑡 = 0, and 𝐵𝑊 is the body weight [g] of the patient at the time of the imaging. If all injected SUV 
is retained in the body and evenly distributed, the SUV everywhere in the body would be 1g/ml 
regardless of patient size and injected dose. If we assume 1 ml of tissue weighs 1 gram, then SUV 
would be dimensionless.  
Many parameters can affect the numerator of the SUV equation such as the definition of the ROI and 
its size, image resolution, reconstruction settings, and uptake period [216]. Concerns regarding its 
normalization factors in the denominator are mainly regarding using BW vs. body surface area vs. 
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lean body mass [119, 217], and BW is sometimes substituted by the other two. This is because if SUV 
is only corrected for BW, it does not consider the relatively lower FDG accumulation in fatty tissues 
in the fasting state. Subsequently, SUV corrected for lean body mass would be a more effective 
quantitative biomarker than BW or body surface area especially for obese patients [119, 218]. There 
are different formulas in the literature for estimating a patient’s lean body mass that usually differs 
for men vs. women [219], as well as international guidelines for standardizing the entire process of 
image acquisition in SUV parameters [220]. Following RECIST criteria, a PET-based assessment 
method was introduced, namely the PET Response Criteria in Solid Tumors (PERCIST), which can 
include quantification of maximum SUV in an ROI called SUVmax, or the average SUV in a 1cc sphere  
moved around the tumor until it is maximized, referred to as SUVpeak [204]. In any case, from this 
discussion, we can clearly identify SUV as an important quantitative imaging biomarker in oncologic 
PET imaging.  
 
1.4. Towards personalized medicine with radiomics 
This section introduces the topic of personalized medicine, following the emerging topic of radiomics 
and its applications. Personalized medicine aims at tailoring therapy to each individual for the best 
response and highest safety margin to ensure better patient care (Figure 1-14) [221]. It paves the 
way for each patient to receive an earlier diagnosis and optimal treatment customized to one’s 
specific clinical/molecular/genomic profile that ultimately improves healthcare and lowers costs. 
Personalized medicine is an innovative approach that takes into account a vast spectrum of data – 
from pharmacogenetic and pharmacogenomics information and protein-based biological markers, to 
molecular and anatomical diagnosis and response and targeted therapies, to family history, 
environment, and lifestyle – in order to achieve tailored decisions for individual patients [222-224].  
Figure 1-14. An illustration of standard care vs. precision medicine. In the former approach, all patients undergo the same 
process/treatment, whereas in precision medicine, a subgroup of patients receive tailored care optimized to their 
clinical/molecular/genomics profile.  
describing
Figure 1-15. Imaging and ‘omics’ in various levels of biological studies 
1.4.1. Personalized medicine in oncology  
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becoming more ubiquitous, it is possible to collect, process and analyze large volumes of high-
dimensional patient-specific data that eventually propels the progress in personalized medicine in 
oncology that aims to improve cancer prevention and prognosis.  
Personalized medicine in oncology aims to customize cancer care, such that cancer can be detected 
in very early stages, or the success of preventive and therapeutic interventions maximizes with 
minimum side-effects. Most research in this area focuses on lower-level personalized medicine using 
genomics and proteomics approaches to characterize tumors, which is invasive and requires 
biopsies. Such studies have enabled the identification and validation of many genes that are cancer-
drivers that can cause malignancy in a model system [236]. Despite all these successful efforts, the 
proper realization of personalized medicine in oncology is still limited. One contributing factor is that 
tumors exhibit diverse spatial and temporal heterogeneity, both within (intra-) and between (inter-
) tumors, causing intra- and inter-tumor heterogeneity [237]. Such inter- and intra-tumor 
heterogeneities are likely to cause phenotypic variations that ultimately affect treatment response 
and resistance. Moreover, heterogeneity can be observed over the course of cancer progression in 
different pattern changes, from initiation to metastases, and even relapse after surgery or other 
therapies [238]. For example, Hatt et al. studied PET and CT images of patients with lung cancer and 
showed that tumors with more non-uniformity, i.e. more heterogeneous tumors, are more resilient 
to therapy compared to more uniform tumors [239] (Figure 1-16). These spatial and temporal 
(longitudinal) intra-tumor heterogeneity assessments require multiple biopsies, which adds to the 
patient’s burden due to their invasiveness. As such, this necessitates the development of non-invasive 
approaches for profiling tumor phenotypes.  




Figure 1-17. PET images of four patients with head and neck cancer with their primary tumors delineated by a nuclear medicine 
physician (maroon line). Based on conventional quantitative imaging, all these tumors have almost the same SUVmax. the right 
three ROIs have almost the same volume, too. But does it mean that all these four patients have the same diagnosis and need 
the same therapy, or can we derive more information about the tumor phenotypes from these images? That’s where radiomics 
comes into play. 
1.4.2. Radiomics 
Radiomics transforms digitally encrypted medical images that contain information regarding tumor 
pathophysiology into mineable high-dimensional data [228, 241]. In other words, it hypothesizes 
that different phenotypic characteristics of tumors such as intra- and inter-tumor heterogeneity can 
be quantified as features called “radiomic features” through advanced image processing and 
computer vision techniques [228]. The information is harnessed through image processing and 
quantitative image analyses [242] and can be leveraged via clinical decision support systems to 
improve decision making and personalized medicine [243]. Radiomics can extract a massive amount 
of data from medical images of different modalities (CT, MRI, PET, etc.) to uncover advanced 
underlying features that non-invasively characterize tumor through data analysis. It aims to identify 
new reproducible and repeatable quantitative image biomarkers for disease staging, predicting 
tumor response, therapy assessment, and understanding tumor evaluation and its intrinsic biology. 
Ultimately, radiomics may pave the way for personalized medicine in different areas of clinical 
practice and provide clinicians with crucial information to guide their clinical decisions.   
   
1.4.3. Applications of Radiomics  
The term “radiomics” was introduced in 2011 (though related research was pursued prior to it, the 
term and field were better crystallized later). Radiomics has witnessed significant interest from 
Figure 1-18. The number of published articles about Radiomics shows an increase in interest 
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1.4.3.1. Oncology  
The majority of radiomics research has been performed for oncology. Radiomics is able (to some 
extent) to predict tumor characteristics such as histology [252] and genetic footprint [253-255], in 
addition to response to therapy in the form of pathological response from primary tumor [256, 257], 
lymphadenopathy [258], response to chemotherapy [259], response to chemo-radiotherapy [260], 
recurrence [261, 262], lymph node involvement [263], distant metastasis [264-266], and survival 
[267, 268] for a spectrum of pathologies. Many studies have demonstrated strong prognostic powers 
of radiomics in CT [265, 269-271], MRI [272-275], PET [247, 276, 277], as well as multiparametric 
imaging [278, 279]. In terms of clinical outcome, some studies have demonstrated the discriminating 
capability of radiomics for stratification of tumor stages [280], tumor histology [281], and other 
clinical outcomes [282]. 
1.4.3.2. Non-oncological applications 
Application of radiomics is not limited to oncologic imaging. In neurology, radiomics has been used 
in Alzheimer’s disease [283], [284-287], multiple sclerosis [288, 289], autism [290], as well as some 
publications from our group in using radiomics for correlating brain DaTSCAN SPECT with motor 
function in Parkinson’s disease patients [291, 292]. We have also developed radiomics analysis of 
cardiac SPECT imaging [293, 294] which this dissertation especially elaborates. Radiomics has also 
been recently studied for immunotherapy [295]. It has also been utilized in assessing radiation injury 
in patients post-radiotherapy [296-298]. 
1.4.3.3. Combination of radiomics and other “-omics” 
Following the emergence of “omics” research and the promising results, researchers have started to 
look beyond a particular modality and combine “omics” for more accurate outcome analysis and new 
applications. In light of this interdisciplinary research, radiomics has been mostly studied in 
combination with genomics and termed “radiogenomics” [230]. It is expected that such combinations 
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may notably contribute to the realization of personalized medicine [299]. Lung cancer has been a 
prominent area in radiogenomics research, due to its prevalence, an abundance of imaging data 
especially from CT, as well as publicly available datasets such as the national lung screening trial 
[300]. Many groups have studied using radiogenomics for diagnosis, prognosis, and predicting 
optimal therapy in lung cancer (see review article [248]). We have also participated in radiogenomics 
research with external collaborators where we used radiogenomics to predict EGFR and KRAS 
mutation of patients with lung cancer [301, 302].  
 
1.5. Our Motivation and Overview of Efforts  
The main motivation behind this dissertation research was to enhance quantitation in nuclear 
medicine imaging, especially in PET and SPECT. Above, I elaborated on the significance of 
quantitation for improved patient care and towards the realization of personalized medicine. My 
multiple research studies can be generally classified under two themes (both of which aim to enhance 
quantitation in nuclear medicine): methods in “image reconstruction” and in “image processing”. 
In the former theme, I specifically studied the impact of point-spread function (PSF) modeling in PET 
image reconstruction, and introduced the concept of generalized PSF modeling, demonstrating its 
superior performance compared to existing PSF modeling techniques. In the latter theme, I focused 
on the radiomics analysis of nuclear medicine images (both PET and SPECT) in oncologic and 
cardiologic applications. I developed a standardized radiomic framework for calculating 
standardized and reproducible quantitative biomarkers (radiomic features), followed by specific 
clinical applications. I developed various extensions and workflows, and have released two software 
packages: (i) PET Simulation and Image Reconstruction; and (ii) Standardized Environment for 
Radiomics Analysis (SERA) that are available for scientific purposes to the imaging community 
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The work and research in the course of my Ph.D. studies resulted in 4 journal and 29 conference 
publications [293, 294, 301-331], of which 11 were as first author, as well as 3 journal submissions 
under review [332-334]. Specifically, we have 1 journal paper [303] and 4 conference works [304-
307] on aspects of point-spread function (PSF) modeling in PET image reconstruction, which chapter 
2 elaborates. We also have 3 journals papers [308-310] and 25 conference works [293, 294, 301, 302, 
310-331],,  on image processing and/or radiomics in different settings. These include my 
standardized radiomics efforts which are elaborated in chapters 3 and 4, including collaboration with 
the image biomarker standardization initiative (IBSI). Some publications also involved collaborative 
usage of our radiomics package (SERA) or other tools developed, such as extensions and workflows 
developed to extract clinical images and quantitative measures via MIM and Matlab software 
packages.  
In what follows, Chapter 2 presents our new approach to PSF modeling—adaptive PSF modeling for 
enhanced reconstruction.  Chapter 3 elaborates concepts behind standardized radiomics workflows, 
following by our IBSI collaborative efforts, and subsequently, two studies on reproducibility analysis 
of radiomic features in two distinct nuclear medicine clinical contexts. Chapter 4 contains a 
comprehensive study of using radiomics in myocardial perfusion SPECT stress tests to predict 
coronary artery calcifications in patients with a normal scan. Finally, concluding remarks and 











2. Adaptive Point-Spread Function (PSF) Modeling for 
Enhanced Quantitation in PET Image Reconstruction 
In this chapter, we fist discuss the partial volume effect (PVE) in PET imaging, shedding light on how 
it impacts images. Subsequently, we discuss methods of partial volume correction (PVC) to 
compensate for PVE. Specifically, we focus on a well-known and widely-used PVC technique referred 
to as  point-spread function (PSF) modeling. Since PSF modeling has pros and cons, there is a debate 
as to whether or not enable it during PET reconstruction. We subsequently propose an alternative 
approach to the dichotomy of using or not to use PSF modeling—namely, an adaptive, contextualized 
PSF modeling framework for enhanced quantitation in PET. For evaluation, we first model our idea 
using a simple framework of deblurring a Gaussian-filtered image. Next, after demonstrating 
promising results from this simplistic model, we move forward to introducing and implementing our 
adaptive PSF modeling in a realistic PET reconstruction framework, and demonstrate how it 
outperforms the abovementioned dichotomy modeling in terms of image quantitation. The first part 
was presented as a conference proceeding in SPIE annual meeting [304], while the main contribution 
of this project was published in the journal Physics in Medicine and Biology [306].  
2.1. Partial Volume Effect in PET 
PET imaging continues to be affected by several resolution degradation factors, some of which were 
discussed earlier in section 1.2.4, resulting in image blurring, also referred to as the partial volume 
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effect (PVE). PVE technically refers to two distinct phenomena that ultimately make the PET voxel 
values different than what they ideally should be [335]. The first effect is the 3D image blurring 
caused by the finite spatial resolution of the PET system. This limitation is caused by the extent of the 
detectors, as well as degradation factors mentioned earlier including positron range (section 1.2.4.4), 
detector blurring (section 1.2.4.7), photon non-collinearity (section 1.2.4.5), depth of interaction 
(section 1.2.4.7), as well as patient motion (section 1.2.4.11). These degradations result in blurred 
images that subsequently cause spillover between regions. Due to this spillover, a region with higher-
than-background uptake will appear larger, but dimmer. This effect can be mathematically described 
by a 3D convolution operation, where the image is generated by convolving the true image with the 
3D image response or point-spread function (PSF) of the imaging system.  
To illustrate this first effect (the spillover effect) due to PVE, we use a digital simulation of a national 
electrical manufacturing association (NEMA) NU-2 image quality phantom that is commonly used for 
image quality calibrations for PET scanners [336]. A phantom is a specially-designed container that 
includes some internal structures (e.g. rods, spheres, etc.) with known measurements that can be 
filled with radioactivity, and when imaged with a scanner, can demonstrate how accurately its image 
is reconstructed. The NEMA NU-2 phantom consists of a large semi-cylinder container that includes 
six spheres with inner diameters of 10, 13, 17, 22, 28 and 37 mm (Figure 2-1). The container and the 
spheres are filled with radioactive solutions with known activities and then imaged using a PET scan. 
The reconstructed image is used to calculate measurements to determine the quality of the scanner 
and the reconstruction protocol. 
Figure 2-1. NEMA NU-2 image quality phantom. Left: an actual phantom design by a manufacturer. Six spheres inside the 
container are filled with known radioactivity. Right: a transaxial slice of the digitally-simulated NEMA NU-2 phantom that 
passes through the center of all the spheres.  
Figure 2-2. A 3D illustration of the partial volume effect (PVE). PVE results in spillover to nearby voxels and blurring. Left: 3D 
illustration of the true image of a 2D transaxial slice of NEMA NU-2 image quality phantom. Right: 3D illustration of the noise-
free reconstruction of the slice on the left with OS-EM algorithm with 2 iterations and 14 subsets.  
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PET imaging. Therefore, the quest for correcting PVE and producing higher resolution PET images 
remains highly relevant.  
 
2.1.1. Methods for Partial Volume Effect Correction 
The first medical applications of PET imaging were focused on the brain, and earlier PET prototypes 
were developed specifically to image functionality of the brain [337]. Similarly, the first methods for 
partial volume correction (PVC) were also developed for neurologic PET procedures to enhance their 
quantitative capabilities [338, 339]. MRI images were used in PVC strategies relying on an adjunct 
co-registered structural image, due to the higher gray and white matter contrast compared with CT 
[340, 341]. Nowadays, the anatomical information provided by the CT component of the hybrid 
PET/CT scanners (section 1.2.2.3) also may enable PVC in other body organs including 
cardiovascular [342], atherosclerosis [343], and whole-body oncologic imaging applications [335, 
344].  
PVC methods can be tackled via reconstruction-based or post-reconstruction-based techniques that 
are broadly categorized into ROI-based and voxel-based methods [345].  The aim of ROI-based 
methods is to produce improved estimates of mean ROI uptake [339, 346, 347]. This is often achieved 
by using anatomical information from MRI images; however, these techniques usually involve an 
assumption of homogeneous PET uptake distribution in the anatomical regions, and more 
importantly, do not produce images. Another technique is the use of recovery coefficient, where the 
uptake in a region is multiplied by a correction factor, which is pre-calculated for an object whose 
size and shapes are similar to those in the ROI [346]. Voxel-based methods, on the other hand, 
produce images. Some examples of voxels-based PVC techniques include multiresolution [348-350] 
and partition-based methods [347], both of which typically include simplifying assumptions. Another 
example is the use of iterative deconvolution [351], which is often used for image restoration—i.e. to 
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recover spatial resolution. Deconvolution can severely enhance noise levels, but promising 
performances can be achieved when utilizing regularization [352] and denoising  [353]. Some 
reconstruction-based PVC methods involve incorporating anatomical information provided from the 
CT or MRI components in the context of Bayesian maximum a posteriori (MAP) PET reconstruction. 
In this method, anatomical regions are often segmented and used as prior images wherein intervoxel 
PET intensity variations are penalized while allowing large intervoxel variations across the 
boundaries. A distinct approach to voxel-based PVC is point-spread function (PSF)-modeling, also 
referred to as resolution modeling (RM), which we elaborate in the next section. 
 
2.1.2. PSF Modeling in PET 
PSF-modeling aims to capture object-domain and/or detection-domain resolution degrading effects 
and facilitate more accurate modeling of the measurement [354]. As a result, it can reduce image 
degradations caused by model-mismatch and yield improvements in reconstructed image quality as 
it compensates for some partial volume effects. As such, PSF-modeling has attracted considerable 
interest in PET over the past decade [177, 354], and has been adopted by major PET vendors in their 
state-of-the-art PET scanners [84, 355-359]. 
2.1.2.1. Types of PSF modeling 
PSF-modeling implementations are commonly divided into (i) image-space, and (ii) projection-space 
methods. Theoretical analyses of these two approaches have been provided [177, 360], and a few 
studies have performed preliminary comparisons between the two [361, 362].  
Imaged-based PSF modeling 
Image-based methods attempt to incorporate resolution blurring effects entirely in the image-space, 
based on the idea that the reconstructed image can be considered as the blurring of the true image 
by a point-spread function. This can be performed within the image reconstruction (PSF modeling in 
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the image space component of the system matrix, thus applied before forward projection and after 
back projection operations), or performed post-reconstruction in the form of iterative deconvolution 
[351, 354, 357, 360, 361, 363-365]. These methods are straightforward to implement, do not impose 
a significant computational burden, and produce images with high quality so that certain vendor PET 
scanners have already provided this option [358].  
Projection-based PSF modeling 
On the other hand, projection-space methods perform modeling of degradation effects within the 
projection-space component of the system matrix. Iriarte et al. published a review on system models 
for statistical reconstruction of PET data; they indicate that the most popular approach of combining 
models of physical degradation factors is to factor the system matrix as a product of independent 
matrices, each one describing one or a collection of effects [354]. This arrangement is a well-
established approach that has led to high-quality efficient reconstructions and yields substantial 
enhancements in storage preserving and computational time. Also, some studies on image-based PSF 
modeling considered anisotropy [357, 362, 364, 365], using more complex functions, e.g. mixtures of 
Gaussians and exponential [360, 362, 365], and PSF estimation methods based on measurements of 
or arrays of point sources [361, 362, 366]. 
The projection-based methods can be categorized into: (a) empirical methods utilizing measured 
data points [139, 367], (b) Monte Carlo simulations [159, 354, 368-370], (c) analytical models [172, 
371-374] including additional modeling for positron range [174, 375-378], and (d) hybrid 
approaches incorporating combinations of these methodologies; e.g. starting with a simple 
geometrical calculation, and then imposing additional effects [373, 379-381]. These studies focus on 
the benefits of different methodologies and exploit their synergies to compute the system matrix 
[354]. In this study, we focus on the analytical models and will elaborate more in section 2.3.2.  
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2.1.2.2. Pros and Cons of PSF modeling  
Advantages of PSF modeling  
PSF-modeling provides a number of advantages: (i) improved spatial resolution and contrast 
recovery [357, 361-363, 377, 382]; (ii) reduced spatial noise or image roughness (IR), resulting in a 
visually smoother image [383], and (iii) improved focal lesion detectability performance [384-386]. 
Disadvantages of PSF modeling 
At the same time, PSF-modeling poses two concerns [387]: First, it impacts noise characteristics of 
the reconstructed images as they appear smoother. Moreover, the resulting noise power spectrum 
(NPS) of the PSF modeled reconstructed image is seen to be amplified in the mid-frequency domain 
while exhibiting smaller values at higher frequencies [388]. Some efforts have been devoted to the 
analysis of the resulting noise properties that have important implications for quantitation and lesion 
detectability performance in PET imaging. These studies performed an experimental evaluation of 
noise characteristics on real data sets [388-391], or through Monte Carlo simulations [392, 393], and 
subsequently analyzed the impact of reconstruction parameters by adopting a variety of figures-of-
merit (FOMs). PSF-modeling has different effects on different noise metrics [384, 388]. Rahmim et al. 
used analytic models of noise propagation [394, 395] to investigate the impact with and without 
resolution modeling. In a PSF modeled system matrix, more lines-of-response (LORs) contribute to a 
single voxel, as each voxel is related to more measurement locations compared to a non-PSF modeled 
system. This results in a more ill-conditioned inverse problem that suffers from slow convergence 
[396]. Moreover, at matched iterations, voxels in a PSF reconstruction depict lower voxel variance 
and higher inter-voxel correlations vs. no-PSF [384, 397]. As a result, PSF modeling noticeably alters 
the noise texture. Tong et al. derived analytical expressions relating image roughness and ensemble 
noise to voxel variance and inter-voxel correlations [384]. Due to PSF modeling, images become 
smoother, but the ensemble standard deviation of ROI mean uptake (a measure of reproducibility) 
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may remain unchanged [384] or even be amplified for smaller ROIs [398, 399]. We elaborate more 
on how this phenomenon impacts different noise metrics in section 2.   
The second issue concerning PSF-modeling is its susceptibility to produce edge overshoot effect – a 
reminiscence of Gibbs ringing patterns at the edges of a region [396, 400, 401], manifesting as 
overshoots in smaller regions. This issue may compromise the accuracy of signal quantitation in 
small regions [177]. Snyder suggested using a less blurred (i.e. underestimated) version of the true 
PSF in the reconstruction [400, 401]. This method was shown to be effective at suppressing the edge 
overshoot effect [396, 399]. Snyder [400] also suggested that a possible reason for the appearance of 
edge overshoots is the mismatch between estimated PSF and true PSF and that the small mismatch 
can be amplified due to the instability of deconvolution process. Nonetheless, it was shown [307, 363, 
396] – as we also demonstrate in this work – that even reconstruction with the true PSF results in 
the edge overshoot effect. Furthermore, for specific detection or quantitation tasks, it is plausible that 
such an effect may even enhance task performance, as we show in this work for quantitation. 
 
2.1.3. Motivation  
Clinical tasks vary from pure detection-related tasks (e.g. diagnosis and staging) to quantitation-
related tasks (e.g. therapy response assessment and prognostication). The features that make a PET 
image suitable for detection task differ from those that make an image effective for tumor 
quantitation. In fact, noise contributes differently to these two general tasks, and PSF-induced noise 
propagation can result in improved quantitation but may reduce lesion detectability performance, or 
vice versa [388]. However, such analyses and optimizations have only been performed for the 
dichotomy case of no-PSF vs. PSF modeling. It is possible to generalize PSF modeling to include 
overestimated and underestimated PSF kernels. This provides a wider range of options to 
study the impact of PSF modeling on image quantitation tasks, thus facilitating task-based 
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optimization for quantitation. Furthermore, given the challenges with reproducibility as well as edge 
overshoots in PSF modeling, it is plausible that generalized PSF modeling may provide adaptive 
kernels that perform optimally, properly balancing different effects. The present work pursues 
such a generalized adaptive PSF framework in the context of tumor quantitation, which in future 
efforts can be thoroughly evaluated for lesion detectability tasks as well.  
In the following sections, first, we present the adaptive PSF modeling idea utilizing a simplistic image 
blurring-deblurring framework that comprises an image-space deconvolution-based PSF modeling. 
We used Gaussian blurring with a predetermined filter size to blur the image and then deblurred that 
image with a range of filter sizes to assess the plausibility of the idea that generalized PSF modeling 
enhances image quantitation. After showing some encouraging preliminary results, we present our 
practical implementation of this idea using an in-house developed realistic PET scanner simulation 
and reconstruction framework. We adopted an “analytically-modeled” “projection-based” PSF 
modeling (section 2.1.2.1). It is important to show the feasibility of these findings in a practical setup, 
therefore, in this step, we intended to design our study as close to a real-world scenario as possible. 
We used analytically modeled PET degradation phenomena and ultimately used them in our 
simulation and reconstruction framework that models PET scanner with its various degradation 
phenomena. We also used a digital anthropomorphic phantom using realistic uptake values by 
modeling tracer kinetic uptake using patient-derived kinetic modeling parameters. We simulated a 
wide variety of scenarios for different tumor sizes with and without noise and introduced a wide set 
of figures of merit to assess the performance of adaptive PSF modeling from different perspectives. 
As mentioned earlier in this chapter, what appears in section 2.2 is published as a conference 
proceeding in [304], and the subsequent section 2.3 is published in the journal of physics and 




2.2. Adaptive Image-Based PSF modeling 
2.2.1. Introduction 
In this section we propose a generalized PSF modeling framework, including extensive task-based 
optimization, wherein we continualize the conventionally discrete framework of PSF modeling vs. no 
PSF modeling, to include varying degrees of PSF modeling. The proposed framework has the 
advantage of providing a trade-off between the enhanced contrast recovery by PSF modeling and the 
reduced inter-voxel correlations in the absence of PSF modeling, and to enable improved task 
performance.  
 
2.2.1.1. Aims of the study 
The concerns regarding PSF modeling in PET discussed earlier have prompted us to propose an 
extensive task-based assessment of a generalized PSF modeling framework, wherein we continualize 
the conventionally discrete framework of PSF modeling vs. no PSF modeling, to include varying 
degrees of PSF modeling, including overestimation and underestimation of the ‘true PSF’. Such a 
generalized scheme allows consideration of a much wider array of images, which are subsequently 
analyzed in the context of different imaging tasks. We elaborate upon these next.  
 
2.2.2. Methods 
2.2.2.1. Generalized image-based PSF modeling 
The investigated context was that of oncologic FDG PET imaging. In this initial assessment, we 
focused on lung tumor imaging, with SUV images at 45min, simulated based on kinetic parameters 
extracted from the literature ([402], Table II). We used a single slice of an XCAT anthropomorphic 
Figure 2-3. XCAT digital anthropomorphic phantom, capable 
of realistically modeling the human body and widely used in 
imaging research.
Figure 2-4. A transaxial slice of the XCAT phantom with a 
simulated lung tumor. The slice includes regions from lung, 
myocardium and blood pool. 
Figure 2-5. Blurring the true image using a Gaussian filter 
with size , which models the image degradation. 
Figure 2-6. Poisson noise added on top of the already-blurred 
image to model the effect of noise.  




2.2.2.2. Quantification task performance 
Analysis of noise-bias pattern is a popular method to assess quantitative performance. We generated 
noise vs. bias trade-off curves, as generated with increasing iterations into the various generalized 
PSF modeling algorithms. We also performed convergence analysis, in which an algorithm was 
quantified as converged when the last 10 iterations altered the bias no more than a certain threshold. 
We then computed the coefficient-of-variability (COV), 𝜎𝑒𝑛𝑠𝑒𝑚𝑏𝑙𝑒  defined below, compare to the mean 
uptake. We further include the contrast vs. noise trade-off. These two noise performance metrics 
were specifically defined as:  
i) Spatial variance 𝜎2𝑠𝑝𝑎𝑡𝑖𝑎𝑙 , calculated for an image at a given noise realization (in the case of 











where 𝑠𝑖 denotes the image values at any voxel 𝑖 within a given ROI (e.g. tumor) consisting of 𝑁 voxels 
and having a mean 𝑚. In the case of multiple noise realization measurements, this expression is 
subsequently averaged. 
ii) Ensemble variance of ROI mean uptake 𝑚𝑟  across multiple noise realizations 𝑟 = 1, … , 𝑅, with the 














Figure 2-8 and Figure 2-9 depict SUVmean COV and SUVmax COV vs. SUVmean bias; respectively. In these 
two figures, neither of no PSF modeling ℎ̂ = 0 nor full PSF modeling (ℎ̂ = ℎ = 6) achieve the best 
noise-bias trade-off; yet, Figure 2-8 demonstrates the best performance achieved through ℎ̂ = 4. The 
higher SUVmax COV in Figure 2-9 compared to SUVmean COV in Figure 2-8 is due to the greater Gibbs 
ringing artifacts for higher ℎ̂. Figure 2-8 also shows that besides the underestimated filter ℎ̂ = 4 mm, 
slightly-overestimated kernels such as ℎ̂ = 8 mm also demonstrates superior performance to both 
no PSF and full PSF modeling. We also observe from Figure 2-9 that slight overestimation results in 
less SUVmean bias and less SUVmean noise at matched iterations compared to both no PSF and full PSF.  
 
Figure 2-8. SUVmean COV vs. SUVmean bias trade-off for iterations 
1-20 
 
Figure 2-9. SUVmax COV vs. SUVmean bias trade-off for 
iterations 1-20 
 
Figure 2-11 contains noise-contrast trade-off plots and shows higher contrast for higher ℎ̂ because 
of greater overshoot of the edges. This effect can be observed more in detail in Figure 2-11, where 
the CRC vs. iterations is plotted. This plot shows contrast converges faster for smaller filter sizes, 
without a significant increase in its value. On the other hand, overestimating filters with higher ℎ̂ 
require more iterations to converge and their CRC value converges to a value higher than 1. The 
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Figure 2-10. Ensemble noise percent of added noise vs. 
contrast percent trade-off for iterations 1~100 
Figure 2-11. CRC trend for fixed iterations for different 
reconstruction filters. Filters with higher spread converge later 
than smaller filters. 
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Table 2-1. Ensemble Noise Values at convergence. 
?̂? FWHM 0 1 2 3 4 5 6 7 8 
COV 3.44 3.42 3.47 3.54 3.58 3.93 4.12 4.75 5.01 




As the first step towards assessing generalized PSF modeling scheme, we proposed a generalized PSF 
modeling framework with extensive task-based optimization to continualize the conventionally-
dichotomized framework of PSF modeling vs. no PSF modeling and applied various degrees of PSF 
modeling for reconstruction. We showed how this framework provides a trade-off between the 
enhanced contrast recovery and the reduced inter-voxel correlations for no PSF modeling and 
improves task performance. We assumed a blurring kernel with FWHM of ℎ and performed iterative 
EM including PSF modeling with varying widths ℎ̂, to demonstrate underestimated and 
overestimated resolution blurring kernels ℎ̂ enhance task performance in terms of lower SUVmean 
noise and bias. Slightly-overestimated kernels showed the possibility to reach a contrast recovery of 
100%. Overall, the results reveal that generalized PSF can result in enhanced quantitation 
capabilities, while lowering COV compared to full PSF modeling, thus providing an attractive solution 
for both diagnostic and treatment response monitoring applications. 
With this promising preliminary result, we now move on to implement generalized adaptive PSF 
modeling using a more realistic scheme.  
 





Following the promising preliminary study of generalized PSF modeling for a simplistic image-based 
blur-deblur scheme, in this section, we present the study of adaptive generalized PSF modeling in 
projection-space.   
Frameworks explored in the past involve a dichotomy of PSF vs. no-PSF modeling. By contrast, the 
present work focuses on quantitative performance evaluation of standard uptake value (SUV) PET 
images, while incorporating a wide spectrum of PSF models, including those that under- and over-
estimate the true PSF, for the potential of enhanced quantitation of standardized uptake values 
(SUVs). The developed framework first analytically models the true PSF, considering a range of 
resolution degradation phenomena (including photon non-collinearity, inter-crystal penetration, 
and scattering) as present in data acquisitions with modern commercial PET systems.  
In the following subsections, first, we elaborate on analytically modeling on the PET system and 
various image-degradation phenomena. Then, in the methods section, we describe our realistic PET 
simulation and reconstruction framework. We subsequently present our results and discussion.  
 
2.3.2. Modeling a PET system in analytical PSF modeling 
In this section, we explain a systematic approach to modeling PET imaging and reconstruction, 
following by analytical modeling of some of the PET image degradation phenomena. These models 
were subsequently be used to realistically model PET forward projection and reconstruction and 
then were implemented in our in-house developed PET simulation and reconstruction software. 
These models were later used to generate a spectrum of PSF kernels to assess our proposed 
generalized PSF modeling scheme.   
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Suppose 𝑝(𝑖, 𝑗) is the element of the detection probability matrix 𝑃 ∈ ℝ𝑀×𝑁 that represents the 
probability of detecting an emission from pixel 𝑗   (𝑗 = 1, … , 𝑁), at detector pair 𝑖   (𝑖 = 1, … , 𝑀). 
Currently factorized schemes for the system matrix are based on the proposed works of Mumcuoglu 
et al. [159] and Qi et al. [368]for 2D and 3D acquisitions respectively: 
𝑃 = 𝑃𝑑𝑒𝑡.𝑠𝑒𝑛𝑠𝑃𝑑𝑒𝑡.𝑏𝑙𝑢𝑟𝑃𝑎𝑡𝑡𝑒𝑛𝑃𝑔𝑒𝑜𝑚𝑃𝑖𝑚.𝑏𝑙𝑢𝑟 2.3 
𝑃𝑖𝑚.𝑏𝑙𝑢𝑟  accounts for image-based blurring effects, particularly the positron range. A detailed 
discussion on analytically modeling positron range effects in statistical image reconstruction can be 
found in [368]. As the current work focuses on [18F]-FDG scanning known to exhibit short mean 
positron range (0.64 mm), its effect can be safely ignored in the PSF model. 
𝑃𝑔𝑒𝑜𝑚is the geometric projection matrix where the (𝑖. 𝑗) element defines the probability that a photon 
pair produced in voxel 𝑗 reaches the front faces of the LOR 𝑖 in the absence of attenuation and 
assuming perfect photon-pair collinearity. We used the built-in Radon transform command in 
Matlab® to perform the geometric projection. The number of projection bins of this function is 
sufficient to compute the projection at unit intervals, even along the diagonal.  
𝑃𝑑𝑒𝑡.𝑏𝑙𝑢𝑟  accounts for blurring in the sinogram space and includes photon pair non-collinearity, inter-
crystal scattering, and crystal penetration [53]. Technically, modeling radial, angular and inter-
sinogram blurring requires a 3D blurring scheme. However, in the present work, we assume a small 
axial acceptance angle, and these blurring effects are confined to a single sinogram using a 2D 
blurring model. Each of these effects can be analytically modelled and eventually combined. We 
briefly discuss modeling of resolution degrading effects in sinogram space and later we show how to 
exploit these analytical expressions to create adaptive generalized PSF kernels. 
Photon non-collinearity has to be technically modeled in the geometric component 𝑃𝑔𝑒𝑜𝑚 in equation 
1. However, as an approximation to considerably simplify the system matrix computation, one can 
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assume photon non-collinearity is depth independent and model it in the projection-space 
component 𝑃𝑑𝑒𝑡.𝑏𝑙𝑢𝑟 of the system matrix [159, 388]. The FWHM of the Gaussian approximation that 
models the effect of blurring on the spatial resolution using simple geometric calculations can be 
given as:  






= 0.0022 × 𝐿 2.4 
where 𝐿 is the detector separation and can be related to the scanner diameter 𝐷 for different angles 
of incidence 𝜃 via 𝐿 = 2𝐷 cos(𝜃). Therefore, equation (2) becomes: 
FWHM ≅ 0.0022 × 2𝐷 cos(𝜃) 2.5 
This results in an angular dependent Gaussian blurring kernel 𝐷𝑛𝑜𝑛−𝑐𝑜𝑙
𝜃 (𝑥, 𝑧), which models blurring 
due to photon non-collinearity along the (𝑥, 𝑧) in radial and axial directions of the sinogram, 
respectively.  
Although the remaining two effects – inter-crystal scattering and penetration – are often not 
distinguished from one another, it would be very beneficial to conceptually separate them for proper 
modeling: inter-crystal penetration occurs when a photon penetrates the incident detector element 
and is detected in the adjacent crystal; whereas inter-crystal scattering of photons can occur even 
when the angle of incidence is 90 degrees.  
The penetration effect can be modeled using our knowledge of the 511 keV attenuation coefficient of 
crystals, 𝜇, as well as the angle of incidence 𝜃. If we model the individual detectors’ penetration by 
𝑝𝜃(𝑥), then we can calculate the resulting penetration distribution 𝐷𝑝𝑒𝑛𝑒𝑡
𝜃 (𝑥) for the coincident pair 
as [371, 372] : 
𝐷𝑝𝑒𝑛𝑒𝑡





where the 1D attenuation distribution 𝑝𝜃(𝑥) can be described by the angular-dependent exponential 
function:  
where 𝑥′ denotes the tangential direction along the detector surface, such that 𝑥 = 𝑥′ cos(𝜃).   
For the scattering component, which can be effectively decoupled from the penetration effect [172], 
we used real measured projection data of a point source at the center of the field-of-view (FOV) and 
determined the average radial and axial scatter blurring in the sinogram space. After correcting for 
the non-collinearity effect through subtraction in squares, we arrive at an estimate for 𝐷𝑠𝑐𝑎𝑡𝑡𝑒𝑟(𝑥, 𝑧). 
An important point is that, since the non-collinearity effect is independent of crystal blurring, it can 
be convolved with the corresponding crystal blurring kernels once they are created, as we briefly 
discuss next.  Consequently, combining the above analytical models, we arrive at the overall 
projection-space blurring kernel 𝐷𝑝𝑟𝑜𝑗
𝜃 (𝑥, 𝑧) through the following convolution expression: 
𝑃𝑎𝑡𝑡𝑒𝑛 in Eq. 1 is a diagonal matrix containing the attenuation coefficients. The attenuation image in 
current work was derived by forward projecting the attenuation map created by the XCAT 
anthropomorphic phantom for a typical 80kVp CT scan. The sinogram was then corrected for 511 
keV 𝛾-rays using a three-step correction method proposed by Abella in [372]. Finally, 𝑃𝑑𝑒𝑡.𝑠𝑒𝑛𝑠 is also 
a diagonal matrix that contains the detector efficiencies for normalization. Here, we obtained a 3D 
normalization sinogram of the GE scanner and incorporated it into our model.  
 
𝑝𝜃(𝑥) = 𝑒−𝜇𝑥
′/ sin(𝜃)  2.7 
𝐷𝑝𝑟𝑜𝑗
𝜃 (𝑥, 𝑧) = 𝐷𝑛𝑜𝑛−𝑐𝑜𝑙
𝜃 (𝑥, 𝑧) ∗ 𝐷𝑝𝑒𝑛𝑒𝑡




In this section, we describe our proposed approach to incorporate and assess generalized PSF kernels 
in the image reconstruction framework. First, we describe a simulation configuration, followed by 
the image reconstruction method incorporating the true PSF kernel. We then explain the 
methodology of generating a spectrum of PSF kernels from the true PSF. Finally, we define the FOMs 
for assessing and analyzing the results. 
2.3.3.1. Simulation and phantom configuration 
We used the 4D anthropomorphic XCAT phantom [403] to generate dynamic FDG-PET images of 
different tumors, as well as the corresponding attenuation map. In this study, we chose to implement 
six liver tumors of different diameters (10, 13, 17, 22, 28 and 37 mm), which was in agreement with 
the NEMA NU-2 image quality phantom [336]. The position of the center of the tumor spheres is fixed 
across all six images for consistency. Figure 1 depicts two of these six reference images. The original 
reference image has a transaxial dimension of 1024×1024 and a voxel size of 0.5856 mm, and 2D OS-
EM reconstructions with seven subsets are performed into 256×256 images with voxel dimensions 
3.47 × 3.47 × 3.27 mm3. Starting from a higher resolution image is more realistic to better capture 
the spatial continuity of the actual object (patient) being scanned, albeit its contribution to the 
reconstruction time.  
  
Figure 2-12. XCAT generated phantom as reference images with liver tumor sizes of (left) 10mm, and (right) 22mm. 
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We simulated a set of 60-min post-injection SUV PET images for a scan duration of 3 minutes. The 
FDG tracer kinetics were modeled based on a patient-derived input function [404], a set of realistic 
kinetic parameters reported in the literature (table 1), and the standard two-tissue compartment 
kinetic model for FDG. Thus, a respective set of time-activity curves (TACs) were generated for each 
tissue and tumor to allow calculation of the activity concentration levels at 60-min post-injection. 
Lesion spheres were also modeled based on rate parameters in the liver region. Additionally, based 
on an evaluation of multiple-patient [18F]-FDG PET scans, we found out that the activity concentration 
values of the soft tissue background outside the liver were about 21% of the corresponding value in 
the liver. We set the liver rate constants to derive the background activity TAC accordingly. The 
dynamic acquisition protocol consisted of 9 passes (from 30 to 90 minutes, 45 seconds for each bed 
position). The uptake activities were then calculated by temporal integration for the duration of the 
scan.  
 
2.3.3.2. Image reconstruction  
We performed the simulations were performed using an in-house validated reconstruction software 
[388]. First, noise-free emission images were generated by assigning the modeled values to the 
respective regions of the voxelized XCAT human torso digital phantom. Then, forward projection of 
the emission images was performed [405, 406] based on the geometry of a GE Discovery RX PET/CT 
[407]. The generated sinograms were subsequently attenuated according to the XCAT attenuation 
factors and scaled based on the reported sensitivity of the scanner (normalization).  
Our reconstruction software performs an analytic OS-EM projection-space based PSF-modeling 
reconstruction and models positron range, geometric projection, photon non-collinearity, inter-
crystal scattering, crystal penetration, and corrects for attenuation and detector deficiencies. A 
detailed modeling of our analytic reconstruction is provided in Appendix A.  
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Analytic simulations were performed for the images reconstructed using 367 radial bins (60 cm 
radial field of view) and 581 angular samples covering 180° with. Poisson noise was subsequently 
simulated to generate 200 independent noise-realizations. Finally, the generated PET projection data 
were reconstructed, using the proposed methods to produce PET images, as described in the next 
subsection.  
Artifacts in reconstructed PET images are location specific; so ideally the location of the masked ROI 
has to be the same for both the tumor and the background to perform more precise quantitative 
analysis. Therefore, we ran our simulation once with tumors present (each of the six tumors) and 
once with the tumor absent, and then use the mask from the tumor-present reconstructed image to 
mask out the background region in the tumor-absent reconstructed image. To add more accuracy to 
our quantitative analysis, we also assure that for every PSF-kernel and every iteration of the noise-
free reconstructed images, the ROI location in the tumor-absent matches the actual location in the 
tumor-present.  
Table 2-2. Kinetic parameters used in the simulation of the anthropomorphic phantom for [18F]-FDG tracer. References: 





𝒌𝟐 (min-1) 𝒌𝟑 (min-1) 𝒌𝟒 (min-1) 𝑽𝒃 
Lung 0.301 0.864 0.097 0.001 0.168 
Liver 0.864 0.981 0.005 0.016 0.00 
Bone 0.091 0.469 0.0023 0.067 0.00 
Myocardium 0.6 1.2 0.1 0.001 0.00 
Liver tumor 0.243 0.78 0.1 0.00 0.00 
Background 
activity 
0.183 0.981 0.005 0.016 0.00 
 
 
2.3.3.3. Generalized PSF-modeling 
In this section, we describe how to generate a spectrum of PSF (generalized PSF) kernels from the 
true PSF kernel. We propose an analytical approach to generate a wide spectrum of PSF kernels that 
portray both underestimations and overestimations of the true PSF, in addition to no-PSF and true 
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PSF. The “no-PSF” kernel assumes the incoming rays are solely detected at their incident detector, 
whereas the true PSF kernel matches exactly with the forward-projector based on scanner 
parameters and mathematical models of blurring as we explain below.  
In order to implement image reconstruction via a spectrum of PSF kernels that has a smooth 
transition from the no-PSF kernel (identity matrix) to the analytically-modeled “true PSF” and 
beyond, we observed that we have to simultaneously vary the outputs of three equations that model 
photon non-collinearity, inter-crystal scattering, and penetration. We constructed a series of 
generalized PSF kernels that included under- and overestimation of the true PSF by applying a line-
space of incremental scaling factors to these three modeled terms. More specifically, three sequences 
of numbers are multiplied by (i) the mass attenuation coefficient for the crystal (LYSO in this case) in 
Eq. 2.7 that models inter-crystal penetration, and (ii, iii) the FWHMs of 𝐷𝑛𝑜𝑛−𝑐𝑜𝑙
𝜃  (Eq. 2.6) and 𝐷𝑠𝑐𝑎𝑡𝑡𝑒𝑟  
that model non-collinearity and inter-crystal scattering, respectively.  
Table 2-3 contains the three scaling factors multiplied by the attenuation coefficient of crystals and 
FWHM of non-collinearity and crystal scattering used in generating 20 generalized PSF modeled 
kernels presented in this study. The column on the right contains the factor we multiplied by the 
attenuation coefficient of LYSO crystal that is 0.087. The second to the right column includes the 
factor we used to rescale the FWHM of photon non-collinearity in Eq. 2.5. The third column contains 
the FWHM of inter-crystal scattering effect being used in Eq. 2.6.  
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No-PSF  1 0.04 0 111.1 
Underestimated PSF  
2 0.392 0.091 44.534 
3 0.785 0.182 18.746 
4 1.438 0.409 6.983 
5 1.962 0.545 2.826 
6 2.354 0.682 1.319 
7 2.616 0.773 1.240 
8 2.877 0.818 1.156 
9 3.139 0.909 1.080 
True PSF 10 3.27 1 1 
Overestimated PSF 
11 3.662 1.091 0.919 
12 3.924 1.182 0.840 
13 4.185 1.227 0.76 
14 4.447 1.318 0.68 
15 4.709 1.409 0.6 
16 4.970 1.5 0.519 
17 5.232 1.545 0.440 
18 5.493 1.636 0.360 
19 5.755 1.727 0.280 
20 5.886 1.773 0.240 
 
 
We defined and used multiple metrics for quantitative task-performance analysis. This included four 
types of noise (image roughness (IR), SUVmean coefficient of variation (CoV), SUVmax CoV, and average 
max-min difference) and two types of bias (SUVmean bias and SUVmax bias). In addition, mean-squared 
error (MSE) of each voxel and MSE of SUVmean were computed. Definitions of these metrics are 




2.3.3.4. Signal and noise figures of merits for quantitative analysis  
We used several figures of merit (FOM) to quantify the performance of generalized PSF modeling 
kernels in our study. Below we define these metrics and elaborate on why each FOM is required for 
studying different aspects of image quantitation.  
We denote the total number of independent noise realizations by 𝑅, the total number of image voxels 
by 𝑁, and the total number of voxels in a (tumor) region-of-interest (ROI) by 𝑀. If ?̂?𝑖  and 𝑣𝑖
𝑟  refer to 
the true and reconstructed uptake values of the 𝑖th voxel (𝑖 = 1, … , 𝑁) at the 𝑟th noise realization, 






𝑖=1  represents the spatial mean of voxels across an ROI 





𝑟=1  represents the mean of a given voxel i, averaged temporally 
across all noise realizations, and (iii) ?̅? =
1
𝑅
∑ ?̅?𝑟𝑅𝑟=1   is the ensemble mean of all SUVmean
𝑟  values across 
𝑅 noise realizations. Since each ROI is set to have a uniform uptake in the true image, we denote ?̂?𝑖 =
?̂? to represent the value of all the voxels inside that region. Subsequently, the following noise and 
bias metrics can be derived:  
Contrast recovery curves (CRC) 
We define two types of CRC: SUVmean CRC and SUVmax CRC. The former is defined as the ratio between 
the contrasts of the reconstructed image and the true object in terms of the ROI average. The latter 
would be the same ratio but in terms of the ROI maximum voxel.  
Bias in SUVmean and SUVmax 
Biases in activity uptake quantitation were defined in terms of SUVmean and SUVmax, calculated as 
follows [384, 388]:  
 











𝑟 =  max𝑖∈{1… 𝑀}{𝑣𝑖
𝑟} represents the voxel with the maximum uptake value inside the 
tumor ROI of realization 𝑟.  
Equations 2.9 and 2.10 show that SUVmean and SUVmax biases are basically defined as the deviation of 
the reconstructed image from the true value of the object. Both biases are then normalized to the true 
value for plots in the results section. It is worth noting that studies of quantitative task performance 
using clinical patient data would not have this level of rigor in determining the bias (given typical 
lack of access to the true value of every voxel).  
The coefficient of variability (CoV) of SUVmean and SUVmax 
We characterized the CoV for both SUVmean and SUVmax. The former was defined as follows: 
 
where ?̅? was defined at the beginning of this section. Similarly, the maximum uptake CoV defined as 
the variability of the maximum voxel of selected ROI across all realizations, and can be calculated as: 
where SUVmax̅̅ ̅̅ ̅̅ ̅̅ ̅̅  denotes the SUVmax values averaged across the noise realizations. Both equations will 
be normalized to ?̅? in plots of the results section 2.3.4.3for more proper comparison.  

































Mean-squared error (MSE) 
MSE is a more general metric that combines noise and bias of voxels within a single quantity. It can 
be averaged over all voxels within an ROI to represent the MSE of the ROI, and then for the 𝑅 
realizations, the mean of all MSEs would be calculated: 
Due to the importance of both the accuracy and precision of SUVmean value in clinical practices and to 
better study the effect of different reconstruction kernels to the mean uptake, we defined the next 
FOM as the MSE of the mean uptake. MSE can also be calculated by summing the squared noise and 
squared bias [411]. The MSE of SUVmean was defined as: 
Image roughness (spatial noise) 
Image roughness (IR) measures the voxel by voxel variability in the image and can be calculated even 
for a single realization. Within a given ROI containing 𝑀 voxels, image roughness was defined as the 
variability of the voxel values with respect to SUVmean. This was then averaged over 𝑅 noise 
realizations: 
where ?̅?𝑟  is the mean of all voxels, 𝑣𝑖
𝑟s, inside the given ROI of realization 𝑟. The noise values plotted 
in the results section were normalized to ?̅?𝑟 .  
Voxel variation (σ0) 
This metric provides a measure of the variability of individual voxels over multiple noise realizations:  










MSE of SUVmean =  SUVmean Bias
2 +  SUVmean CoV
2 2.14 


















Voxel variation impacts both image roughness and SUVmean CoV [384].  Assume a uniform region 
consisting of 𝑀 voxels with voxel variance 𝜎0
2 for each voxel and inter-voxel covariance cov(𝑖, 𝑗) 
between two voxels 𝑖 and 𝑗. Tong et al. showed that the expectations of image roughness (Eq. 2.15) 
and SUVmean CoV (Eq. 2.11) is given by:  
and 
In Eq. 2.17, it is seen that the reduced voxel variance and increased inter-voxel covariance due to PSF 
modeling result in overall reduction in image roughness. In Eq. 2.18 however, these two works 
against one another and the increasing (positive) covariance contributes positively to SUVmean CoV.  
Averaged differences of max and min uptake 
To better quantify edge effects, we assessed the range of uptake within the ROI after reconstruction. 
For a total of 𝑅 realizations, the average max-min difference was calculated as follows: 
where SUVmin
𝑟 = min 𝑚{𝑣𝑟}, referring to the lowest uptake values within the ROI of the 𝑟th realization. 
The result was then averaged over all realizations. For plotting purposes in Results section, we 






























































Figure 2-13. Isocontours of selected PSF modeled radial profiles: radial bins positions vs. radial bins. The intensity of contours 
is the probability of an incoming radial bin (LOR) from different angles (vertical axis) to a particular bin and its seven neighbor 
bins (zero for the centred bin and ±7 bins in the horizontal axis). The dashed line represents the LOR perpendicular to the 




It is worth breaking down how each of the three degradations phenomena affects the PSF kernel. 
Inter-crystal scattering symmetrically blurs the neighboring crystals of the incident detector. 
Equation 2.5 addressing photon non-collinearity also yields a symmetric blur. However, in inter-
crystal penetration, photons penetrate the neighboring crystals and cause the parallax effect. This 
skews the PSF with respect to the true LOR, thereby inducing symmetry.  
The generalized PSF-modeling kernels presented here has an advantage over the underestimated 
PSFs performed in image-space in previous studies that characterize PSF kernels by varying the 
FWHM of the measured PSF [396, 412]. Those approaches overlooked two issues with the realistic 
PSF kernels that we can observe in Figure 2-13. First, realistic PSF kernels are anisotropic, so their 
FWHM varies with the angle of LOR. Second, under- and overestimating the true PSF not only changes 
its FWHM but also shifts its peak location that is angular dependent. This can be observed in Figure 
2-13, where the peak of radial bins corresponding to LORs entering with an oblique angle (radial bins 
1 to 150 in Figure 2-13) drifts from 1 to 4 as we increase the PSF kernels width.  
 
2.3.4.1. Reconstructed images 
Noise-free reconstruction. 
Figure 2-14 shows images of the noise-free reconstruction with 10 iterations and 7 subsets. PSF-
modeling is known to improve resolution and enhance contrast. This can be observed by comparing 
the no-PSF reconstructed images in the left column with the columns representing kernel #7 (slight 
underestimation) and beyond. The two major drawbacks of PSF modeling can also be addressed here, 
as we point out in some observations from this figure:  
(i) Following a few iterations, edge ringing phenomenon – a staple aftermath of PSF-modeling – starts 
to appear from kernel 6 (not shown in this figure – an intermediate underestimation of the true PSF 
– in all tumor sizes) and intensifies as the PSF kernel index – i.e. its deblurring effect – increases. This 
Figure 2-14. Noise-free reconstruction images of liver tumor and background (cropped to include liver tumor and its 
background tissue) after 10 iterations and 7 subsets. Rows represent different tumor sizes. Columns starting from the left 
indicate no-PSF reconstruction, four under estimating PSF kernels (#3, #5, #7 and #9), true PSF, and four overestimating PSF 
kernels (#12, #14, #16 and #18). The intersection of white dashed lines indicates the center of the tumor in the true object. The 
center of the FOV is located at the left-hand side of the tumor, and hence the tumor edges in its left and right sides pointed at 
by A and C arrows are more pronounced than top and bottom indicated by B and D.  
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(iii) The edge overshoot in PSF reconstructed images of tumors larger than 17mm is not uniform 
across its ring; i.e. the edge is more pronounced in the left and right, compare to the top and bottom. 
This can be observed in bottom-middle reconstructed image in Figure 2-14 by comparing the regions 
pointed to by “A” and “C” having a darker red color with “B” and “D”. The reason is closely related to 
the parallax effect. Photons from annihilation events away from the center of the FOV may experience 
significant inter-crystal penetration. Thus, the apparent LOR may not exactly match the true LOR and 
would be closer to the center of the FOV. In no-PSF modeling reconstruction, this LOR mismatch 
resulting in skewed lesions towards the center of the FOV will not be “deblurred”, whereas it will be 
deblurred by incorporating a true PSF-modeling kernel. The edge overshoot appears as an aftermath 
of this deblurring. The overshoot would be more pronounced in the direction of the parallax effect 
that skews the regions towards the center. In this figure the center of the FOV is located 
approximately on the left side of the tumor, so the left and right edges of tumor undergo more 
deblurring compared to the top and the bottom (“A” and “C” directions compare to “B” and “D”), thus 
exhibiting more edge overshoot.  
(iv) Furthermore, the overshoot on the right side of the ring (pointer “C”) is longer than the one on 
the left side (pointer “A”). The reason is the partial ring section in the right is farther with respect to 
the center of the FOV than the left. Therefore, the amount of deblurring and edge overshoot is larger, 
and subsequently, an asymmetric edge overshoot will appear on the left and the right of the region.   
(v) The final observation is that the apparent tumor location manifested in the reconstructed image 
drifts away from the center of the FOV as we apply higher kernels. This movement can be tracked 
using the white dashed lines representing the center of the tumor in each image. The reconstructed 
ROI with the 10th kernel (true PSF) is in a perfect position; while it slightly shifts towards the center 
of the FOV for underestimated kernels including no-PSF, and slightly shifts away from the center for 
overestimated ones. These effects result from under-/over-correcting for the parallax effect by 
various PSF kernels. By applying the underestimated kernels, the full correction (i.e. deblurring) is 
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not yet accomplished, thus the apparent position of the ROI is not back in its initial location; whereas 
the overestimated the kernels are actually over-correcting (over-deblurring) the region in the 
reconstruction. 
 
Noisy reconstruction.  
Figure 2-15 shows noisy reconstructed images. These images display the edge overshoot in the 
reconstructed ROIs of kernels 7 and above, in addition to its asymmetry, as explained in the last 
section. However, they also demonstrate another principal of PSF modeling: modified noise texture. 
With more blurring kernels, images look smoother, voxel variance reduces in both the tumor and the 
background, and the noise becomes more correlated and blobby. The inter-voxel correlation 





Figure 2-15. Noisy reconstruction images of liver tumor and background (cropped to include liver tumor) for iteration #10 
iterations with 7 OS-EM subsets and no post-smoothing. Rows represent different tumor sizes. Columns starting from the left 
indicate no-PSF reconstruction four under estimating PSF kernels (#3, #5, #7 and #9), true PSF, and four overestimating PSF 
kernels (#12, #14, #16 and #18) 
2.3.4.2. Contrast recovery analysis 
Figure 2-16 shows plots of contrast recovery for SUVmean and SUVmax (CRCmean and CRCmax, 
respectively) of the tumor reconstructed with 20 PSF kernels. The first six images show that neither 
PSF nor no-PSF kernels can yield a CRC of one. PSF overestimation, however, yields a CRC value closer 
to one. Yet in most cases, extreme overestimation, i.e. kernels 15 and above, results in CRCmean higher 
than one, which is as undesirable as CRC<1 for underestimated kernels (mostly due to PVE at the 
edges) and induces an overestimation bias in the reconstructed region that alters quantification. 
The CRCmean curves have a smooth and monotonic transition with respect to increasing PSF kernel 
width. PSF modeling corrects for PVE and thus reduces blurring at the edges, therefore no-PSF 




   
   
   
   
 
Figure 2-16. Averaged CRC of SUVmean and averaged CRC of SUVmax vs OS-EM iterations for six tumors over 200 noise 
realizations. The dashed line highlights CRC=1. CRCmean plots have a fixed vertical axis range of [0.5, 1.3], and the range for 
CRCmax plots is fixed to [0.5, 3.5]. 
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Another observation from this figure is that the true PSF reconstruction yields CRCmean less than one. 
The reason is that the overshoot at the edge of the ROI does not actually involve the outmost set of 
voxels of the region. The set of voxels undergoing overshoot are encircled by another ring(s) of voxels 
that (i) contain more voxels than the overshoot ring, and (ii) have less uptake than the reference 
truth. This is because the edge has not been completely recovered until after 40-60 (total) iteration 
updates, and the algorithm has not yet perfectly converged. These surrounding voxels at the very 
edge of the ROI decrease CRCmean to less than one—even in the presence of the overshoot edge—and 
consequently induce negative bias, as can be seen in the results of section 2.3.4.3. The EM algorithm 
is known to improve with every iteration towards convergence that eventually reconstructs edges 
perfectly after a massive number of iterations. However, this is impractical in PET reconstruction due 
to the presence of noise and its severe amplification. Therefore, the PVE at the edges of the region 
impacts CRCmean and causes it to be suboptimal. Thus, the observed underperformance is an attribute 
of the EM algorithm in PET reconstruction, and it disturbs image reconstruction with any degree of 
PSF modeling. But it can be observed from Figure 2-16 that overestimated PSF modeling kernels tend 
to mitigate this deficiency. 
CRCmax plots interestingly follow a reverse pattern, where, in contrary to CRCmean, underestimated 
and no-PSF attain higher CRCmax values and the curves decline as kernels’ widths increase. We 
observe that most of the curves lay above one, which is due to (i) the presence of noise and (ii) not 
performing any post-smoothing on the images that are shown to reduce CRC [396]. Moreover, 
iterative reconstruction algorithms, including OS-EM, are known to intensify the noise as they iterate. 
Therefore, this produces a monotonic increase regardless of the generalized PSF kernel. However, 
PSF reconstruction with wider kernels yields more correlation between the voxels. As a result, voxels 
cannot oscillate freely in the presence of the noise and their fluctuation decrease as the PSF kernel 
width increases. This inter-voxel correlation not only contains the oscillation of each voxel due to 
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noise but also limits the overshoot from rising too much in reconstruction with overestimated PSF 
kernels. The combination of these two effects contributes to the reduction of SUVmax thus CRCmax.  
The CRCmax curves also show that the smaller tumors (first three ROIs) have smaller CRC values; even 
the first few iterations may generate a CRCmax of one. The reason is again that the region is not fully 
recovered within 30 iterations. It is because the few voxels of the region mostly have values less than 
the reference truth due to the PVE, even when reconstructed with wide PSF kernels. The noise will 
then be added on top of this PVE and cause the CRCmax to become closer or even exceed one. More 
importantly, edge overshoot has not yet developed in early iterations of smaller tumors because the 
very few voxels across the ROI have not created enough extent for the overshoot to rise. Larger 
tumors, on the other hand, have an ample amount of space for multiple overshoot- and undershoot 
rings to appear. Therefore, as the diameter of the region grows, CRCmax increases, but it decreases 
with wider PSF kernels. 
 
2.3.4.3. Noise-bias performance comparison 
We defined three measures of bias, six measures of noise and two types of MSE in section 2.3.3.4, and 
are presenting their plots in this section. Note that the curves representing reconstruction with PSF 
kernels in all plots follow the same legend as Figure 2-17. In all figures, the starting iteration for 
plotting is two. 
 
Image roughness (IR) vs. SUVmean bias.  
Figure 2-17 shows image roughness vs. SUVmean bias for six tumors. The range on all six plots is fixed 





Figure 2-17. Image roughness vs. SUVmean bias for six tumors. Each point in the curves represents the results for a single OSEM 
iteration.  
IR decreases as the kernel index increases, which is consistent with PSF-modeling reducing spatial 
voxel variation and yielding a smoother image. Comparing no-PSF with true PSF (kernel #10) and a 
medium overestimated PSF kernel #15 (orange curve) at matched iterations shows a range of 
25%~35% and 38%~45% less noise for kernels #10 and #15 within all six tumors, respectively. At 
matched noise, SUVmean biases of these two kernels compared to no-PSF degrade significantly for first 
four tumors (25%~45% less bias for kernel #10 and 60%~94% for kernel #15), while its variation 
with respect to different kernels drops for two larger tumors (-16%~2% difference in bias for kernel 
#10 and 6%-16% less bias for overestimated kernel #15. Excessive overestimation, such as for 
kernel indices over 16, usually leads to a positive bias.  
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The behavior of IR curves can be explained by Eq. 2.17. No-PSF and underestimated kernels have 
higher 𝜎0 and lower covariance value; both of which contribute to amplify the spatial noise. As the 
kernels approach, true PSF and its overestimation, 𝜎0 degrades and voxels exhibit more covariance, 
and both yield lower image roughness. Moreover, IR has a small increase for larger ROIs. These 
regions consist of more voxels that result in less weight of the second term on the right-hand side of 
Eq. 2.17; which also results in a lower range of IR for larger tumors.  
 
SUVmean CoV vs. SUVmean Bias 
The plot of SUVmean noise vs. bias is shown in Figure 2-18. Unlike the other figures displayed earlier, 





Figure 2-18. SUVmean CoV vs. SUVmean bias for six tumors. Note that axes ranges are not the same for each plot in this figure.  
Compared to the previous noise vs. bias performance curves with noise extending over 60%, the 
three plots for larger tumors in Figure 2-18 have much lower values and a smaller range of SUVmean 
CoV. Observing lower values for SUVmean is predictable, because not only it is an averaging process, 
but also the PVE at the edges contributes largely to the negative bias. As the PSF kernel’s width 
increases, some undershoots also may appear that increase the impact of overshoots and contribute 
to maintaining lower SUVmean values. For matched iterations (7th iteration; same for earlier two 
figures), no-PSF reconstruction demonstrates 0~5% and -1%~10% less noise compared to kernels 
#10 and #15, respectively. One immediate reason for such a small SUVmean CoV level for these larger 
ROIs is a higher number of voxels. Nonetheless, in the first three smaller ROIs, the SUVmean CoV values 
and ranges are slightly higher: no-PSF shows (mostly) improved noise performance compared to 
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kernels #10 and #15 by -2%~15% and 7%-11%, respectively. Some relevant discussions are 
provided in the next section explaining the observed patterns. 
 
SUVmax CoV vs. SUVmax bias 
The plot is shown in Figure 2-19 displays an approximately linear relationship between noise and 
bias. 
 
Figure 2-19. SUVmax CoV vs. SUVmax bias for all six tumors.  
SUVmax noise vs. bias curves of the overestimated PSF kernels typically demonstrate lowered noise, 
lowered bias and thus a higher quantitation performance compared to other earlier PSF kernels. In 
terms of SUVmax CoV, kernels #10 (true PSF) and #15 show 43%~57% and 58%~72% less noise, 
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respectively, as compared to no-PSF. In terms of SUVmax bias, the numbers are 18%~42% and 
43%~55%, respectively. This is mainly due to increased inter-voxel correlation explained for CRCmax 
in section 2.3.4.2. The first three curves in this figure also show that smaller ROIs exhibit a negative 
SUVmax bias for the first few iterations (maximum of 7) for the overestimated PSF curves, whereas 
the three larger ROIs do not show a negative bias, due to reasons explained in 2.3.4.1 about the 
smaller ROIs greatly suffering from PVE.  
 
Average max-min difference vs. SUVmean bias 
The noise vs. bias plot is presented in Figure 2-20. It was mentioned in section Averaged differences 
of max and min uptake that this noise metric essentially is a measure of shape and quantifies regions’ 




Figure 2-20. Averaged max-min difference vs. SUVmean bias for each of the six tumors studied. 
The significance of this metric is its ability to assess edge overshoot effect and PVE. Comparing this 
shape metric for no-PSF with kernels #10 and #15 with matched iterations shows 15%~20% and 
21%~28% less shape variability, respectively. Underestimated kernels are more prone to noise and 
post-smoothing was not performed here, so most of the higher variabilities measured in the smaller 
blurring kernels are due to the noise. Nonetheless, it is interesting to observe the monotonic decrease 
of this shape variability that mostly depicts the effect of higher correlation because of more 




MSE vs. PSF modeled kernels indices 
Figure 2-21 depicts plots of MSE vs. PSF kernels, where MSE effectively combines noise and bias 
within a single metric. Every line in the plot corresponds to an OS-EM iteration, and the results are 
shown for different ROIs. Interesting observations can be made. Except for the first few iterations in 
the smallest ROI, we see generally decreasing MSE values with increasing PSF widths for each given 
iteration. Also, plotting MSE and performing minimization while allowing for iteration number to 









MSE of SUVmean vs. PSF modeled kernels indices 
We calculated the MSE values for SUVmean using equation 12 and plotted them vs PSF kernel indices, 
as shown in Figure 2-22 (note that each plot has a different horizontal axis range). We indicated that 
the MSE of SUVmean captures the effects of both its noise and bias, thus providing us with an indicator 
of the overall performance of SUVmean, which itself is robust to spatial noise and can be used to 
quantify PVE. In these figures, following the trends of increasing iterations implies wider PSF kernels 
require more iterations to converge than narrower PSFs. Furthermore, we observe that the best 
performance, in terms of the minimum MSE of SUVmean, was obtained for overestimated PSF kernels.  
More specifically, it is seen that for small tumors, minimum overall MSE is obtained with medium PSF 
overestimation, whereas for the two largest regions, the slight decrease in SUVmean CoV (higher 
SUVmean reproducibility, as explained in SUVmax CoV vs. SUVmax bias) boosts the performance of 
underestimated PSF kernels. However, the MSE improvement between underestimated PSFs and 
true PSF for the two largest regions are 0.10 and 0.11, while the improvements for the overestimated 
PSFs (kernel 14 for instance) vs. the true PSF are 0.56, 0.61, 0.36 and 0.08 for ROIs 1 to 4, respectively. 






Figure 2-22. MSE of SUVmean vs. PSF kernels. Note that each plot has a different scale.  
 
Plots vs. sphere diameters 
In the following Figure 2-23, six of the FOMs are plotted vs. ROI sphere diameters. The iteration is 







Figure 2-23. Various quantification metrics vs. ROI diameters (in mm) at iteration 10 from different kernel sizes: (a) image 




These six plots provide better intuition about the impact of PSF kernels for ROIs with different sizes 
and help make interesting observations. Figure 2-23.a shows a small reduction in average voxel 
variation as the diameter increases. This is related to the fact that with larger ROIs, a smaller fraction 
of voxels is impacted by edge overshoot effect, which itself amplifies voxel variability [388]. Also, as 
seen in Figure 2-23.b, image roughness decreases with increasing ROI size. This is also related to the 
above effect, as well as the fact that second term in Eq. 2.17 decreases with increasing voxels (M).  
Figure 2-23.c shows an important trend. As mentioned in section SUVmean CoV vs. SUVmean Bias, the 
only plots that show overestimated PSF kernels have inferior performance were for SUVmean CoV. But 
as we explained, both Figure 2-8 and Figure 2-23.b indicate that this inferior reproducibility is not 
substantial; even in its worst case the CoV for the 10mm and 13mm ROIs, they vary within a range of 
1.5% from minimum to maximum SUVmean CoV. This figure also shows a considerable decline in CoV 
with an increase in a number of voxels in an ROI, as expected, as the mean measure becomes 
substantially more robust.  
An analogous trend observed in Figure 2-23.d, Figure 2-23.e and Figure 2-23.f is a peak in SUVmean 
CoV, SUVmean bias and SUVmax bias curves, respectively for 13-17mm tumors, especially with PSF 
overestimation. This pattern is mostly generated because of edge overshoot effect. We explained in 
2.3.4.2 that although this aftermath is referred to as edge overshoot, it does not involve voxels exactly 
at the edge of the ROI. The outermost ring of voxels always undergoes PVE (even at extreme PSF 
overestimation) where they have not yet recovered their true value. Excluding this outermost ring, 
four rings of voxels can contribute to the first overshoot ring as can be observed in large ROIs in the 
last row of figure 3 for kernel #10 (true PSF), and even more rings in the case of extreme 
overestimation. In larger ROIs the distance between one end of the region to the other is much larger 
than 10 voxels, therefore a complete doughnut can arise in the edge of the region. The center of this 
doughnut accommodates smaller undershoots and overshoots in mid-sized ROIs, as well as a flat 
region in larger ROIs. However, in smaller lesions, such as the 13mm and 17mm tumors, the extent 
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from one edge to the other is less than what is needed for these two overshoots to remain separate 
(thus generate a doughnut). Hence these two overshoots merge together and create a single 
overshoot with a value higher than each of the individual edges. This results in higher SUVmax FOM 
values, including higher SUVmax noise (Figure 2-23.d) and bias (Figure 2-23.f). Due to this 
phenomenon in smaller regions, most of the voxels inside the reconstructed ROI undergo an 
overshoot and exhibit a positive bias, resulting in a more positive SUVmean bias. This is the main 
reason for the peak in 13mm and 17mm regions in Figure 2-23.e. In larger tumors, the outermost 
ring of voxels contains more voxels than the overshoot rings exhibiting overshoot. Moreover, the 
negative bias that these outermost voxels experience due to PVE is much larger than the positive bias 
that inner ring of voxels exhibits due to the edge overshoot, which eventually causes the SUVmean bias 
to become negative.  
 
2.3.5. Discussion 
2.3.5.1. Noise vs. bias analysis 
In the current work, we plotted various noise vs. bias curves to assess the quantitation performance 
of true PSF, no-PSF and generalized PSF-modeling kernels. We performed a comprehensive analysis 
of generalized PSF modeling reconstruction for assessing quantitative task-performance, including 
noise vs. bias analysis between four types of noise (IR, SUVmean CoV, SUVmax CoV, and average max-
min difference) and two biases (SUVmean bias and SUVmax bias). Past efforts have focused on 
quantitation performance comparison between PSF vs. no-PSF-modeling reconstructions. These 
included bias (and/or contrast) vs. noise trade-off curves, commonly illustrating outperformance of 
PSF when defining noise as IR [357, 361, 363, 413], or SUVmean CoV [360, 362, 370, 382]. Our present 
study shows improvement in IR, SUVmax CoV, and the average max-min difference for the true PSF 
kernel vs. no PSF, complying with previous reports and demonstrates medium overestimated PSF 
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kernels outperforming the true PSF. At the same time, reproducibility in terms of SUVmean CoV 
between true PSF vs. no PSF shows less significant improvement (for small tumors with the same 
number of OS-EM iterations) or even a slight degradation (for small regions for PSF vs. no PSF or 
which complies with the previous reports; both of which complies with previous reports [384, 398, 
399]. The same behavior is observed for overestimated PSF vs. true PSF. However, since SUVmean 
metric is involved averaging voxels yielding a smoother value, its coefficient of variability is generally 
very low. Therefore, in practice, reproducibility degradation of overestimated PSF vs. no-PSF is 
negligible (<10% variability for a CoV of 3%).  
We also notice that more thorough analysis of reproducibility vs. bias can be performed for many 
other metrics (beyond SUVmean and SUVmax) in the emerging area of radiomics and heterogeneity 
quantification [247, 306, 309, 414-428]. This requires a distinct effort which can be pursued in the 
context of varying PSF kernels. 
 
2.3.5.2. Important factors in quantitation analysis  
In the present work, it was seen that two essential and determining parameters need to be carefully 
tuned for task-performance optimization: (i) number of iterations and (ii) segmentation of the target 
region or thresholding the ROI.  
The number of iterations in reconstruction.  
It can be seen from the plots in sections 2.3.4.2 and 2.3.4.3 that matched iterations cause different 
levels of contrast, noise or bias in reconstructions with different PSF kernels. This is because the 
degree of convergence in true PSF versus no-PSF reconstructions differs at the same number of 
iterations. This is very important when assessing and analyzing quantitation task performance. As 
an example, consider the four plots of SUVmean bias vs. sphere diameters in Figure 2-24 for iterations 
5, 7, 11 and 13. We observe that these plots follow a comparable pattern, where curves peak at 13mm 
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and 17mm ROIs. However, the values are considerably changing. No curve demonstrates a positive 
bias in iterations 5 and 7, whereas in iterations 11 and 13 the maximum value of the plot increases, 
creating positive bias. As such, merely comparing images reconstructed with different PSF kernels at 
the same number of iterations for PSF and no-PSF would not be sufficient (although this practice 
commonly appears in the literature [354, 412]). Therefore, it is necessary to observe the trend of 















ROI segmentation.  
ROI segmentation was performed using thresholding, and the level was set to 55% in the present 
work, which we explored and assured visually to correspond very closely to the reference truth 
region. In any case, we observed that ROI segmentation has a significant impact on quantitation. This 
is because the uptake values of the outermost voxels at the boundaries of a reconstructed ROI suffer 
from PVE and hence have relatively lower values compared to the reference truth, which eventually 
impacts the noise and bias metrics. Correspondingly, the maximum voxel in a noise-free 
reconstructed ROI may represent either the overshoot due to the edge overshoot effect in mild 
underestimated, full, and overestimated PSF-modeling, or the true value of the ROI in no- and heavily 
underestimated PSF-modeling. On the other hand, the minimum voxel in such an ROI may represent 
a voxel in an undershoot of the ringing effect in mild underestimated, full, and overestimated PSF-
modeling, while it may also refer to a low uptake in the very edge of the region due to PVE. In this 
case, the thresholding should be defined properly so that the masked ROI excludes low uptakes at 
the edges. Otherwise, in the case of mild underestimated, full, and overestimated PSF-modeling, it 
would be hard to determine whether the minimum uptake is due to an undershoot of the edge effect 
that occurs inside the first overshoot ring, or it is a blurring due to PVE at the border of the ROI. To 
prevent this confusion, we optimized the thresholding ratio to preserve the region shape, while 
excluding blurred voxels due to PVE in noise-free reconstruction, and then apply it to the noisy 
reconstructed images. 
 
2.3.5.3. Noise metrics 
From the analysis provided in section Voxel variation (σ0) of Section 2.3.3.4, it can be deduced that 
noise, when measured spatially, can be significantly reduced by PSF modeling (given the same 
iteration number) whereas SUVmean CoV actually could be unchanged [384], increase [399], even 
110 
 
multi-fold [398]. This potential increase in SUVmean CoV means a reduction in SUVmean reproducibility. 
The present work explored how generalized PSF modeling (under or over-estimated kernel 
estimation) impacts quantitative performance given these different metrics, and the effect of 
iterations number was also especially considered. 
We observed in section SUVmean CoV vs. SUVmean Bias that SUVmean CoV vs. bias curves of 
underestimated PSF kernels demonstrated slightly better performance for small regions. Visual 
assessment of these plots reveals that the underestimated PSF kernels outperform true and 
overestimated PSF kernels only within the first few iterations. However, if iterations exceed 40 (not 
depicted), the noise vs. bias curves of underestimated PSF kernels for the largest ROI in Figure 2-18 
would eventually follow the pattern observed in Figure 2-17, Figure 2-19 and Figure 2-20—i.e. 
overestimated PSF curves outperforms underestimated and true PSF. The reason for this behavior 
can be partially explained by equations 2.17 and 2.18 in section 2.3.3.4; especially Eq. 2.18, in which 
the two terms of 𝜎0 and covariance act against each other. Although more iterations increase 𝜎0 and 
decrease covariance, the effect of a 1/ 𝑀 factor in the first term of Eq. 2.18 further diminishes the 
effect of 𝜎0 compared to the first term in Eq. 2.17, thus the first term cannot impact SUVmean CoV in 
Eq. 2.18 as much as it impacts IR in Eq. 2.17. Furthermore, increased covariance values in earlier 
iterations contribute to SUVmean CoV, increasing it and thus decreasing reproducibility of the higher 
PSF modelled kernel indices. Nonetheless, this degradation of reproducibility for overestimated 
kernels, particularly the kernel #15, was lower (<10%) compared to improvements (reductions) in 
IR (~50%) and 𝜎0 (30%~50%), while increasing CRC (a CRCmean of 0.95 for kernel #15 vs. 0.85 for 
kernel #10 and 0.80 for no-PSF). In the present work, we did not include any noise-suppression or 
control in the current analysis, but surely studies should be pursued to analyse methods such as post-
reconstruction smoothing, penalized EM, and other credible methods and study their effects along 
with various degrees of PSF modeling in quantitation. Also, the present work was focusing on a single 
tumor contrast derived from clinically derived kinetic parameters for a liver tumor. Future studies 
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need to be performed that includes tumors with higher contrasts. The present work proposes and 
expands on a particularly neglected dimension of imaging, namely on the extent of PSF kernels. But 
in future studies it s,hould be integrated along with various filtering regimes and number TOF kernels 
to find the optimal combination for optimizing the overall PET quantification. 
 
2.3.5.4. Comparison with past efforts 
A preliminary study of projection-space generalized PSF-modeling was performed involving a 
spectrum of underestimated PSF kernels [307]. In that study, we quantitatively analyzed projection-
space reconstructions with a spectrum of PSF kernels generated from the true PSF using a convex 
combination approach; i.e. (1 − 𝛼) × “no-PSF kernel” + α × true “PSF kernel”, 𝛼 ∈ [0,1], where the 
“no-PSF” kernel is a delta function that assumes the incoming rays are solely detected at their 
incident detector. Those intermediate kernels are considered underestimations of the true PSF 
kernels. The convex combination method used to generate PSF kernels for that study cannot be 
extended to generate overestimated kernels, thus we chose to rescale reconstruction parameters as 
we explained in Appendix B. Therefore, although some of the underestimated PSF kernels on that 
study do not perfectly match the PSF kernels used in this work, the results follow the same pattern: 
the SUVmean CoV of slightly underestimated kernels showed a 12% increase compared to true PSF.  
The present work pursues such a generalized PSF framework in the context of quantitation [305], 
which in future efforts can be thoroughly evaluated for detection tasks. Additional work is being 
pursued in this area on the front of heterogeneity analysis, including studies on the effect of PSF 
modeling on heterogeneity quantification task performance, with the aim of adopting more 
reproducible and robust shape and textural features and optimizing them for enhanced prediction 
and prognostic tasks [306]. 
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Positron range is another PET degradation that induces more blur to the system matrix, as it 
increases the FWHM of the PSF. Some vendor PET scanners use Ge-68 point sources to characterize 
the PSF as modeled within PSF-reconstruction [139]. However, in comparison, the most popular 
isotope, F-18, has a relatively small positron range. Therefore, utilizing a PSF kernel obtained from 
Ge-68 point-sources that has a significant positron range to reconstruct F-18 PET data is 
approximately equivalent to an overestimated PSF kernel in the reconstruction, since both increase 
the FWHM of the PSF. It is interesting to note, based on our observations with overestimated PSF 
kernels, that this may not be a problem in fact, and may effectively lead to improvements in 
quantitative performance, though further analysis is required to implement the exact model of 
radiotracers with higher positron range, that is left for future study. 
 
2.3.6. Conclusion  
PSF-modeling is an increasingly employed partial volume correction method. We studied the impact 
of an array of projection-space-based PSF models on PET reconstructed images for optimized 
quantitative task performance. The system PSF was constructed using models of photon non-
collinearity, inter-crystal scattering, and inter-crystal penetration, as well as the patient attenuation 
map and scanner normalization sinogram. Using these models, we generated 20 generalized PSF-
modeling kernels – including no and true PSF, as well as 8 underestimated and 10 overestimated PSF 
kernels. We used an XCAT anthropomorphic phantom with 6 different liver tumor sizes and 
kinetically derived [18F]-FDG time-activity curves to reconstruct noise-free, as well as 200 noisy 
images using the OS-EM algorithm. The quantitative figures of merit included contrast recovery, 
mean-squared error, and various noise metrics (image roughness, voxel variation, SUVmean and 
SUVmax coefficient of variability (CoV), averaged max-min difference) and biases (SUVmean, SUVmax). 
We evaluated these metrics for different tumor sizes/iterations/PSF kernels/noise realization.  
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The results of our main study follow those of our preliminary image-based PSF modeling presented 
in section 2.2 earlier in this chapter. Our results show that for the standard range of iterations 
employed in the clinic (not excessive), edge enhancement due to overestimation counter-
intuitively lowered SUV bias in small tumors, while inter-voxel correlations suppressed image 
roughness and enhanced uniformity in all tumors, only slightly degrading SUVmean reproducibility 
in the smallest tumors. One may at first imagine that overestimating the PSF would lead to higher 
overshoots at the edges. However, we only observed this at higher iterations. In fact, using an 
overestimated PSF resulted in improved contrast and limited edge overshoot effect at lower 
iterations, in turn enabling enhanced SUV quantitation. Overall, our work suggests that one ought 
not necessarily to utilize an exactly matched system PSF for enhanced image reconstruction 
performance, and that slightly overestimated PSF modeling can improve PET image 
quantitation. Our proposed framework can as such be pursued as a powerful and viable approach 
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3. Standardized Radiomics in Nuclear Medicine Imaging 
3.1. Introduction 
“Images are more than pictures, they are data” [244]. Radiomics refers to the mapping of images to 
data and then mining that data towards improved clinical decision support. Initially, radiomics was 
utilized for oncologic studies, but it has expanded to other clinical areas. Also, while first efforts on 
radiomics were mostly performed on high-resolution images from CT and MRI, starting in 2009 
radiomics-type approaches were also studied in PET imaging, and later on, our group applied 
radiomics to SPECT imaging [291]. In the field of radiomics, image features (also known as radiomic 
features) are extracted from regions of interest (ROIs). An ROI can consist of a functional region; e.g. 
a tumor (possibly also including its immediate background), or an anatomic region (e.g. putamen in 
brain studies, left anterior descending segment of the heart, or other tissues of interest). However, 
this relatively new field faces substantial challenges on its path to routine clinical usage [244]. 
Chapter 1 provided an introduction to radiomics and some of its applications (section 1.4.3). In this 
chapter, we elaborate on the radiomics workflow. Then, we discuss the importance of standardized 
and reproducible radiomics, following by our collaborative efforts with the image biomarker 
standardization initiative (IBS) to standardize radiomic features and processes. Finally, we present 
two of our studies applying standardized radiomics to PET and SPECT clinical datasets, where we 
perform radiomics feature selection, a first and important step towards reliable radiomics analysis.  
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3.1.1. Motivation  
As we explain in detail in section 3.2, radiomics workflows suffer from different sources of variability, 
and it is crucial for a systematic and reliable radiomics study to account for and present a method to 
correct for all these variabilities. In this chapter, we describe radiomics standardization efforts and 
our contribution to a global initiative aiming at standardizing radiomics studies (section 3.2.3) that 
have been published in the form a global collaboration effort [311, 325, 333, 429]. We have also 
released our work as a software package entitled Standardized Environment for Radiomics Analysis 
(SERA). Furthermore, in section 3.3, we present our studies on reproducibility of radiomic features 
in two distinct nuclear medicine projects, some of which we have previously presented to the 
community [314, 317].   
 
3.1.2. Radiomics workflow 
Figure 3-1 shows a sample radiomics workflow. Following the acquisition of high quality and 
standardized image, the ROI is first defined and segmented, since most radiomics analyses are 
defined for ROIs, not the entire image. The segmentation task can be performed manually by an 
imaging expert such as a radiologist or radiation oncologist for a CT or MRI image, or a nuclear 
medicine physician for a PET image. It can also be performed semi-automatically or be fully 
automated, but it is recommended for these efforts to be supervised by an imaging expert. The 
segmented ROI may then need to be resampled to a cubic voxel size, and this resampling also involves 
interpolation.   
In the next step, radiomic features are calculated automatically from the segmented ROI. Radiomic 
features can be from different feature families (or classes) based on the property that they 
characterize from the ROI. Features families are namely divided into first-order, and higher-order 
features. The first order features are those that are directly calculated from the ROI. Examples include 
Figure 3-1. A typical radiomics workflow. Following image acquisition, the ROIs are segmented, then radiomics features are 
calculated from the segmented ROI. Features are narrowed down in the feature selection step.  
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3.1.3. A brief introduction to radiomic features calculations 
The detailed procedures at every step of the radiomic workflow, including the definitions of over 100 
essential radiomic features, are not provided in this dissertation, and the reader can refer to the IBSI 
documentation for these details [429]. In this section, we briefly describe some of the preprocessing 
procedures prior to feature calculation following by the main radiomic feature classes, and the name 
selected features from each class.  
 
3.1.3.1. Image preprocessing 
Below we briefly describe some image preprocessing steps prior to feature calculations. 
Segmentation  
Segmentation can be performed manually by radiology or nuclear medicine expert, or semi-
automatically using methods such as gradient-based approaches, thresholding based on maximum 
voxel (e.g. SUVmax), thresholding based on deviation from reference (liver) uptake, or performed 
automatically using available deterministic techniques and/or deep learning. The segmentation 
mask would be a 3D binary matrix of the same size as the image following a similar grid system.  
 
Interpolation 
Texture features may require resampling to have isotropic (cubic) voxel sizes to be rotationally 
invariant. It also enables a comparison between analyses from different samples and cohorts. 
Resampling requires voxel interpolation, and it affects image feature values since they are sensitive 
to variations in the voxel size [430-432].  
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Interpolation algorithms map voxel intensities from the original image grid to an interpolation grid, 
where voxels are spatially represented by their centers. Commonly-used interpolation algorithms 
include: 
• Nearest neighbors 
• Linear  
• Cubic convolution 
• Cubic Spline 
More details on interpolation processing including grid orientation and grid translation can be found 
in the IBSI document [429]. 
 
Re-segmentation 
Re-segmentation is a process following image segmentation and interpolation in which certain voxels 
may be removed from the ROI if they are outside of a certain range. One example that demonstrates 
the benefit of re-segmentation is excluding air voxels from an ROI of a lung tumor. Two main methods 
to perform re-segmentation are:  
Range re-segmentation 
This method excludes voxel intensities beyond a predefined interval (e.g. exclude voxels with 
intensities outside of [−500,400] HU in a lung tumor radiomics study. 
Intensity outlier filtering 
In this re-segmentation method voxel with intensities that are considered outliers may be removed 
from the ROI. One method is to calculate the mean 𝜇 and the standard deviation 𝜎 of the grey-levels 
(defined below) inside the ROI and then exclude voxels outside of the range [𝜇 − 3𝜎 , 𝜇 + 3𝜎] [264]. 
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The ROI is called the morphological mask before performing re-segmentation and after re-
segmentation is referred to as the intensity mask.  
 
Intensity discretization 
ROI voxel intensity discretization or quantization is often required for calculation of higher-order 
texture and heterogeneity features to make them tractable and suppress noise [245]. During the 
discretization process, voxel intensities are discretized into new values called grey-levels (GL). They 
are two commonly-used approaches to ROI discretization: 
Fixed bin-number discretization 
In this method, voxel intensities 𝑋𝑖 , 𝑖 = 1, … , 𝑁𝑅𝑂𝐼 , where 𝑁𝑅𝑂𝐼  is the total number of voxels in the 
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max are the minimum and maximum values of all 𝑥𝑖 , 𝑖 = 1, … , 𝑁𝑅𝑂𝐼 .  
Fixed bin-number discretization imposes some attributes to the ROI. First, it removes the 
relationship between image intensity and the physiological underlying matter (if any). Second, it has 
a normalizing effect which is an advantage in case of imaging modalities with arbitrary units such as 
MRI and SPECT. Third, certain classes of radiomic features are highly dependent on the number of 
GLs, and fixed bin-number discretization enables a direct comparison of feature values across 
multiple ROIs or multiple patients.  
Fixed bin-size (or fixed bin-width) discretization 
This discretization type is a simple concept where a new bin is assigned for every intensity interval 
with a width 𝑤𝑏 . In this case, 𝑤𝑏 is the bin width, and it starts at a minimum fixed GL referred to as 
3.1.3.2. Radiomic features 
Figure 3-2. A 2D ROI over a prostate tumor on a PET image. The original segmented ROI has SUV values (middle matrix) with 
a certain size. The ROI is then resampled to a finer resolution and discretized with a fixed bin-size of  SUV. 
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Table 3-1. List of radiomic features in compliance with IBSI guidelines. For details on subtypes, refer to section Grey-level co-
occurrence matrix (GLCM) on page 128. 
 















Morphology - 29 
Local Intensity - 2 
Intensity-based Statistics - 18 
Intensity Histogram - 23 
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Morphological features or shape features describe geometric aspects of an ROI. These features are 
based on ROI voxel representations of the volume. Voxel representations of morphological features 
can be set as coordinates of the voxel centers, or a surface mesh representation of the ROI. The latter 
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can be performed by different algorithms including Marching Cubes [433]. These different definitions 
can impact the calculated values. For instance, the definition of “volume” based on the mesh 
representation calculates the volume of the space contained by the triangulate mesh surrounding the 
ROI, whereas the volume based on the voxel representation would be simply the number of voxels 
times the volume of a single voxel. The IBSI guideline refers to the first approach as “volume” and the 
second approach as “approximated volume” since the mesh representation provides a value nearer 
to the truth. Below is the list of some morphological features.  
1- Volume 
2- Approximate volume 
3- Surface area 
4- Surface to volume ratio 
5- Compactness 1 
6- Compactness 2 
7- Spherical disproportion 
8- Sphericity 
9- Asphericity 
10- Centre of mass shift 
11- Maximum 3D diameter 
12- Major axis length 
13- Minor axis length 
14- Least axis length 
15- Elongation 
16- Flatness 
17- Volume density-AABB 
18- Area density-AABB 
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19- Volume density-OMBB 
20- Area density-OMBB 
21- Volume density-AEE 
22- Area density-AEE 
23- Volume density-MVEE 
24- Area density-MVEE 
25- Volume density-convex hull 
26- Area density-convex hull 
27- Integrated intensity 
28- Moran’s I index 
29- Geary’s C index 
Most of the above features solely depend on the morphological ROI (as defined earlier), and are 
independent of voxel values. For the definition and formulation of these features please refer to the 
IBSI documentation [429]. 
 
Local Intensity features 
Local intensity refers to two specific features that are computed based on the voxel intensities within 
a defined neighborhood around a centered voxel. The centered voxel should belong to the intensity 
ROI, but the neighboring voxels may be from outside of the intensity ROI if the centered voxel is at 
the edge of the ROI. The two local intensity features are: 
1- Local intensity peak 
2- Global intensity peak 
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The former is the maximum mean intensity of a 1cm3 sphere, that is, voxels found in a set of voxels 





≈ 0.62 cm of the centered voxel. The difference between the two is 
that in the local intensity peak, the center voxel should belong to the intensity ROI, whereas in the 
global peak, the centered voxel can be from anywhere on the image. The former is close to the 
definition of SUVpeak in PET imaging. 
 
Intensity-based statistical features 
These features describe how voxel values within the ROI are distributed. These voxel-values do not 
need discretization. They intensity-based features would not be meaningful in the case of arbitrary-
unit modalities such as MRI and SPECT. Below is a list of these features. For their formulation please 







7- Percentile 10 
8- Percentile 90 
9- Maximum 
10- Interquartile range 
11- Range 
12- Mean absolute deviation 
13- Robust mean absolute deviation 
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14- Median absolute deviation 
15- Coefficient of variation 
16- Quartile coefficient of dispersion 
17- Energy 
18- Root mean square 
 
Intensity histogram features 
To calculate these features, first, we have to generate an intensity histogram by discretizing the 
original set of voxel intensities 𝑥𝑖  into grey-level bins based on one of the approaches described in 







7- Percentile 10 
8- Percentile 90 
9- Maximum 
10- Mode 
11- Interquartile range 
12- Range 
13- Mean absolute deviation 
14- Robust mean absolute deviation 
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15- Median absolute deviation 
16- Coefficient of variation 
17- Quartile coefficient of dispersion 
18- Entropy 
19- Uniformity 
20- Maximum gradient 
21- Maximum gradient grey level 
22- Minimum gradient 
23- Minimum gradient grey level 
 
Intensity-volume histogram (or cumulative histogram) features 
The (cumulative) intensity volume histogram (IVH) is generated by producing a cumulative 
histogram from the distribution of discretized voxels into bins. It describes the relationship between 
a GL and the fraction of the volume of the histogram containing at least that particular GL. IVH is the 
only feature class that may have its own discretization type. For consistency, it is recommended to 
set the range of the IVH to be the same as the re-segmentation range. The following features can be 
calculated from IVH: 
1-  Volume fraction at 0.10 intensity 
2- Volume fraction at 0.90 intensity 
3- Intensity at 0.10 volume 
4- Intensity at 0.90 volume 
5- Difference volume fraction at 0.10 and 0.90 intensity 
6- Difference intensity at 0.10 and 0.90 volume 
7- The area under the IVH curve 
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Below we continue with higher-order feature classes. For brevity, we only explain three higher-order 
classes of features through the rest of this section. Readers can refer to the IBSI guideline for 
definitions of other higher-order feature classes [429] which we have implemented in our SERA 
software.  
 
Grey-level co-occurrence matrix (GLCM)-based features 
These features were originally developed to assess the texture of a surface in 2D images, but they can 
be extended 3D objects as well. Voxel intensities are usually discretized prior to calculation of the 
texture features with methods that were explained in section 3.1.3.1.  
The grey-level co-occurrence matrix (GLCM) is a matrix that expresses how two voxels “co-occur” 
with respect to one another; in other words, it expresses how combinations of discretized GLs of 
neighboring voxels are distributed along a certain direction and with a certain distance [434]. GLCM 
with a neighboring distance of 1 has a 26-connected neighborhood in 3D and 8-connected 
neighborhood in 2D, yielding 13 unique directions in 3D and four in 2D. Thus, for a 3D approach with 
a distance of one, an ROI has 13 unique GLCMs for every 13 direction.  
GLCM calculation across a certain direction is as follows. Let 𝑀𝑚be the 𝑁𝑔 × 𝑁𝑔GLCM matrix with 𝑁𝑔 
number of GLs present in an ROI intensity mask, and 𝑚 is a certain direction from one of the possible 
choices we presented in the previous paragraph. The element (𝑖, 𝑗) of the GLCM matrix 𝑀𝑚 contains 
the frequency at which combinations of GL 𝑖 and GL 𝑗 co-occur in neighboring voxels along the 
direction 𝑚. The GLCM, consequently, is a symmetric matrix. An example of GLCM with some 
highlights to help understand the matrix evaluation is presented in Figure 3-3. 
Figure 3-3. A sample GLCM 2D matrix for direction (1,0) and distance 1. GLCM is calculated on the discretized intensity ROI. 
Each element of the GLCM matrix is the frequency of neighboring voxels  and  in the given direction and the given distance. 
For example, the GLs in this image are between 1 to 4. they are 6 co-occurrence of GL “1” with GL “2” in the “right” direction 
with distance one in the figure above as marked by green color.   
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16- Inverse difference moment 
17- Inverse difference moment normalized 
18- Inverse variance 
19- Correlation 
20- Autocorrelation 
21- Cluster tendency 
22- Cluster shade 
23- Cluster prominence 
24- Information correlation 1 
25- Information correlation 2 
Each of the above features is derived from GLCM and returns a single value; i.e. each of the above 
features would have 13 values for each of the 13 GLCMs for 13 directions. GLCM can be calculated 
both in 2D with 4 different directions and in 3D with 13 directions, yielding 4 2D and 13 3D features, 
respectively. But only one value is ultimately reported as the final value, which means either GLCMs 
or features should be somehow combined. According to IBSI guidelines, there are six different 
methods to aggregate GLCMs and arrive at a single feature value, which results in six different feature 
calculation options as mentioned in Table 3-1. These methods are: 
1- 2D, averaged: Features are first computed from each 2D directional matrix. Then average 
feature over all directions and all slices.  
2- 2D, merged: First merge all 2D directional GLCMs over all directions per slice, then calculate 
features for this single merged GLCM, then average calculated features over all slices.  
3- 2.5D, averaged: First merge all 2D directional GLCMs over all slices per direction, then 





Grey-level run length matrix (GLRLM)-based features 
Figure 3-4. An example of GLRLM generation. The generated GLRLM is based on the (1,0) direction. Each element of GLRLM 
refers to the number of instances that a certain GL (rows) has appeared in the ROI with a certain run-length (columns). For 
example, there are only 2 instances of GL “3” with run-length of “2” as marked by green color.   
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Below is a list of IBSI features for GLRLM: 
1- Short runs emphasis 
2- Long runs emphasis 
3- Low grey level run emphasis 
4- High grey level run emphasis 
5- Short run low grey level emphasis 
6- Short run high grey level emphasis 
7- Long run low grey level emphasis 
8- Long run high grey level emphasis 
9- Grey level non-uniformity 
10- Grey level non-uniformity normalized 
11- Run length non-uniformity 
12- Run length non-uniformity normalized 
13- Run percentage 
14- Grey level variance 
15- Run length variance 
16- Run entropy 
Elaborating each feature is outside of the scope of this thesis, yet, we briefly describe an interesting 
pattern for generation of some GLRLM features that make them more intuitive to understand and 
occurs in other higher-order classes such as GLSZM, GLDZM and NGLDM. The first eight GLRLM 
features with an emphasis on high or low GLs and/or run-lengths are calculated by distributing 
weights in different patterns on the GLRLM matrix and then performing a weighted average based 
on these patterns to arrive at a single number. Figure 3-5 can be used to explain this. In the figure, 
darker colors represent higher weights, and lighter color represent lower weights. We observe that 
e.g. for short runs emphasis (SRE), more weight is given to the left side of the GLRLM where it 
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represents the elements with shorter run-length. As another example,  the long run low grey-level 
emphasis (LRLGLE), gives more weight both to (i) “long runs”, i.e. towards the right of GLRLM, and 
(ii) to “low grey-levels”, i.e. towards the upper side of the matrix. Therefore, the pattern is to give 
more weights towards the upper-right side of the GLRLM.  
 
Figure 3-5. The first 8 GLRLM features can be visualized by these weighting patterns for a 6 × 6 GLRLM. For example, short-
run low GL, puts more weight towards “short run-lengths” that is towards the left side of the matrix, and “low GLs” that is 
towards the upper side of the matrix, creating a weighting pattern towards the upper-left side of the matrix, and calculating 
the feature based on this weighted-average.  
 
Grey-level size zone matrix (GLZSM)-based features 
The grey-level size-one matrix (GLSZM) counts the number of zones, or connected components, of 
linked voxels. Voxels are considered in the same zone if their neighboring voxel has the same GL. As 
such, GLSZM, like other higher-level feature classes, require discretization of the ROI. However, 
unlike GLCM and GLRLM, GLSZM is not directionally-dependent.  
Let 𝑀 be the 𝑁𝑔 × 𝑁𝑧 GLSZM with 𝑁𝑔 representing the maximum GL present in the ROI intensity 
mask, and 𝑁𝑧 is the maximum zone size of any connected group of voxels. Then, an element of this 
matrix 𝑠𝑖,𝑗  represents the number of zones with GL 𝑖 and size 𝑗. Figure 3-6 shows an example of 
GLSZM generation.  
Figure 3-6. An example of GLSZM. Each element  represents the number of zones of connected voxels with grey level  
(rows) and zone size  (columns). For instance, they are two instances of grey level 2 with size 1, as it marked with a black color.  
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across all slices. The first 8 GLSZM features have the same intuition behind as the first 8 features of 
GLRLM as discussed in the previous page. They are based on weighted-average of GLSZM with a 
certain pattern described by the feature name, as shown in Figure 3-7. 
 
Figure 3-7. Weighing patterns of the first 8 GLSZM features. A similar approach to Figure 3-5.  
 
Other higher-order feature classes 
As mentioned before, there are other more complex higher-order radiomic feature classes that we 
do not elaborate here, and readers can refer to the IBSI guideline for detailed elaboration [429]. In a 
nutshell, these feature classes are as follows: 
Grey level distance-zone matrix (GLDZM)-based features 
GLDZM counts the number of groups of connected voxels with a specific GL value and distance to ROI 
edge. It contains an extra-level of information compared to GLSZM: it captures the relation between 
the distance from the edge, zone-size, and GL. Sixteen feature are derived from GLDZM.  
Neighboring grey level dependence matrix (NGLDM)-based features 




Neighborhood grey tone difference matrix (NGTDM)-based features 
NGTDM contains the sum of GL differences of voxels with a specific GL and the average discretized 
GL of neighboring voxels within a distance. Five features are computed from NGTDM.  
Overall, in our SERA product, we defined 487 unique radiomic features in 11 classes. These features 
can be calculated with different discretization levels (either fixed bin-size or fixed bin-number). 
Under the assumption that only two discretization levels are considered, the number of features in 
our parameters space is easily increased to 1000. At the same time, most radiomics studies hardly 
include more than a few hundred data points. As such, the important question is: Can we use these 
hundreds or thousands of features to correlate with or predict clinical outcome?  
 
3.2. Properties of Responsible and Reproducible Radiomics Research  
Although radiomics is a relatively young discipline and has experienced relatively fast growth (Figure 
1-18), it has not been yet been translated to routine clinical practice. This may be due to the low 
reproducibility of most current studies [436]. Radiomics has a complex workflow involving many 
steps that often suffers from incomplete reporting of methodologic information. Consequently, few 
radiomics studies available in the current literature are readily reproducible from start to the end 
[436]. Another major issue is the relatively small number of images in radiomics research datasets 
that may induce overfitting and high false-positive rates. This further worsens with the tendency to 
report overly-optimistic results [436].  
Guidelines and protocols are available for quality control measures in nuclear medicine imaging to 
standardize patient preparation, dose production and administration, image acquisition, image 
reconstruction, SUV normalization, etc., such that the absolute SUV values are interchangeable in 
multicenter studies [216]. To perform radiomics in PET, such standardized SUV measurements are 
crucial; yet, the methodology to prepare the image and calculate radiomic features is also subject to 
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variability, showing a crucial need for standardization [247, 437, 438]. Several studies have shown 
the importance of robust and standardized protocols to enable reliable quantification of 
heterogeneity with textural features.  They demonstrated an important need to standardize the 
computation methods due to the complexity of the radiomics workflow [216, 247, 436, 439]. In what 
follows, first, we briefly mention the causes of variability in radiomics workflow, following by an 
introduction to the IBSI effort, and then elaborate on the properties for a responsible radiomics 
research.  
3.2.1. Causes of variability in the radiomics workflow 
A serious challenge with the calculation of radiomic features is the very large number of features that 
can theoretically be calculated and different ways to calculate them. In addition, acquisition protocol, 
scanner variations, quantitative corrections, reconstruction algorithm settings (e.g. PSF vs. no PSF, 
number of iterations, etc.), post-reconstruction processing (Gaussian post-smoothing), as well as 
user-induced variations such as ROI definitions are all other sources of variability that increase the 
complexity and hamper the reproducibility. Figure 3-8 shows a flowchart of a typical radiomics 
workflow and summarizes a few of the choices that the user confronts during each step of the 
process.  
 
Figure 3-8. Points of variability in a radiomics workflow aiming at radiomic feature calculation and selection. 
3.2.2. The image biomarker standardization initiative (IBSI)  
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Table 3-2. Different configurations of the IBSI standardization effort  
 Config. A Config. B Config. C Config. D Config. E 
Approach 2D 2D 3D 3D 3D 
Interpolation - Yes Yes Yes Yes 
Voxel dimension - 2×2 2×2×2 2×2×2 2×2×2 
Interpolation Method - Linear  Linear Linear Cubic 
Range re-segmentation [-500,400] [-500,400] [-1000,400] - [-1000,400] 
Outliers re-segmentation - - - 3𝜎  3𝜎  
Discretization FBS FBN FBS FBN FBN 
Bin size 25 HU 32 bins 25 HU 32 bins 32 bins 
 
 
3.2.3. Standardized Environment for Radiomics Analysis (SERA) 
Using the comprehensive guidelines from the IBSI effort, we developed an entirely in-house Matlab®-
based framework to perform radiomics analysis, named as Standardized Environment for Radiomics 
Analysis (SERA). SERA is able to process images from different clinical imaging modalities such as 
CT, MRI, PET, and SPECT. Radiomic features calculated with SERA are standardized and in 
compliance with IBSI, which ensures their reproducibility, and have been adopted for a number of 
published research studies [293, 294, 310, 312, 325-328, 333].  
SERA calculates 487 IBSI-standardized features, including 79 first-order features (Morphology, 
Statistical, Histogram, and Intensity Histogram features), 272 higher-order 2D features, and 136 3D 
features. In addition to 487 IBSI features, it also calculates 10 Moment Invariant features, that are not 
included in IBSI. The detailed list of the number of features in each class is the same as Table 3-1.  
3.2.3.1. SERA configurations 
SERA has options to set and modify all parameters that have been defined or used in the IBSI 
guideline. The image preparation configuration includes the following: 
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Resampling and interpolation:  
SERA can resample to 2D and 3D isotropic voxel sizes; interpolation algorithm used in resampling 
image and ROI (nearest/linear/cubic); partial volume threshold (mostly used for CT HU). 
Discretization:  
Parameters to change include bin size, discretization type (fixed bin-size/fixed bin-numbers), and 
separate discretization for IVH features. 
Other settings 
Other settings including grey-level rounding, image re-segmentation (range re-segmentation, 
outliers). 
3.2.4. Results of our IBSI standardization effort 
From the 21 participating centers, SERA was one of the only three packages that included 100% of 
the IBSI features. It took several trials for some of the features to be fine-tuned, where we fixed our 
definitions and code by receiving feedback from IBSI organizers. Table 3-3 shows the results of our 
most recent feature calculation on the five categories defined in Table 3-2. It includes a number of 
features in each category, the number of features SERA matched with IBSI benchmarks, and the 
overall accuracy of each category. 
Table 3-3. Results of our IBSI standardization effort 
 Config. A Config. B Config. C Config. D Config. E 
No. of features for config 351 351 215 215 215 
No. of matched features 320 315 207 209 20 
No. of no matched 18 16 3 1 5 
No. of partial matched 0 0 0 0 0 
No. of features with no consensus  14 20 5 5 191 





3.2.4.1. Observations  
One very interesting and important observation from our IBSI effort is that even with different 
centers using the same detailed workflow configuration and feature formulation, the reported 
feature values were highly variable when using the exact same image and the same ROI!  This further 
emphasizes the variability issue in radiomics research, though it also demonstrates that inter-center 
agreements can increase over time with coordinated efforts. Another observation was more 
variability in configurations D and E in Table 3-2 where more sophisticated interpolations were used.  
3.2.5. Properties of an effective radiomic feature 
Aside from standardization of radiomic features, further steps should be taken within a radiomics 
workflow to reduce the feature-space dimension and to prevent overfitting. Below we discuss some 
important properties of an ideal radiomics feature, as well as some recommended techniques to 
assess them [247]. 
3.2.5.1. Repeatability 
Repeatability is related to the variability of a given radiomic feature when obtained under the same 
conditions; i.e. from two separate scans of the same subject performed close together in time. To 
assess repeatability, some studies have suggested comparing metrics calculated on test-retest PET 
images using e.g. the Bland Altman method for comparison. [441, 442]. 
 
3.2.5.2. Reproducibility  
Reproducibility is related to the variability of a given radiomic feature when obtained under varying 
conditions; e.g. by varying processing parameters to compute the features (Table 1-5). Section 3.2.3 
outlined several causes that may induce variability before, during, or after data acquisition. As an 
example, different configuration settings within the radiomics workflow itself, such as segmentation 
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method, discretization type, discretization bin size, etc. can be sources of variability. To assess the 
reproducibility of radiomic features, they can be calculated through differing analysis pipelines [442]. 
Features can be computed for different parameter settings, followed by analysis to identify features 
with substantial variability (i.e. low reproducibility) when varying certain parameter settings. 
Examples of these analyses will be provided later in section 3.3.  
3.2.5.3. Redundancy  
Features can be quantified through statistical and rank correlation analyses in order to find and 
eliminate redundant features [314, 317, 438, 443]. Certain machine learning techniques can be used 
to select features or combine them [444].  
3.2.5.4. Offers value with regards to a given clinical endpoint 
Features that survive the above refinement steps should also be analyzed with respect to the tasks 
or outcomes of interest, e.g. response to treatment, diagnosis, prognosis, etc., to select only those that 
offer value. A number of robust machine learning techniques are available to use for these regression 
or classification techniques [445].  
 
3.3. Feature Selection and Reproducibility of Radiomic Features in Nuclear 
Medicine 
In this section, we present two studies on feature selection and reproducibility of radiomic features 
in SPECT and PET. Each study was performed on a unique nuclear medicine dataset. We aimed to 
investigate the feature-space to eliminate non-reproducible, or redundant features. Some of these 
efforts have been presented to the community [314, 317]. At the same time, we did not perform 




3.3.1. Reproducibility of Cold Uptake Radiomics in 99mTc-Sestamibi SPECT Imaging of Renal 
Cell Carcinoma  
99mTc-Sestamibi SPECT/CT imaging of renal cell carcinoma (RCC) has recently shown significant 
promise to distinguish benign oncocytomas from malignant RCC, where the former appears as high 
uptake in SPECT images and the latter as cold uptake. We aim towards radiomics analysis of cold 
uptake in SPECT images towards another significant yet more daunting task of discriminating 
between RCC subtypes.  
3.3.1.1. Introduction 
Recent studies on 99mTc-sestamibi single-photon emission computed tomography / computed 
tomography (SPECT/CT) imaging of renal tumors have shown promising results for distinguishing 
renal cell carcinoma (RCC) from benign oncocytomas [446]. While normal renal tissue has positive 
radiotracer uptake on 99mTc-Sestamibi SPECT, these studies reported positive (hot) uptake for benign 
cases and negative (cold) uptake for RCC. RCC has several histologic subtypes including clear cell, 
papillary, and chromophobe variants (Figure 3-9). It is an open question as to whether cold 99mTc-
sestamibi uptake has the potential to discriminate between these subtypes of RCC. 
Radiomics analysis, via its combination of effective metrics that quantify shape and texture/ 
heterogeneity, holds significant promise towards identifying patients with higher risk and to help 
realize personalized medicine. It is been widely studied in oncologic MRI, CT, and PET [229, 291, 424, 
447-449], and recently also was explored in brain SPECT imaging by our group [292]. This work 
presents another novel exploration of radiomics in SPECT analysis. In addition to, it is, to our 
knowledge, the first application of radiomics to cold uptake imaging. Overall, we aim to preform 
radiomics analysis of 99mTc-sestamibi SPECT for the potential to discriminate different RCC types. 
The purpose of the present specific study is to perform feature selection, by assessing the 
reproducibility and reliability of radiomic features in ⁹⁹ᵐTc-Sestamibi SPECT images, and to derive 
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robust features for correlation with tumor histology. Radiomics analysis usually involves evaluating 
hundreds of radiomic features for correlating with clinical data. The present reproducibility analysis 
aims to exclude radiomic features that are non-reproducible, non-repeatable, and redundant, in 
order to avoid data overfitting and to enable proper classification with clinical endpoints [247, 314, 
317, 442, 445, 450-452].  
 
Figure 3-9. a) postcontrast CT image of a patient with Oncocytoma, b) 99mTc-sestamibi SPECT/CT scan of the patient shows 




50 patients presenting with a solid solitary clinical T1 renal mass were imaged with 99mTc-sestamibi 
SPECT/CT as part of a prospective study evaluating the diagnostic performance of this imaging test. 
All patients also had a contrast-enhanced CT or MRI scan. A trained radiologist used contrast-
enhanced CT or MRI scans along with co-registered SPECT/CT images to manually segment a region 
of interest (ROI) around the renal mass on the SPECT image. Segmenting the tumor with a cold uptake 





registering two image sets: 1) CT of SPECT/CT and 2) a contrast-enhanced CT or MRI to anatomically 
localize the mass. Then, both CT images should be co-registered with the SPECT. Second, low-
resolution SPECT images and their large voxel sizes require more meticulous contouring to minimize 
exclusion of tumor voxels. Third, the inclusion of normal renal tissue with high activity right next to 
the tumor conspicuously disrupts the cold uptake ROI and should be also minimized. At the same 
time, the segmented cold-uptake ROI should be free from any voxels from the cold-uptake 
background, too. These reasons evidently show the importance of studying the reproducibility of 
segmentation for 99mTc-sestamibi SPECT RCC images.  
To study the impact of segmentation on reproducibility, we generated three more ROIs from the 
manually segmented ROIs, with removing one (shrinkage) and adding one and two voxel-layers 
(enlargement) to the ROI in all three dimensions. These ROIs were created by thresholding a 
Gaussian-blurred version of the binary ROIs with different values. Images were then uniformly 
quantized using the fixed bin-number discretization into eight different gray-levels (GLs) (22, 23, …, 
29). We used SERA (section 3.2.3) with all features except 2.5D higher-order features as presented in 
Table 3-1. Table 1 contains the details about the radiomic features classes.  
For the four segmentations, Spearman’s rank correlation was calculated between each quantization 
pair to find relatively consistent quantization levels. The intra-class correlation (ICC) between 
remaining GLs across all patients was used to adopt robust features for segmentation. Furthermore, 
features were studied with regards to their characteristics to propose a more practical and 
reproducible set of features. 
 
3.3.1.3. Results  
Reconstructed RCC SPECT images are not expressed in the form of quantitative metrics such as 
standard uptake value (SUV) in PET imaging. Instead, voxel intensities denote the number of counts, 
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which might be further different from the true counts due to specific scaling by some scanners. In the 
current dataset, the range of the maximum voxel intensities was 600~8000. For such a non-
normalized dataset, radiomic features assuming normalized voxel intensities are meaningless. Thus, 
only a subgroup of the non-normalized statistical features will be practical. These features include 
variance, skewness, kurtosis, the coefficient of variation and quartile coefficient of dispersion. 
Moreover, a fixed number-of-bins quantization should be performed, as fixed bin-width quantization 
is impractical due to the same reason of non-normalized images.  
We evaluated the intra-class correlation (ICC) of features vs. segmentation to assess their 
reproducibility to segmentation. We defined two sets of ROIs: all four ROIs, including the manually 
segmented plus the three resized ROIs denoted by G1, and all ROIs except the shrunk one denoted by 
G2. We subsequently evaluated the ICC of features to segmentations in G1 and G2 separately. We also 
evaluated the ICC for different GLs, too. Figure 3-10 shows four plots depicting ICC of features vs. 
segmentation (both G1 and G2) and for two GLs (32 and 512). The comparison of these ICC values 
had led us to several interesting observations. The general trend shows a higher ICC for moderate 
GLs (e.g. 32) as can be seen in Figure 3-10.c and Figure 3-10.d. A large group of features evaluated 
with higher GLs exhibits lower ICC. This is due to the presence of outlier voxels from the nearby high-
uptake tissue that becomes more pronounced in higher GLs causing more variability. Moreover, we 
observe that ICC generally decreases as we include the shrunk ROI in the segmentation set (i.e. G2 vs. 
G1) for most features without altering the trend (Figure 3-10). This indicates a high sensitivity of 
most of the features to segmentation. More precisely, ICC>0.7 and ICC>0.85 for G1 and G2, 
respectively, leads to exactly 204 features, and these two feature sets have Spearman correlation of 
one; i.e. adding one more ROI nearly decreases ICC values but does not change their order. 
Figure 3-10. ICC type C-1 between all 363 radiomic features and segmentation: a) three segmentations (all except shrunk ROI) 
with 512 GLs, b) all four ROIs with 512 GLs, c) three segmentations (all except shrunk ROI) with 32 GLs, b) all four ROIs with 
32 GLs. Feature classes introduced in Table 1.
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Figure 3-11 depicts the Spearman correlation between GL=512 and seven smaller GLs. It shows a 
relatively consistent Spearman-correlation≥0.5 for gray-levels≥32, suggesting the exclusion of lower 
GLs. Also, ordering of features was retained for GL larger than 32, but not for 16 and under. At the 
same time, very high GLs like 256 and 512 should also be avoided due to their sensitivity to the 
inclusion of high counts and misregistration/segmentation as mentioned above. Therefore, unlike 
radiomics analysis of the high-uptake images such as in PET, having higher GLs does not necessarily 
imply better quantification.  
 
Figure 3-11. Absolute Spearman rank correlation between feature classes calculated with all eight GLs and GL=512. The figure 
shows consistent corr>0.8 for GL≥32 and all radiomic feature classes except NGTDM 2D 
Furthermore, we plotted the Spearman correlation between the top 20 most reproducible features 
(from the previous steps) and tumor volume in Figure 3-12. We observe a decreasing trend that 
indicates radiomic features may provide complementary information to tumor volume, which is 
partially due to the impact of partial volume effect in the reconstructed image.  
Figure 3-12. Spearman correlation between tumor volume and top 20 most reproducible features with the highest Spearman 
correlation with volume, GL=512, manual segmentation. Most features exhibit a decreasing trend as the volume increases. Only 
for volumes>5cc other radiomic features may provide complementary information, that is due to the partial volume effect 
3.3.1.4. Discussion  
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does not carry much information from a tumor with a cold uptake and is sensitive to misregistration/ 
segmentation. Instead, features with a rather uniform waiting on all GLs should be adopted. These 
features are recommended for further investigation of the significant discrimination task amongst 
RCC tumor subtypes. 
 
3.3.2. Reproducibility of Radiomic features in 18F-DCFPyL PET Imaging of Prostate Cancer 
3.3.2.1. Introduction  
Prostate cancer (PC) is the second most common cause of cancer-related death in men [453]. PC is 
often curable; however, many patients experience a residual, recurrent, and metastatic disease that 
require imaging for diagnosis, lesion detection, therapeutic monitoring, and staging [454]. Prostate-
specific membrane antigen (PSMA) is a transmembrane protein that is highly relevant in prostate 
cancer theranostics because of its marked overexpression in prostate cancer [455]. The past decade 
has seen significant growth in design, synthesis, and evaluation of radiotracers targeting PSMA for 
imaging and therapy. An increasing number of studies are demonstrating additional diagnostic value 
in the primary staging of intermediate- to the high-risk stage and in the late metastatic phase of PC. 
PSMA PET/CT imaging is capable of localizing lesions for primary PC staging that is not evident on 
standard-of-care imaging, leading to major impact in early diagnosis and treatment planning [456]. 
PSMA PET is also shown to demonstrate higher lesion detection rate at lower serum prostate-specific 
antigen (PSA) levels compared to other PET radiotracers or standard-of-care imaging. This has major 
implications on biochemical recurrence staging and therapy planning [457, 458].  
18F- and 68Ga-labeled inhibitors of PSMA have entered early clinical development for PET imaging of 
PC since 2012, and have demonstrated great promise for identification of local and distant sites of PC 
with high sensitivity and high specificity [454, 459]. One of these 18F-labeled PSMA inhibitors, 
developed at Johns Hopkins University, is 2-(3-(1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-
Figure 3-13. An example of a [18F]DCFPyL PET/CT image. “A” shows a coronal CT slice, “B” shows the corresponding PET slice, 
and “C” shows the fused PET/CT. Primary lesion in prostate gland is shown by a purple arrow in “B”, and three metastatic 




• four threshold-based segmentations ranging from 30% to 60% of SUVmax, seed placement by 
a nuclear medicine physician.  
Images were resampled to isotropic cubic voxels of 2 mm for consistency. Two different methods of 
fixed bin-number discretization (uniform and Max-Lloyd [461]) were considered with seven 
different GLs (4, 8, 16, 32, 64, 128, and 256) that were used for higher-order textural features 
extraction. In addition to five conventional quantitative uptake measurements (SUVmax/peak/mean, 
tumor volume (TV), total lesion activity (TLA)), a total of a selected set of 87 radiomics features were 
extracted for each ROI per each patient and for each discretization level. These 92 features include: 
11 first-order, 9 morphological, 26 GLCM, 12 GLRLM, 13 GLSZM, 5 GLTDM and 10 moment-invariant 
(MI) features [462] (Table 3-4). Spearman rank correlation analysis was performed for the seven 
discretization levels and the two methods to determine reliable and practical GLs. We further 
quantified the intra-class correlation (ICC) to inspect the reproducibility of features across six 
segmentations and seven GLs of two quantization methods. The statistical relationship between all 
92 features was also explored based on the optimum GL and manual segmentation. 
3.3.2.3. Results 
SUVmax derived from primary tumors of 25 patients ranged from 5.6 to 51.8 (15.8±11.5). Tumor 
volume ranged from 0.5 to 61 cc (7.3cc±11.8cc). Figure 3-14 shows the distribution of SUVmax and 
tumor volume across these 25 patients for each of the 6 segmentation types. The left plot in Figure 
3-14 shows an almost identical distribution of the 25 cases across all segmentation, which is due to 
the very high reproducibility of SUVmax with respect to segmentation. The right image shows the 
proximity of PET-edge segmentation and manual segmentation. It also demonstrates the closes 
threshold-based segmentation distribution to the manual segmentation is 30% and 40% 
segmentation. 
Table 3-4. List of selected radiomic features categorized based on each feature class used in this study. 
Figure 3-14. Statistical distributions of SUVmax and MTV for 25 patients across 6 different segmentation methods, 64 GLs of 
uniform quantization 
Figure 3-15. Heat map depicting the absolute value of Spearman correlation coefficients between pairs of textural features 
(left) and their log p-values (right). 
Figure 3-16. Spearman correlation of top 20 most reproducible features with the highest Spearman correlation based on and 
uniform quantization gray-levels with SUVmax (left) and MTV (right), with 64 uniform gray level and manual segmentation. 
Most features exhibit a decreasing trend as the range shortens. 
Figure 3-17. ICC between all six segmentations for (left) and between only 2 user-guided segmentations (right) for all 92 




(GLSZM) exhibit high reproducibility and reliability in this study of 18F-DCFPyL prostate PET. This is 
an interesting finding since these features are also reported to be reproducible for radiomics studies 
using FDG PET as well [247]. This finding indicates high reproducibility across radiotracers for the 
aforementioned features. As a result, these set of features are recommended for investigation of their 
possible prognostic or predictive value. 
 
3.3.3. Conclusion 
In this chapter, we provided more details about the radiomics workflow and explained how the 
complexity of radiomics analysis impacts reproducibility and reliability. In addition, we presented 
recommendations on how to configure and then assess radiomics analyses to mitigate these issues. 
We further explained our efforts in joining the image biomarker standardization initiative (IBSI)—a 
global group of top universities and cancer centers aimed to standardize the preprocessing and 
feature calculation of radiomics analyses. We developed a standardized environment for radiomics 
analysis (SERA) – an entirely in-house toolbox for image preprocessing and feature calculation based 
on the IBSI guidelines with 100% coverage of the features, released for use by the wider community. 
Furthermore, we presented two studies on reproducibility analysis of radiomic features: in renal cell 
carcinoma SPECT and prostate cancer PET imaging. Some radiomic features such as GLCM entropy 
as well as GLSZM zone-size non-uniformity and zone-size variance were reported as reproducible in 
both studies. Also, fixed bin-number discretization with 64 to 128 GLs was reported to convey 
enough details about variabilities inside ROIs that can be captured by different feature classes 
without discarding important heterogeneity information. Several of the reported features were not 
only found to be reproducible in our specific studies but also have been reported to be reproducible 
in studies with other radiotracers, indicating their broader appeal and potentials. Furthermore, 
features reproducibility was significantly challenged by segmentation methods. We suggest that 
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more advanced segmentation methods with higher accuracy and less inter- and intra-reader 
variability may need to be adopted for reproducible radiomics. Overall, the two presented projects 
are the first studies of their kind in their specific clinical applications and can be used in future efforts 









4. Radiomics Analysis of Clinical Myocardial Perfusion Stress 
SPECT Images to Identify Subclinical Coronary Artery 
Disease 
4.1. Introduction  
This chapter aims to enhance the clinical utility of routine clinical myocardial perfusion (MP) SPECT 
imaging through advanced radiomics analysis. We hypothesize that identification of mild 
heterogeneities via radiomic analysis can enable identification of subclinical coronary artery disease 
(CAD) that would carry important diagnostic and prognostic information. In this chapter, we aim to 
evaluate our exciting and novel hypothesis that MP SPECT radiomic features extracted from clinically 
normal (non-ischemic) MP SPECT scans correlate with coronary artery calcification (CAC) as 
extracted from CT imaging. This chapter starts with an introduction to myocardial perfusion imaging 
using SPECT, as well as coronary artery calcification scoring using CT, as well as clinical motivations 
for our work; subsequently, we describe our methods, following by results and conclusion.  
 
4.1.1. Myocardial Perfusion stress SPECT test 
4.1.1.1. Basics of Myocardial Perfusion Imaging  
Myocardial perfusion SPECT (MPS) is established for non-invasive evaluations of patients suspected 
with coronary artery disease (CAD)[463, 464]. It is probably the most widely-used technique of 
nuclear cardiology, and its purpose is to assess the adequacy of blood flow to the myocardium [465]. 
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Although MP imaging can be performed with either planar or tomographic techniques [465, 466], 
nowadays tomographic MP imaging through SPECT scanners has become widely-popular, more 
accessible and more affordable to patients.  
A standard MP SPECT exam consists of two SPECT scans, one under rest and one under stress 
condition, although recent studies have shown if first the “stress” test is taken, and the image is 
interpreted as normal, there is no need for the second “rest” test, which is referred to as “stress-only” 
image [467]. The stress MP test is usually performed following a physical exercise (e.g. on a 
treadmill), or intravenously administered stress pharmaceuticals such as adenosine or dipyridamole.   
MP stress SPECT has an established pathophysiologic basis with radiotracers capturing blood flow. 
If a patient with CAD is at rest, typically, blood flow through a diseased coronary artery (e.g. narrowed 
through plaque build-up) is not decreased until coronary stenosis exceeds 90% of the artery. On the 
other hand, coronary reserve, which refers to the ability to increase coronary blood flow in case of 
increased metabolic demand, is reduced if coronary stenosis exceeds 50% [468, 469]. As a result, 
patients suffered from CAD may have a homogenous uptake of myocardial blood flow even in the 
presence of severely-narrowed coronary artery. But the same degree of narrowing can result in 
reduced flow reserve when the heart is stressed under exercise, resulting in inhomogeneity of 
regional MP (Figure 4-1). Such inhomogeneity can be captured using radiotracers that are distributed 




Figure 4-1. MP SPECT image of a patient with myocardial ischemia. The top and the bottom views show images acquired at 
stress and rest, respectively. The arrow shows decreased blood flow (reversibility) at the inferior wall in the stress image at the 
place of the arrow compared to the rest—a typical sign of myocardial ischemia. 
MP SPECT is typically performed by administrating 99mTc-sestamibi. Technetium-99m is a gamma-
ray emitting radionuclide that rays at 140 keV and is optimally suited for imaging with a gamma 
camera. It is possible to give patients two doses of 99mTc-Sestamibi on a single day, while the latter 
dose must be higher than the first one, e.g. 10mCi for the first scan and 35mCi for the second one. The 
image acquisition varies between 20 to 45 minutes.  
Several visual patterns are common in MP imaging. A normal pattern consists of uniform 
homogenous uptake of the radiotracer all around the left ventricle. A defect may be identified at areas 
where the myocardium exhibits relatively lower tracer uptake, such as the one shown with a red 
arrow in Figure 4-1. A defect is considered reversible if it is present at the stress image but is no 
longer present, or partially improved, on the rest image. A fixed defect, such as a myocardial infarct, 
remains unchanged in extent or severity on both rest and stress images.  
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4.1.1.2. Applications of MP SPECT imaging 
MP SPECT imaging has extensive clinical applications. The sensitivity and specificity of stress imaging 
for detection of CAD using visual assessment have been reported at over 90% with SPECT and 95% 
with PET (using 82Rb or 13N) [470]. However, 13N requires an on-site cyclotron for production, and 
82Rb has a monthly associated cost of generator replacement, plus SPECT cameras have a clear 
affordability advantage over PET scanners. In addition, MP SPECT has high prognostic value, and 
whether a patient has a reversible perfusion defect plays a strong role in the assessment of risk [471]. 
Patients with reversible MP defects have a higher likelihood of CAD events during follow-up 
compared with patients with fixed defects. Further applications of MP SPECT imaging include 
preoperative screening before major noncardiac surgical procedures to assess their perioperative 
risk [472-474], imaging after coronary angioplasty to detect restenosis—a common problem in 20 to 
40 percent of the patients undergoing this procedure [475], assessment of MP in acute ischemic 
syndrome in patients with unstable angina [476], and accurate assessment of myocardial viability 
[477].  
4.1.2. Coronary artery calcification quantitation using coronary artery calcium scoring 
Large prospective studies have shown that coronary artery calcification (CAC) scoring is associated 
with the risk of future cardiovascular events [478-481]. Studies have shown that noninvasive tests 
for CAD including electrocardiogram (ECG), ultrasound imaging, and even MP SPECT scan, which are 
used quite often in cardiac patients’ assessment and diagnosis, were of limited value to detect this 
calcification due to their low sensitivity [482]. A minimum of 25% of the patients that experience a 
non-fatal acute myocardial infarction or sudden death do not have previous symptoms [483], and it 
is necessary to identify asymptomatic individuals at greater risk of future cardiovascular events to 
plan for preventive strategies.  
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Our Motivation: CAC is a highly specific marker of coronary atherosclerosis, and higher CAC scores 
are associated with increased plaque burden and increased cardiovascular risk [484, 485]. Previous 
studies demonstrated that a considerable number of stenoses do not result in abnormal perfusion on 
MP imaging [486, 487], which is why in our work we set the inclusion criteria of “non-ischemic 
normal” MP stress scans. Furthermore, the CAC score is shown to offer incremental diagnostic 
information over MP SPECT for identifying patients with significant CAD and negative MP imaging 
results [488]. Therefore, finding a feature or a set of features (a radiomics signature) from MP stress 
SPECT images that can predict CAC score would be beneficial as it eliminates an additional non-
contrast CT for CAC assessment, thus reducing excessive dose to the patient. Unlike MP SPECT, CAC 
test is not reimbursed by CMS, while it is known to improve risk stratification in asymptomatic 
individuals [484, 486]; but our study enables CAC assessment from MP SPECT. Moreover, CAC 
calculation requires sophisticated software and trained radiologists. It is included in the CAD 
patients’ diagnosis package in large institutions such as our Johns Hopkins Hospital but is not readily 
available in community settings.  
CAC scoring is performed using a CT scan based on its axial slices in synchrony with ECG without 
administrating any contrast agent [489]. Calcification is referred to an area of hyper-attenuation with 
≥ 1 mm2, or ≥ 3 adjacent voxels, of >130 Hounsfield Units (HU) [490]. The main scoring CAC protocol 
is the Agatston method [490] that is widely-used, especially as a reference for most population 
databases and risk stratification studies, thus, is the most important method often used in clinical 
practice. This method uses the weighted-sum of lesions with a density above 130 HU, where the area 
of calcium is multiplied by a factor related to the maximum plaque attenuation as follows: 
• 130 – 199 HU, factor 1 
• 200 – 299 HU, factor 2 
• 300 – 399 HU, factor 3 
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• ≥ 400 HU, factor 4 
According to the Agatston method, this score is calculated for each of the four three arteries of the 
heart, namely the left anterior descending (LAD) the right coronary artery (RCA) and the left 
circumference (LCX), as well as the left main (LM). LM is a small artery that divides into LAD and LCX 
(Figure 4-2). This calculation, despite being relatively straight-forward, requires special software and 
the cost associated with its licensing requirements might be another hurdle in the widespread 
application of CAC scoring in smaller cost-effective radiology centers.  An example of CAC present in 
a CT image shown in Figure 4-3. 
 
Figure 4-2. Main coronary arteries of the heart: left main (LM) which divides into left anterior descending (LAD) and left 
circumference (LCX), and right coronary artery (RCA). Coronary artery calcification is present in LAD that results in reduced 
blood flow to this artery (pale color of the LAD).  
Figure 4-3. Coronary artery calcification in three main arteries of a patient. The left image depicts slices of heart with CAC in 
their RCA and LAD, and the right image shows CAC in LCX.  
4.1.3. An overview of our framework 




4.2. Radiomics of MPS to Predict Coronary Artery Calcification 
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4.2.1. Three Steps in Our Study 
Step 1: Improved quantitative assessment through analysis of standardized radiomic features on MP 
SPECT images. We start by identification of patients with normal MP SPECT test and CAC CT, 
following by image segmentation.  
Step 2: Eliminating non-reproducible and redundant features (feature selection).  
Step 3: Use of machine learning to extract CAC information directly from MP SPECT image radiomics, 
in contrast to the routine use of CT scans.  
  
4.2.2. Methods 
4.2.2.1. Patient collection  
After obtaining approval from the institutional review board (IRB) at Johns Hopkins University, we 
searched for patients with stress myocardial perfusion SPECT scans from 2011 till 2015. In this effort 
which lasted about 4 months, we investigated over 1,800 reports of patients undergone MP stress 
SPECT, out of which n=428 cases were selected. All of these patients had a CT scan for CAC scoring at 
the same time as their MP stress SPECT scan in the PACS database. A nuclear medicine physician 
(NMP) investigated the MP stress SPECT images to be free from i) image artifacts, and ii) 
overcorrection and iii) spillover from nearby liver or stomach. Our NMP also derived detailed CAC 
score for each of the 4 arteries of the heart using a clinical software. 
The dataset consists of mages collected from scanners with different vendors at the Johns Hopkins 
Hospital throughout these years, but all were reconstructed with an “attenuation-corrected iterative 
reconstruction” (AC-IR) algorithm and with a consistent voxel size of 4.8 mm. According to the quality 
factors of radiomics research, this is an important characteristic of a study to have imaging 
167 
 
acquisition protocols that are “well described and ideally similar across patients”, and “methodologic 
steps taken to incorporate only images of sufficient quality” [436]. 
We recorded many parameters for each patient, including basic information, clinical factors, scan 
info, and any possible outcome info, as detailed in Table 4-1.  
Table 4-1. Information recorded for every patient during dataset collection. 




• Hight  
• Weight (at scan 
time) 




• Family history of 
cardiac disease 
• Systolic blood 
pressure (SBP) 
• Diastolic blood 
pressure (DBP) 
 
• Scan date 
• Scan impression 
(normal, fixed 
defect, ischemia)  
• Stress test type 
(Bruce vs. drug) 
• Left ventricle 
ejection fraction 
(LVEF)  
• CAC score (LM, LAD, 





• Date of 
death/cardiac 
related progression 
• Date of the last 
follow-up 




4.2.2.2. Image segmentation  
The study involves three different layers of segmentation as applied to MP SPECT images: i) total 
myocardium, ii) three vascular segments, and iii) 17 polar segments. Feature evaluation and 
statistical analysis were performed over all three layers. These three segmentation methods are 
presented in Figure 4-5. The reason we selected two different methods for vascular segmentation is 
that both methods are widely-used in the clinic. The 3 vascular segment method has a more stringent 
segment, while the subsets of the 17 polar segments span the whole heart, as can be observed from 
Figure 4-5.  
We used MIM software® and developed a workflow that automatically draws 3D contours over 21 
regions of the heart, namely: endocardium, epicardium, 3 vascular segments (as depicted in Figure 
4-5.B), and 17 polar segments (as depicted in Figure 4-5.C). The workflow was generating the 
Figure 4-5. Three methods of segmentation used in our study. A) myocardium segment. B) 3 vascular segments of the heart 
(LAD, RCA and LCX), and C) subsets of 17 polar segments of the heart grouped into LAD, LCX and RCA.  
4.2.2.3. Radiomics Framework 
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(section 3.2.2). SERA calculates 487 standardized radiomic features aiming to standardize the 
preprocessing and feature evaluation phases and to meet ISBI’s standards in order to conduct and 
pursue reproducible research [450]. 
Images produced for MP SPECT scan are arbitrary-unit. Therefore, as explained in the last chapter in 
“Intensity discretization” subsection under section 3.1.3.1, we ought to use the fixed bin number 
discretization. We considered and investigated a range of GL discretizations, specifically using 4, 8, 
16, 32, 64, 128, 256, and 512. All the images in our dataset were reconstructed into 3D images with 
identical voxel sizes of 4.8×4.8×4.8 mm3; thus, no resampling and interpolation was needed. We did 
not perform any GL rounding or re-segmentation. The framework was then ready to calculate 487 
features for 8 GLs and 7 segments of the heart. 
 
4.2.2.4. Statistical Analysis 
We used statistical analysis to eliminate non-useful features, including features that are identical, 
non-robust, and redundant. We performed a multistep feature selection to significantly reduce the 
size of our feature-space of 487×8 features. This process was performed completely independent of 
outcome (e.g. CAC score, etc.). The selected feature set was subsequently passed on to univariate and 
multivariate analyses schemes to predict correlate with clinical outcome. We also accounted for false-
discovery by employing false-discovery correction methods such as Benjamini-Hochberg [491].  
 
4.2.3. Analyses and Results  
4.2.3.1. Analysis of dataset statistics 
In this section, we present the data statistics based on variables previously introduced in section 
4.2.3.14.2.2.1. We searched for patients with stress myocardial perfusion SPECT scans from 2011 till 
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2015. In this effort which lasted about 4 months, we investigated over 1,800 reports of patients 
undergone MP stress SPECT, out of which n=428 cases were selected. All these patients had a CT scan 
for CAC scoring at the same time as their MP stress SPECT scan in the PACS database. Our NMP also 
derived detailed CAC score for each of the 4 arteries of the heart using a clinical software. 
The dataset consists of mages collected from scanners with different vendors at the Johns Hopkins 
Hospital throughout these years, but all were reconstructed with an “attenuation-corrected iterative 
reconstruction” (AC-IR) algorithm and with a consistent voxel size of 4.8 mm. According to the quality 
factors of radiomics research, this is an important characteristic of a study to have imaging 
acquisition protocols that are “well described and ideally similar across patients”, and “methodologic 
steps taken to incorporate only images of sufficient quality” [436]. 
We recorded many parameters for each patient, including basic information, clinical factors, scan 
info, and any possible outcome info, as detailed in Table 4-1. 
Basic statistics 
The dataset was comprised of 229 female (49.7%) and 232 male (50.3) subjects. Distributions of 
patient age, height, weight, and body-mass index based on gender is depicted in Figure 4-6. 
Figure 4-6. Distribution of patients’ A) age, B) weight, C) height and D) BMI at the time of scan grouped into male (orange) and 
female (blue) 
Table 4-2. Distribution of the race of the patients 
Clinical factors 
Table 4-3. Distribution of patients’ clinical factors 
Figure 4-7. Distribution of LVEF in the dataset 
et al.
Figure 4-8. Distribution of our patients’ CAC score based on widely-used stratification criteria [486]. 
Patient outcome  
Figure 4-9. Distribution of cardiac-related progression and patients’ death for normal patients in our dataset
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4.2.3.2. Feature selection  
All 487 features in our SERA software from 11 main categories as mentioned in Table 3-1 were 
initially considered and were calculated for 8 different GLs. In this section, we aim to systematically 
narrow down this large feature set and arrive at a smaller set of meaningful, robust, non-redundant, 
and reproducible features for further investigation of their predictive or prognostic value and, at the 
same time, discourage overfitting. Our feature selection phase can be generally divided into i) pre-
feature calculation and ii) post feature calculation, as explained below. Following feature selection, 
we discuss how to narrow down to an optimum discretization level.  
 
Pre-feature calculation  
In the first step, prior to performing any analysis, we eliminate irrelevant feature families based on 
the nature of our dataset and our knowledge about what each feature captures.  
Removing 2D and 2.5D feature families 
Our dataset originally consists of images with isotropic voxels. Therefore, there would be no 
additional information provided to us from 2D or 2.5D feature families. These feature families would 
have been beneficial when slice thickness (i.e. voxel size in z dimension) was different from the voxel 
size in x and y dimensions. In that case, resizing and interpolating the images to isotropic voxel sizes 
may have resulted in modification of the original voxel distribution, causing possible loss or 
modification of data. In any case, the following feature families were eliminated: 2D and 2.5D GLCM 
(25 features) and GLRLM (16 features) (both merged and averaged), 2D and 2.5D GLSZM (16 
features), GLDZM (16 features), NGTDM (5 features), and (17 features). This removed 272 features, 
narrowing down our feature space to 215. 
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Removing useless feature families  
MP SPECT images have voxels with arbitrary units (they are not quantitative unlike PET or some 
SPECT imaging applications). Therefore, any feature that conveys information regarding the exact 
intensity values of the original ROI is not considered meaningful. As such, intensity-based features 
(18 features) and local intensity features (2 features) were excluded. Furthermore, the seven 
segments were created by an automatic segmentation procedure that generates ROIs with similar 
shapes (all registered to the same reference space). As such, the shape of the segments does not carry 
any differentiating information, and we are interested mainly in the heterogeneity caused by voxel 
intensity variations which carry information about the blood flow in different heart segments. As 
such, morphological features (29 features) were excluded as well. At the end of this step in our 
analysis, we were left with 166 features out of 487, eliminating the majority via our knowledge of the 
underlying nature of the features.  
 
Post-feature calculation  
Removing feature with identical values 
Following this, we searched for features with identical values across all patients for further exclusion. 
In our dataset, these were 4 features with identical values across all patients: histogram minimum, 
maximum, and range, and NGLCM dependence count percentage. We now arrive at 162 features.  
Removing feature families with more than one variety  
In the next step, we calculate the Spearman rank correlation between each feature and all other 
features to explore the relationship of the features with respect to each other and find redundant and 
highly correlated features. At this step, we had one subtype of every higher-order feature class (i.e. 
only 3D, after excluding 2D and 2.5D) except for GLCM and GLRLM, each remaining with two 3D 
subtypes: 3D merged, and 3D averaged. We investigated the correlation between each variety of 
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higher-order 3D calculation, i.e. 3D GLCM averaged vs. merged, and also, 3D GLRLM averaged vs. 
merged. Figure 4-10 shows a heatmap of their correlation. In the diagonal of both heatmaps in Figure 
4-10, we observe very high Spearman correlation (between 0.98 to 1) between all the same features 
within the two feature families, i.e. GLCM-averaged entropy vs. 3D GLCM-merged entropy, etc., 
indicating the redundancy of features calculated in two varieties (merged vs. averaged). Let us 𝑆{𝐴}|{𝐵} 
as the Spearman rank correlation between feature families {𝐴} and {𝐵}. We subtracted 
𝑆{3D GLCM-averaged}|{All feature families except 3D GLCM-merged} from 
𝑆{3D GLCM-merged}|{All feature families except 3D GLCM-averaged}, and did the same for GLRLM, and observed it 
yields values very close to zero, which further indicates that using one variety vs. the other does not 
add additional information to our analysis, suggesting exclusion of one variety from both GLCM and 
GLRLM. Subsequently, to decide which of the two varieties to exclude, we calculated the range of 
features in both varieties and removed the one with a smaller range, which yield to exclusion of the 
3D-merged of both categories and keeping 3D GLCM-averaged and 3D GLRLM-averaged. This further 
reduced the number of features down to 121. This observation is also consistent with findings in 
[425], where the authors reported merged features with tighter distribution in a smaller range, and 
subsequently remove, them from the rest of their study. 
Figure 4-10. Heatmaps of Spearman rank correlation between A) 3D GLCM-averaged vs. 3D GLCM-merged, and B) 3D GLRLM-
averaged vs. 3D GLRLM-merged. The diagonal of both plots have values >0.98 
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Removing redundant features 
After using Spearman correlation to reduce the feature space at the feature-family level, we move on 
to investigate the correlation at the feature level. The next set of features to remove are the feature-
pair with Spearman rank correlation coefficient of 1, indicating their redundancy. These features 
included three pairs: i) “3D GLSZM-zone percentage (ZP)” and “3D GLDZM-ZP”, ii) “3D GLSZM-GL non 
uniformity (NU) normalized” and “3D GLDZM-GL NU normalized”, and iii) “3D GLSZM-GL NU” and 
“3D GLDZM-GL NU”, From each pair, we selected the feature with a lower range for exclusion that 
yielded the removing of the GLDZM features from each pair.  
Removing features with a low dynamic range 
In the next step, we calculated the percent variance of the features (variance/mean) representing 
their dynamic range. Subsequently, we removed features with a very low dynamic range less than 
10-5, which were five: Histogram-skewness, Histogram-kurtosis, Histogram-min gradient, GLCM-
averaged cluster shade, and GLCM-averaged 1st measure of information correlation. Now the dataset 
has 113 features.  
Removing highly-correlated features 
In the last step of this phase, using the Spearman correlation of features with respect to each other 
calculated earlier, we opt to remove highly correlated features as defined by those having a Spearman 
correlation coefficient |𝜌| ≥ 0.95 as suggested in lthe iterature [495]. These feature-pairs are 
considered to be highly correlated and likely to provide redundant rather than complementary 
information. We remove these features through the following recursive operation. 
We use the heatmap of feature-pair Spearman correlation to find features with |𝜌| ≥ 0.95. We 
subsequently record the number of instances a feature fits this criterion. Then, we sort these features 
based on which feature has more instances of |𝜌| ≥ 0.95 with others in a descending order and call 
it ℱ𝑠𝑜𝑟𝑡𝑒𝑑 . We then start from the first feature in this set. We denote this first feature by 𝒻𝑘𝑒𝑒𝑝, i.e. the 
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feature to keep, it and save it to 𝒦 that denotes the set of features we intend to keep. Subsequently, 
we mark the highly correlated features with 𝒻𝑘𝑒𝑒𝑝 and save them to an empty set denoted by ℛ, i.e. 
for removal. We then loop over each feature inside ℛ and find other highly correlated features with 
these features and append them to ℛ. Once the procedure is complete, we update ℱ𝑠𝑜𝑟𝑡𝑒𝑑  by 
removing 𝒻𝑘𝑒𝑒𝑝 and all features inside ℛ. The algorithm then continues recursively with this updated 
ℱ𝑠𝑜𝑟𝑡𝑒𝑑 , letting its first member be 𝒻𝑘𝑒𝑒𝑝 and append it to 𝒦, and find features and add them to ℛ for 
removal. This process continues until ℱ𝑠𝑜𝑟𝑡𝑒𝑑  becomes empty.  
The above algorithm cuts the number of features into a half, removing 57 features from 113, yielding 
56 features remained that are not highly correlated with each other and are more likely to provide 
complementary information.  
  
Selecting the best discretization level (GLs) 
The above procedure reduced the feature set from 487×8 to 56×8 features for 8 GLs. Now we focus 
on discretization levels to systematically remove non-useful GLs.  Firstly, we observe that for the 
three smallest GLs, the number of identical features is higher than the other five GLs. Furthermore, 
features with smaller dynamic range increase by 22%, 4%, 29%, and 29% compared to GL=64 or 
128. Moreover, the two highest GLs have 11% and 22% more feature-pairs with Spearman 
correlation ≥ 0.9. Therefore, we can safely remove all GLs except 64 and 128.  
The procedure in the previous paragraph could have been performed without the analysis of the 
range and Spearman rank correlation of features. We can safely remove the first three GLs since the 
intervals that voxel intensities were discretized into are so large that they do not provide enough 
opportunity to capture the heterogeneity of a region. On the other hand, the two largest GLs produce 
so many bins to discretize voxels into that many bins will be empty or just have very few 
representations in the ROI. For instance, the LAD segment consists of averagely 460 voxels. When it 
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is discretized into 512 GLs, they are actually more bins than voxels, and many bins would be empty 
or just occur very scarcely. In this case, our higher-order matrices such as GLRLM, GLSZM, GLDZM, 
etc. in which the number of columns represents different run-lengths, zone sizes, distance zones, etc., 
would be very long and narrow matrices with very small variability. As a result, these higher GLs 
should be eliminated, too. 
Interestingly, this finding is consistent with our observations and conclusion from the previous 
chapter (section 3.3.3), as well as some previously published studies on radiomics of PET imaging 
[425, 443].  
Finally, out of the remaining two GLs, 64 and 128, we found very similar behavior from both 
discretization levels in terms of the range of the features and number of feature-pairs with high 
Spearman correlation. We decided to choose 64 for the rest of this study, because 1) as mentioned 
GL=128 does not demonstrate different statistical properties, 2) our results in previous chapter 
suggested 64 GLs for the other SPECT study – imaging of renal cell carcinoma with 99mTc, which is the 
same radiotracer as the one used for MP stress SPECT imaging, and 3) some previous studies have 
demonstrated that GL=64 provided higher textural feature reproducibility [496] and robustness 
[443]. 
 
Wrapping up feature selection  
Through the above procedures, we reduced our feature set of 487×8 to 56. One important note is that 
these features were excluded in a completely unsupervised manner without any involvement of the 
clinical outcome (e.g. CAC score, patient survival, etc.). This is an important factor to make our effort 




4.2.3.3. Outcome prediction 
In this section, we elaborate on our efforts towards outcome prediction using the narrowed down 
feature set. We also included our negative findings and unsuccessful attempts, as we believe 
reporting them helps future researchers, and thus, is of scientific value. 
Univariate analysis 
We define our outcome as the CAC score of each region of the heart calculated from the CT scan, and 
we aim to predict this outcome from the radiomic features extracted from the same region of the MP 
SPECT image, as explained in section 4.2.2.2. We started by investigating whether our selected 
radiomic features (previous section) directly correlate with the outcome, that is the CAC score. We 
adopted two approaches to represent the outcome. In the first approach, the actual CAC score with a 
continuous scale was utilized. In the second approach, we discretized CAC scores of each region of 
the heart based on the 5-scale clinical stratification criteria explained in section “Clinical factors” and 
plotted in Figure 4-8.  Spearman rank correlations between features of every segment with the CAC 
score of the same segment were calculated for both CAC approaches (continuous and discrete). We 
also employed Benjamini-Hochberg false-discovery rate (FDR) correction with q = 0.05 to discourage 
overfitting. None of the features were able to survive FDR correction and still significantly correlate 
with outcome under this univariate scheme. Figure 4-11 shows the absolute value of Spearman 
correlation coefficient values between 56 selected radiomic features and discretized CAC for eight 
segments, where we can observe the mediocre correlation values. Figure 4-12 shows their 
corresponding p-values (not FDR corrected in this plot). Following Benjamini-Hochberg FDR 
correction no feature survives. This emphasizes the difficulty of the task at hand, and that it is 
necessary to adopt a more sophisticated, multivariate algorithm for regression (for continuous CAC 




Figure 4-11. Spearman rank correlation between a selected feature of each segment (56 selected features) and the CAC of that 




Figure 4-12. Spearman rank correlation p-value between a selected feature of each segment (56 selected features) and the CAC 
of that segment. 
  
Multivariate analysis 
We observed from Figure 4-11 that in general, the correlation values between features and CAC score 
are relatively low. But despite their low correlation, these selected features had a relatively-higher 
significance, giving us the hope that while none of these slightly-significant features are highly 
correlated with the outcome, but a certain multivariate combination of them might actually be 
predictive and provide significant prediction information. Thus, we pursue a multivariate approach 
to predicting CAC scores. In this subsection, first we introduce stepwise linear regression, then we 
describe how we handle feature selection. We then explain how our proposed algorithm manages 
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data to produce a fair analysis, and finally we run the analysis for three different configurations: i) 
radiomics features-only, ii) clinical features-only, and iii) radiomic + clinical features and present the 
results. 
Stepwise linear regression  
In this stage, we pursue a multivariate analysis approach employing stepwise linear regression. 
Stepwise regression is a systematic method for adding and removing terms from a linear or 
generalized linear model based on their statistical significance in explaining the response variable. 
The method begins with an initial model, which in our case is a linear model, and then compares the 
explanatory power of incrementally larger and smaller models, which is performed by adding or 
removing terms by stepwise regression and returning the linear model at the end. The initial fit can 
be a linear or a constant (intersect) model. After the initial fit, the function examines a set of available 
features and adds the best one to the model if an F-test for adding the term results in a p-value of 
𝑃𝑒𝑛𝑡𝑒𝑟 , or less. If no terms can be added, it examines the terms currently in the model and removes 
the worst one if an F-test for removing it has a p-value of 𝑃𝑟𝑒𝑚𝑜𝑣𝑒 , or greater. This process is repeated 
until no terms can be added or removed. The constant term (intercept) is never removed from the 
model.  
Feature handling  
At each step, the method searches for terms to add to or remove from the model based on a criterion, 
which we selected it to be AIC, a commonly-used estimator of the relative quality of statistical models 
for a given dataset. AIC estimates the quality of each model relative to other models, providing a mean 
for model selection. It reduces the chance of overfitting and underfitting by providing a balance 
between goodness of fit and having too many parameters [497].  
We can specify the order at which this algorithm starts to add features and later removes them. 
Instead of an unstructured approach of starting from the arbitrary first feature in the list, we 
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developed a feature selection method to enter those with higher Spearman correlation to the model 
first. For this purpose, the Spearman rank-correlation between each individual feature in the training 
set and the outcome (CAC score of the same segment) was calculated. The Spearman correlation 
coefficients and their corresponding p-values were recorded. Then, merely-significant features with 
a p-value smaller than a certain range (e.g. 0.3) were selected and others were discarded. The selected 
features were then sorted into descending order, based on the value of their Spearman correlation. 
The input dataset is then rearranged based on this subset of Spearman correlation-sorted features to 
enter features with the highest correlation to the stepwise algorithm first.  
Training/cross-validation/testing setup  
The following procedures were performed for each of the cardiac segments separately. First, the 
given dataset was shuffled and 15% of the data was set aside as the “independent test set”. This set 
was not used until at the very end for independent assessment. Then, the following procedure was 
performed 20 times: the remaining 85% of the data “training + dev set” was randomly divided into 
training and cross-validation sets with 75%/25% ratios. The procedure described in the previous 
subsection has already reduced the number of radiomic features to 56. We use the procedure 
described in the previous subsection to further reduce the number of features and input more useful 
features for the regression algorithm first. We subsequently perform stepwise linear regression on 
the training set. We set 𝑃𝑒𝑛𝑡𝑒𝑟  as 0.05 and 𝑃𝑟𝑒𝑚𝑜𝑣𝑒  as 0.2.  
Once the training is over, we perform cross-validation using the dev set. The aim of cross-validation 
is to reduce overfitting to the training set. The cross-validation algorithm is configured the same as 
training, except for the training algorithm the initial fit was a constant (intercept), whereas for cross-
validation the initial fit is the output fit from the training dataset. During the above steps, we recorded 
the model, including the set of features remaining in it, the value of the log-likelihood, p-value and 
the final AIC.  
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The model fit is typically comprised of several features that survived the stepwise algorithm, and it 
might be possible that only the intercept term survives. If by coincidence the best model consists of 
only the intercept term, we skip that and choose the best fit with more than one term.  
Following the above procedure, we select the model with the highest AIC of the 20 runs to run on the 
independent test set blind to the entire operation. To assess its prediction performance, Pearson’s 
correlation was used to assess the relationship between the two distributions (prediction vs. actual), 
and subsequently recorded the correlation coefficients (𝜌) and their corresponding p-values. The 
above operation was performed for each of the segmented lesions of the heart separately.  
But this is not where we come to conclusion yet. We kept the test set aside during the whole analysis 
to assure a completely independent and blind-to-training assessment; however, our result might still 
be biased to a specific randomly-selected test set chosen. To even further mitigate such a bias, we 
took an extra step and run the entire above operation 50 times. That is, randomly shuffling and 
dividing the dataset into “training + dev” and “test” sets 50 times, then run the stepwise algorithm 20 
times over the “training + dev” set. We subsequently perform 50 predictions on 50 independent test 
sets that give us 50 best regression fits and their p-values, which we subsequently used to derive our 
conclusion. A flowchart of the algorithm is depicted in Figure 4-13. 
Running the multivariate analysis for three configurations 
We performed the above entire operation three times: A) with radiomic features only (imaging), B) 
with clinical features (non-imaging), and C) with both radiomics and clinical features. The ten clinical 
features employed were i) gender, ii) race, iii) age, iv) smoking, v) diabetes, vi) hypertension, vii) 
hyperlipidemia, viii) family history of cardiac disease, ix) BMI, and x) LVEF. We also assured that a 
certain subset of clinical features such as gender, race, diabetes, etc. was treated as “categorical” 
variables, as opposed to continuous, by the algorithm.  





squared distribution for a degree-of-freedom of 2×50=100 is 135.81. Table 4-4 shows the result of 
applying Fisher’s method to the three configurations, where significant results are shown in bold. We 
observed that radiomic features were unable to yield a significant model for any of the 
segmentations, and clinical features were able to result in a significant fit for most of the segments. 
But the combined clinical + radiomic features results in significant fit across all segments.  
Table 4-4. The value of chi-squared distribution for each segment and feature configurations. The value of the chi-squared 
distribution with degree-of-freedom of 100 is 135.81, and values above this threshold (shown in bold) are considered significant 
under the null hypothesis.  
 RCAMIM LCXMIM LADMIM Myocardium LAD17 LCX17 RCA17 
Radiomics 95.87 88.02 115.02 111.93 139.25 53.8 53.28 
Clinical 84.12 153.14 253.13 294.43 253.13 153.14 84.12 
Combined 174.53 194.73 348.97 341.39 326.97 189.2 141.6 
 
 
 shows the distribution of the absolute value of Pearson’s correlation coefficient |𝜌| for all seven 
segments. We observe the same pattern across all segments that the combined radiomics + clinical 
features are more correlated to the CAC scores of that region. Moreover, Figure 4-15 shows the 
distribution of p-values of the best fit out of the 50 independent runs of the stepwise regression 
algorithm, each include 20 model fits where the best is selected. This plot shows that adding 
radiomics to the 10 clinical features will enhance the significance of the regression model and 
promising a more robust prediction.  
Figure 4-14. Distribution of absolute value of Pearson’s  of the best fit out of 50 randomized trials of stepwise linear regression 
for radiomics, clinical and combined features, and for all 7 segmentations (the higher, the better). Adding radiomics to clinical 
features increases the correlation to the CAC score of the corresponding ROI.  
Figure 4-15. Distribution of p-values (log-scale) of the best fit out of 50 randomized trials of stepwise linear regression for 
radiomics, clinical and combined features, and for all 7 segmentations (the lower, the better). Adding radiomics to clinical 
features is seen to enhance the regression significance across all segmentations.  
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4.2.4. Discussion  
The current proposal is the first demonstration of employing radiomics of normal MP stress SPECT 
to predict CAC score as derived from the CT scan. To our knowledge, no study has been published on 
radiomics of cardiac SPECT imaging. Moreover, we did not find any study with the same approach as 
ours that incorporate readily-reconstructed 3D images and preserves the voxels intensities. They 
focus on using the polar plot for their analyses, which is a 2D projection of the 3D reconstructed 
image. Recently, few studies have investigated the use of deep learning to predict CAD [499-501]; 
nonetheless, no studies, to our knowledge exist on predicting CAC scores from SPECT scans, which 
is, as indicated earlier, a very challenging task.  
4.2.4.1. Challenges with the proposed idea 
The study of MP stress SPECT radiomics is a challenging task due to several reasons. First, SPECT is 
a low-resolution imaging modality that results in a substantial loss of heterogeneity information that 
had the potential to provide extra knowledge about the blood flow and other functionalities of the 
heart that could have captured by radiomics. Moreover, the lack of quantitation in SPECT imaging 
further causes a major loss of information, resulting in a mostly-qualitative interpretation of the scan. 
Of course, the absence of quantitation prevents the utilization of many useful radiomic features. It 
also impedes performing cross-scan comparisons. Another drawback of non-quantitative SPECT 
images can be explained by an example of a patient that has calcification in all three main arteries 
but has a uniform uptake in his SPECT image reported as normal. This can be due to a condition 
where blood flow is reduced in all three main arteries, resulting in uniformly decreased flow all 
around the heart. But since blood flow is not quantifiable, this effect cannot be noticed. However, 
methods to perform quantitative SPECT scan have been published and even recently been 
commercialized [502, 503]. Quantitative SPECT is shown to carry many clinical implications [504] 
and promises an increased chance of more accurate and impactful radiomics analysis of the heart.  
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One other reason that significantly contributes to the challenges in SPECT radiomics is heterogeneity 
caused by inherent artifacts of SPECT imaging. MP SPECT, specifically, can cause artifacts on the 
reconstructed image that can appear as reduced uptake in the image, an example of which is shown 
in Figure 4-16. This effect is called apical thinning and is a well-known phenomenon in MP SPECT. It 
is often attributed to a reduced myocardial thickness at the apex of the left ventricle. Attenuation 
correction during the reconstruction appears to exaggerate this effect [505]. Moreover, soft tissue 
attenuation artifacts also impact MP SPECT images [506]. These artifacts generally appear as fixed 
defects. Attenuation due to breast tissue usually results in a perfusion defect along the anterior wall 
of the left ventricle, also affecting the lateral wall, septum, and apex [507]. The effect would be similar 
to that in Figure 4-16. During our data collection phase, we observed many cases with this effect 
apparent in their reconstructed image. Undoubtedly, the heterogeneity caused by this effect may be 
captured by the radiomic features, while it is completely irrelevant to calcifications in arteries. 
 
Figure 4-16. A normal MP stress SPECT with apical thinning.  
Figure 4-17 shows an example of an MP stress SPECT scan image in a polar plot form, which a 2D 
projection of the 3D SPECT image into its apex (center circle). This image is interpreted as normal, 
due to the absence of any reversibility and/or defect. But the CT scan of this patient shows an 




Figure 4-17. A normal MP SPECT with severe calcification. This scan is reported as normal due to relatively uniform uptake 
with no reversibility and/or fixed defect, but the CAC CT scan shows an extraordinary CAC score of 2239. The promise of our 
proposed research is to be able to provide assistance in finding such cases with elevated CAC score.  
4.2.4.2. Radiomics intuition  
We mentioned that radiomic features mostly included in the fit were GLSZM GLSZM-small zone large 
GL emphasis, and GLDZM-short distance large GL emphasis. Both features emphasize on higher GLs, 
and higher GLs in a discretized SPECT image depicts higher blood flow.  It is interesting to observe 
and seems intuitive that the radiomic features who capture higher blood flow in each cardiac segment 
end up being in the fit.  
4.2.4.3. Our other efforts  
We wish to also point out that we explored more than 10 other regression methods, including 
different types of regression trees, support vector machine (SVM) regressors, etc., as well as several 
classification techniques (bagging, SVM, K-nearest neighbor, etc.) to find a significant prediction 
model, but our investigation did not return any significant results from the aforementioned 
techniques. Yet we do not exclude the possibility that with further tuning, those algorithms can 
potentially return significant results. 
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4.2.4.4. The significance of the study 
 In the current study, after many feature elimination steps discussed in section 4.2.3.2, and 
significantly reducing the feature space by a factor of 70, univariate analysis was not able to find any 
potential correlation with the outcome. On the other hand, our multivariate analysis carefully 
designed to mitigate the impact of dataset bias on the outcome prediction was able to successfully 
make a prediction for all segments of the heart.  Our statistical analysis in section 4.2.3.1 showed that 
just around 60% of the patients had a non-zero CAC score and one-third of them had a CAC score≥100 
that is shown to progressively increase the chance of myocardial ischemia. As a result, our 
multivariate analysis has the potential to make a prediction of CAC which is the most prevalent type 
of atherosclerosis, showing promise for this study.   
 
4.2.5. Conclusion 
This chapter investigated the hypothesis that heterogeneity in MP stress SPECT images can possibly 
convey information regarding calcification in coronary arteries. Many community settings are 
incapable of providing CAC CT scan for patients, it is not reimbursed by the CMS, and requires 
sophisticated software. We employed our in-house developed standardized SERA package that can 
evaluate 487 radiomic features. We segmented MP SPECT images into LAD, RCA, LCX, each with two 
varieties, as well as the whole myocardium, evaluating features for all 7segments. We also explored 
8 different GLs to find the most appropriate setting for our study that yields higher reproducibility, 
robustness and less redundancy. Our dataset consists of 428 patients with normal (non-ischemic) 
MP stress SPECT images that were verified to be free from artifact or spillover, in addition to their 
detailed CAC score acquired from CT, and other clinical parameters. Our focus was on patients with 
normal stress scan since the possible prediction of coronary artery calcification in those images 
would have been of clinical significance. Through a multi-step blind-to-outcome unsupervised 
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feature selection phase, we significantly reduced the feature space 70 folds from 487×8 to 56 
features. We also performed the entire operation 50 times to randomly divide our dataset into 
“training + dev” and “test” sets to mitigate any bias to a specific set of test data. Our univariate analysis 
using Spearman rank correlation between each feature of the cardiac segment with the 
corresponding CAC score of that segment was not significant. Our multivariate analysis, however, 
was able to significantly predict CAC score of all cardiac segments when combining radiomic features 
with clinical features. Our method has the potential to identify such cases with high coronary artery 
calcification that can be prompted for more appropriate care, suggesting that radiomics analysis adds 







5. Summary and Future Work 
This section briefly summarizes the main takeaways from the chapters in this dissertation.  
5.1. Introduction  
Our work aims to advance two frontiers of nuclear medicine imaging, namely image reconstruction, 
and radiomics, with the goal of enhanced quantitation. We devoted the first chapter to introduce the 
basics of these two fields. We started by introducing nuclear medicine and tomographic imaging, PET 
and SPECT, their components, as well as image generation and tomographic reconstruction 
techniques. We briefly discussed the vast applications of each modality. We subsequently elaborated 
12 causes of image degradation. These were required to better illustrate the problem statement of 
chapter 2 since the promise of PSF modeling is to correct for a subset of those image degradations. 
The next part introduced medical image quantitation, where we provided a detailed definition of 
image quantitation, biomarkers, quantitative biomarkers, and provided an example of one of the 
most commonly-used imaging biomarkers in nuclear medicine. We subsequently discussed 
radiomics, the large-scale data-oriented study of radiological images for potential discovery of 
imaging biomarkers that can be used in the clinic and provide additional valuable information to 
radiologists. The promise of radiomics is to enable personalized medicine, which we discussed in 
section 1.4. We provided a roadmap of how radiomics can lead to advancements in personalized 
medicine. We briefly introduced radiomics and mentioned a number of selected applications utilizing 
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radiomics. We then concluded by an overall motivation for our dissertation and a brief summary of 
our published work.  
 
5.2. Chapter 2: Adaptive PSF modeling  
5.2.1. Summary   
This chapter focused on a commonly-used “image reconstruction” technique in PET imaging—PSF 
modeling. The advantages and challenges of PSF modeling were discussed and a new approach was 
proposed with the aim to enhance image quantitation. The new approach stepped beyond the past 
frameworks involving a dichotomy of PSF vs. no-PSF modeling, focusing on a wide-spectrum of PSF 
models for the potential of enhanced quantitation of standardized uptake values (SUVs). Starting 
from a simplistic simulation and reconstruction framework, our proposed method was shown to 
enhance quantitative task performance. Following elaboration of system modeling in PET as well as 
analytical modeling of image degradation effects, a comprehensive PET simulation and image 
reconstruction framework were proposed that considered a range of realistically-modeled 
resolution degradation phenomena that analytically modeled the true PSF. Various measures of noise 
and bias were defined and subsequently used to demonstrate the efficiency of the proposed scheme. 
The results of our study were shown to follow that of our preliminary image-based PSF modeling 
presented earlier in the chapter. Our results demonstrated that for the standard range of iterations 
employed in the clinic (not excessive), edge enhancement due to overestimation counter-intuitively 
lowered SUV bias in small tumors, while inter-voxel correlations suppressed image roughness and 
enhanced uniformity in all tumors, only slightly degrading SUVmean reproducibility in the smallest 
tumors. Unlike what one may at first imagine that overestimating the PSF would lead to higher 
overshoots at the edges, this was only observed at higher iterations. In fact, using an overestimated 
PSF resulted in increased contrast and limited edge overshoot effect at lower iterations, in turn 
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enabling enhanced SUV quantitation. Another important takeaway of this chapter was that the exact 
matched system PSF might not be the optimized option for enhanced image reconstruction 
performance and that slightly overestimated PSF modeling can improve PET image quantitation.  
5.2.2. Future work 
An interesting real-world implication of this work is in PET scanner calibration. Some commercial 
PET scanners use Ge-68 point-sources to characterize the PSF as modeled within PSF reconstruction. 
However, in comparison, the most popular isotope, F-18, has a relatively small positron range. Thus, 
utilizing a PSF kernel obtained from Ge-68 point-sources with a significant positron range to 
reconstruct F-18 PET data is approximately equivalent to an overestimated PSF kernel in the 
reconstruction, because both increase the FWHM of the PSF. It is interesting to note, based on our 
observations with overestimated PSF kernels, that this may not be a problem in fact, and may 
effectively lead to improvements in quantitative performance, though further analysis is required to 
implement the exact model of radiotracers with higher positron range, that is left for future study. 
Our aim during the course of our research was to introduce and explore more groundbreaking ideas, 
as opposed to making slight improvements to existing concepts. Although our comprehensive noise-
bias study demonstrated the effectiveness of our proposed model, it can be further investigated 
against some other important parameters in image reconstruction, including different tumor 
contrast, adding post-smoothing with different filters, adopting penalized reconstruction, and the 




5.3. Chapter 3: Standardized radiomics 
5.3.1. Summary  
While radiomics was briefly introduced in Chapter 1, Chapter 3 presented a detailed and systematic 
view of standardized radiomics workflows. As a typical workflow contains numerous steps, as 
outlined, including image preprocessing, workflow configuration and feature calculation, the overall 
complex framework was understood to be highly prone to variability, impacting its robustness and 
reproducibility. Certain precautions were also discussed to prevent overfitting and to correct for 
false-discovery rate, which, many past published radiomics efforts suffer from. Our efforts within the 
IBSI collaboration were illustrated, where it was seen that even for centers using the same images 
and ROIs, the computed features were not consistent.  
We introduced our developed standardized environment for radiomics analysis (SERA) consisting of 
487 radiomic features.  SERA was used in multiple projects, including studies at the end of this 
chapter aiming at discovering robust and reproducible radiomic features for two nuclear medicine 
datasets: renal cell carcinoma 99mTc-Sestamibi SPECT and 18F-DCFPyL PSMA PET images of prostate 
cancer. Although both studies were the first demonstration of radiomics for these radiotracers, our 
results were in agreement with past efforts on more commonly-used tracers such as FDG. Our results 
also matched the findings in Chapter 4. This chapter further reported on the importance of GL 
discretization selection, where 64 GLs was seen to convey enough details about image heterogeneity, 
as well as the preference for more sophisticated segmentation to improve reproducibility of features.  
5.3.2. Future work 
Immediate future research from the concepts introduced in this chapter is to assess the reported 
robust and reproducible features in outcome prediction tasks. For our study of radiomics of cold-
uptake in RCC SPECT described in section 3.3.1, we tried to use some machine learning techniques to 
predict benign vs. malignancy of tumors, which were not successful, which we attribute to the 
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relatively small number of datasets that are more appropriate for reproducibility analysis. Many 
radiomic studies have been published, yet some of the details of the feature evaluation setting has 
not yet been carefully studied. For instance, different feature families may be optimized at different 
discretization levels. The assumption in the efforts presented in this dissertation, as well as other 
published studies,  is to consider one GL for all feature families. However, the effect of discretization 
levels in different feature families should be investigated. Even further, the effect of discretization in 
every feature can study too. The concern of the scientific community over radiomics study with 
relatively-low reproducibility as well as the tendency to report positive results require more efforts 
on developing and publishing workflows for performing standardized feature selection, and/or 
standardized feature classification, similar to IBSI that aims at standardized feature evaluation. They 
are not as many studies with feature selection/classification analysis that are statistically sound. For 
instance, how to approach the feature classification at the presence of hundreds of features, many of 
which might not convey any useful information. Or if we are interested to study differentiation of two 
features that can be performed using the widely-used area under the curve (AUC) analysis of the 
receiver operative characteristics (ROC) curve, how can it be compared with a third or more variable; 
i.e. how can we hypothesize ROC analysis of more than two features.  
 
5.4. Chapter 4: Radiomics of Myocardial Perfusion Stress SPECT to predict CAC 
Score as Captured by CT 
5.4.1. Summary 
The final chapter contained an end-to-end application of radiomics in nuclear cardiology. This was 
the first demonstration of utilizing radiomics on cardiac SPECT imaging to derive CT-based CAC 
information that otherwise is absent from conventional analysis.  The importance of MP stress SPECT 
and CAC scoring from CT in the clinic were described. Given that CAC assessment is not commonly 
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performed nor reimbursed in a wide community setting, this project has an important implication in 
the clinic.  
SERA-derived radiomic features were utilized in a multi-step feature selection framework, followed 
by application of machine learning to radiomic feature. Feature selection was completely blind to the 
outcome, and the selected features were subsequently utilized in machine learning efforts. Results of 
this chapter demonstrated the possibility that certain information about CAC scoring can be derived 
from radiomics of MP SPECT, further emphasizing the value of radiomics in extracting visually-
unseen information from radiological images. 446035288325 
5.4.2. Future work 
This was a difficult challenge! And we explained several reasons that contribute to the complexity of 
this problem in section 4.2.4: Discussion. We started with a problem for which univariate analysis 
demonstrated very poor performance. We tried a number of regression and classification techniques 
for outcome prediction in this project. The results demonstrated added value in utilizing extracted 
radiomic features; significantly predicting CAC score of the LAD segment of the heart using a 
combination of radiomic features of MP SPECT and clinical features. There is scope for the use of 
more advanced machine learning techniques for mapping the complex data to the outcome. Our 
dataset consisted of a medium-sized patient population of 428 patients. Larger datasets can be 
collected and applied to deep learning frameworks where features are implicitly extracted, which 
may be better able to handle complex datasets.  
Moreover, we note that CAC scoring is only an intermediate step in clinical decision making, aiming 
to help and improve patient stratification. As such, important future studies can be designed to use 
the radiomics of SPECT to directly predict patient outcome and to enable clinical decision support, 
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